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chapter 1     
INTRODUCTION 
 
Recent history of pulmonary oncologic diagnostics in general and in the Isala 
Clinics 
 
The analysis of patients with suspected thoracic malignancies is a daily activity for 
pulmonologists. Over the last decades the diagnostic arsenal of our profession 
broadened extensively and resulted in improved patient care. In this introduction a 
few landmark developments will be addressed because of their huge influence on 
thoracic oncology. The excitement about new diagnostic equipment and their 
strategic patient-orientated application encouraged research in this field and finally 
writing this thesis. 
 
The first landmark development is the introduction of positron-emission tomography 
(PET) in the mid-nineties. Before that time, starting in the early seventies, imaging of 
presumed thoracic malignancies leaned mainly on computed tomography (CT). With 
the improvements of helical scanning in 1991 and subsequent increasing numbers of 
detectors, smaller lesion became visible and the anatomic delineation for tumors was 
sharper as ever before [1]. Although superior in anatomical detailing, metabolic 
information was lacking. 
PET with radiolabeled fluorodeoxyglucose (FDG) provided this functional quality and 
was incorporated so gradually took its position in the diagnostic approach of lung 
cancer next to CT. The high impact of FDG-PET on detecting thoracic malignancies 
was described in several studies [2-4]. FDG-PET enabled the differentiation of 
benign from malignant lesions, the detection of (occult) distant metastatic disease, 
provided a more accurate mediastinal staging, disease monitoring and determination 
of recurrence than before. 
It took several years before PET and CT were integrated into one instrument. 
Integration of both modalities resulted in superior tumor and nodal staging[5]. 
In 2005 an integrated PET-CT was installed in the Isala Clinics improving the 
accessibility and applicability enormously. 
 
The second landmark development was the endoscopic technique that arose 
originally in the field of gastroenterology in the late nineties. Endoscopic ultrasound 
guided fine-needle aspirations (EUS-FNA) appeared to be extremely useful for the 
analysis of leftsided mediastinal and subcarinal abnormalities and upper abdominal 
masses. Therefore, EUS found its way to disciplines such as pulmonology and 
especially thoracic oncology [6, 7]. 
The diagnostic performance of EUS-FNA was studied extensively in subsequent 
years and impressive sensitivities and specificities were reported [8].  
In 2005 EUS became available in Isala Clinics and was implemented by skilled 
pulmonologists. Isala Clinics became a regional center for EUS and many patients 
from referring hospitals were analyzed. 
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The role of PET-CT and EUS-FNA in relapsing lung cancer patients has been 
studied. There was, and there still is, much debate about the feasibility and relevance 
of restaging lung cancers after induction treatment. Safer surgery with support of an 
excellent intensive care unit made it possible to perform surgery in more extensive 
stages but were we able to stage those patients reliably enough to decide whether 
any treatment would be beneficial? The almost simultaneous appearance of FDG-
PET and EUS made it possible to focus on the value of restaging in lung cancer after 
concurrent chemoradiotherapy. These results are described in chapter 2. 
 
EUS-FNA is a very safe procedure also as a restaging procedure. Complications are 
rare and usually mild. Is EUS-FNA also safe in patients treated with an angiogenesis 
inhibitor such as bevacizumab? Bevacizumab is used in combination with 
chemotherapy as first-line treatment in NSCLC. It is known for its side-effect of 
impaired wound-healing. Chapter 4 describes a patient who underwent EUS-FNA 
while on treatment with bevacizumab. 
 
EUS is not only suitable for diagnosing malignant disease but has also a role in 
benign diseases such as sarcoidosis [9]. Other benign diseases can be diagnosed 
with EUS and are reported in literature [10]. As an example we report on two patients 
with infectious spondylodiscitis diagnosed with EUS and who are described in 
chapter 3. The cases illustrate the accessibility of posterior located mediastinal 
structures – previously inaccessible except by major surgery - and these cases 
emphasize the importance of cross-over knowledge between different medical 
disciplines. 
 
While getting familiar with transesophageal and transgastric ultrasound (US) images, 
the step to percutaneous US guided sampling was rapidly made. In 2006 the first 
percutaneous ultrasound guided aspirations by pulmonologists in Isala Clinics were 
performed in supraclavicular lymph nodes. Many patients followed and percutaneous 
ultrasonography is now fully integrated in our diagnostic process. 
The diagnostic performance characteristics of percutaneous US guided biopsies and 
aspirations of abnormalities detected with PET-CT are described in chapter 5. The 
role of percutaneous US guided sampling in staging is illustrated as well as its 
usefulness in non-palpable lesions. 
 
To extent the use of ultrasound guided biopsies we looked to patients with suspected 
mesothelioma and in whom it was difficult to get a histological diagnosis. In this 
subgroup of mesothelioma patients, characterized by the absence of pleural effusion, 
it is hardly feasible to perform a medical thoracoscopy. Since tissue is required for 
diagnosing mesothelioma, a study of the diagnostic accuracy and safety of US 
guided TCB in this particular subgroup of patients was performed. The results are 
described in chapter 6.  
 
A few years after EUS, the endobronchial variant made its appearance, partly 
overlapping and complementary to EUS in enabling the analysis of the right-sided 
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mediastinum and hilar lymph nodes [11, 12]. EBUS has a likewise excellent 
diagnostic performance in the hands of experienced operators [13]. 
Just like EUS, EBUS is a new and important tool for staging the mediastinum and the 
combined use of both techniques has driven surgical staging to the background [14]. 
In August 2008 endobronchial ultrasound (EBUS) was operational in Isala Clinics 
and patients from the wide region were referred.  
 
A substantial amount of patients were referred for mediastinal lymphadenopathy 
detected incidentally on CT scans made for other purposes than cancer analysis 
such as pulmonary embolism or coronary arterial disease. With the increasing use of 
advanced CT technology for all kinds of indications and the developments in lung 
cancer screening ahead with low-dose CT, we expected increasing numbers of 
referrals for these so-called mediastinal incidentalomas. The question arose whether 
it is useful to further analyse these thoracic abnormalities? A prospective study was 
performed on these incidental findings by characterizing them radiologically and 
pathologically. Results are described in chapter 7. 
 
This state-of-the-art diagnostics provided the opportunity for a fast-track diagnostic 
program for patients with an abnormal chest radiograph suspected for lung cancer. 
The core of this program is the immediate availability of invasive techniques after 
FDG-PET performed at the same day. However, is this fast diagnostic approach 
really of benefit for the patient and is it really faster? The results of this diagnostic 
program are described in chapter 8.  
 
The third diagnostic landmark was the introduction of molecular diagnostics into 
pulmonary oncology. For a long time lung cancer was divided into small cell lung 
cancer (SCLC) and non-small cell lung cancer (NSCLC). The diagnosis was based 
on morphology with haematoxylin and eosin stained slides from tumor tissue. 
In 2008 a study demonstrated a relation between chemotherapeutical efficacy and 
tumor histology[15]. From that moment subtyping of NSCLC was essential to select 
the proper chemotherapy. Histology remained important but it was not always 
possible to obtain enough tumor tissue. Under those circumstances cytology was 
used to come to a diagnosis. Initially only cytologic aspirations were obtained for 
staging lung cancer but gradually, depending on the indication and the size of the 
lesion, also tissue core biopsies (TCB) were taken. 
To use cytological specimen in more elaborate way, cytological aspirates had to be 
deposited in a fixative medium for the preparation of formalin fixed paraffin-
embedded (FFPE) cell blocks. With these cell blocks and the use of 
immunocytochemical staining a diagnosis can be made. The question is however 
whether cytology or pathology specimen are required for an adequate lung cancer 
diagnosis. 
In the late 2000s more and more evidence appeared that certain activating mutations 
in the epidermal growth factor receptor (EGFR) gene predicted good response to 
treatment with EGFR tyrosine kinase inhibitors (TKIs). DNA analysis would be 
essential in the near future and the first plans to start a molecular biology laboratory 
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in the Isala Clinics arose in 2007. After KRAS mutation analysis in colon carcinoma 
was made operational by the end of 2009, the first DNA isolation for lung cancers 
followed by the end of 2010. 
 
The first study that showed a superior outcome of EGFR-TKIs over chemotherapy in 
first-line treatment of lung cancer patients with an activating EGFR mutation 
emphasized the importance of EGFR mutation analysis[16]. Many large subsequent 
studies showed comparable results. In these studies, mutation analysis was 
uniformly performed on tumor tissue with different molecular tests. The slogan “tissue 
is the issue” was widespread and a consensus report recommended mutation 
analysis to be performed preferably on tumor tissue[17].  
 
As many of the diagnoses of our patients are based on cytologic material, a study 
was started to compare the usefulness of EUS guided aspirations with EUS guided 
TCBs for pathological classification and mutation analysis. The question was whether 
aspirations with adequate number of tumor cells are comparable with tumor tissue for 
molecular diagnosis. The result of such a comparison is described in chapter 9. 
 
In recent years, lots of evidence appeared about the feasibility of mutation analysis 
on cytologic samples, on samples with less and less tumor cells. Even single cell 
genome-wide sequencing was introduced for research purposes. In our laboratory a 
very sensitive sequencing method was implemented that required very small tumor 
quantities. This so-called pyrosequencing method was tested systematically on EUS 
and EBUS aspirations and compared with the results of the High Resolution Melting 
(HRM) technique. The results are described in chapter 10.  
 
The integration of all these diagnostic modalities into an appropriate diagnostic 
pathway for an individual patient is the art of the pulmonologist. A few principles 
should guide diagnostic decision-making to obtain maximal information from a 
minimal number of tests.  
First, the clinical consequences and personal wishes of the patient should be 
considered before appointments are made. 
Second, waiting in uncertainty about the diagnosis is tormenting for the patient, 
diagnosing time must be short.  
Third, imaging should precede invasive tests. Imaging provides the location and 
extensiveness of disease and determines whether and how tumours should be 
sampled for pathological analysis depending on differential diagnostic considerations. 
Fourth, invasive test should ideally provide a diagnosis and, in case of malignancy, a 
stage confirmation. 
How can we diagnose patients suspected for thoracic malignancies without losing 
sight of these principles? In chapter 11, diagnostic tools and their practical 
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Background: After induction treatment restaging of mediastinal  disease in patients 
with stage III non-small cell lung cancer (NSCLC) may lead to selection of candidates 
for  further surgical treatment. Nodal down-staging is the best predictive 
characteristic for proceeding with surgery.    
We report our experience in restaging with endoscopic ultrasound-guided fine-needle 
aspirations (EUS-FNA ) and with repeated integrated positron emission tomography 
and computed tomography (PET-CT). 
Methods: Twenty-eight patients with stage III NSCLC were staged with integrated 
PET-CT, cerebral Magnetic Resonance Imaging (MRI) and pathologically proven 
nodal disease.   
Restaging was performed with PET-CT and EUS-FNA on the same nodes that 
showed initially metastatic disease provided this nodal sites determined the tumor 
stage. Cerebral MRI was not repeated.  
When restaging EUS-FNA revealed no malignant cells anymore, patients were 
operated. The postoperative pathologic results were compared with the pre-operative 
restaging EUS-FNA results. Also, patterns of decreased fluoro-2-deoxyglucose 
(FDG) uptake were compared with the postoperative pathologic results. 
Results: Restaging EUS-FNA was well tolerated in all patients even in those with 
clinical signs of radiation esophagitis. 
Of the 28 patients 15 were down-staged based on cytologic findings with restaging 
EUS-FNA and in one patient the cytology was not conclusive. Of these 15 patients, 
down-staging was histologically confirmed after mediastinal exploration in 11 patients 
and one patient had persistent nodal disease at resection. In 3 patients no 
mediastinal tissue verification was performed. Two subjects were not fit for operation, 
and in the other patient intraoperative nodal staging was omitted. The negative 
predictive value for restaging EUS-FNA was 91.6%. The accuracy of EUS-FNA was 
92.3%. 
Concordance between findings of restaging EUS-FNA and metabolic response of 
lymph node metastases occurred in 17 out of 27 patients.  
Conclusion: Restaging with EUS-FNA after induction chemo(-radiotherapy) is well 
tolerated and predicts the absence of nodal metastasis reliably. Although changes in 
mediastinal FDG-PET uptake show a high concordance with EUS-FNA , pathological 
confirmation is still superior and therefore necessary. EUS-FNA is the procedure of 















Several studies demonstrated that down-staging mediastinal node metastases 
predicted prolonged survival after induction therapy with chemotherapy and chemo-
radiotherapy in patients with locally advanced Non-small Cell Lung Cancer 
(NSCLC)[1-6]. Concurrent chemoradiotherapy seems the most  effective way to clear 
tumor cells from nodal stations in stage III disease[6]. Diagnostic procedures for 
restaging vary in performance and the way they come to conclusions. It is important 
to determine down-staging of mediastinal nodes and subsequently for selecting 
patients for surgery. Restaging is difficult especially when mediastinoscopy has been 
performed previously. Remediastinoscopy gives inadequate information caused by 
incomplete procedures in 40% of patients due to fibrosis[7]. PET-CT is by far 
superior to re-mediastinoscopy[8].. Restaging mediastinal metastases with PET as 
described in four studies show sensitivities of 50-71% after various induction 
therapies reflecting the need for pathologic confirmation[9]. A study in 93 patients, 
restaged after chemoradiotherapy with repeated PET-CT and various biopsy 
techniques (including EUS) demonstrated a false negative rate of 20% and a false 
positive rate of 25%.  Repeated PET-CT was more accurate than repeated CT for all 
stages[10]. 
Endoscopic techniques are of interest because they can be performed repeatedly 
and deliver material for cytopathologic analysis through transbronchial fine needle 
aspirations (TBNA). Recently a study was published on restaging with TBNA after 
induction chemo-radiotherapy[11]. A correct diagnosis was obtained in 71% of 
patients. Nowadays this technique can be performed under guidance of linear 
ultrasound bronchoscopes (EBUS-TBNA). This technique is very useful in staging 
the mediastinum in patients without a prior treatment[12, 13]. A recent study 
described the experience with EBUS-TBNA in restaging the mediastinum after 
induction chemotherapy in patients with stage IIIA NSCLC[14]. A sensitivity, 
specificity, positive and negative predictive value and diagnostic accuracy of 76%, 
100%,100%, 20% and 77% respectively were found. 
Also endoscopic ultrasound (EUS) is feasible in mediastinal restaging after induction 
chemotherapy as demonstrated in a study of 19 patients with a reported sensitivity of 
75% and accuracy of 83%[15]. This sensitivity is lower than sensitivities reported in 
the pre-treatment analysis[16]. EUS-FNA for restaging after chemo-radiotherapy has 
been described in two studies[10, 17][1, 2]. One study described restaging results in 
93 patients but did not report data on the accuracy of EUS in this setting[10]. One 
study in 14 patients reported a diagnostic accuracy of 86%[17]. 
The paucity of articles describing the use of EUS for restaging might be caused by a 
reluctance to perform this procedure on patients with a radiation esophagitis. 
In this prospective study, both PET-CT and EUS-FNA were used for restaging 
patients with stage III NSCLC after induction therapy (chemotherapy or concurrent 
chemo-radiotherapy).  
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The performance of both tests was compared with those of surgical dissection of the 
mediastinum. 
 
PATIENTS AND METHODS 
 
Entry Criterion 
Between February 2006 and May 2008 patients with stage III NSCLC were included 
after a written informed consent was obtained. 
All patients were initially staged with MRI or CT of the brain and  integrated PET-CT. 
Subsequently the mediastinal nodal status was verified with EUS-FNA in 26 patients, 
cervical mediastinoscopy in 1 patient and Transbronchial Needle Aspiration in 1 
patient. Patients were eligible if the pathologically proven metastatic site determined 
the disease stage and could be reached with EUS-FNA at restaging.  
Pulmonary function tests were performed to estimate operability after induction 
treatment.  
 
Endoscopic ultrasound and pathologic analysis 
EUS was performed with Pentax ultrasound endoscopes with a Hitachi EUB-5500 
processor. The procedures were performed under conscious sedation with 
midazolam and with local anaesthesia that was sprayed in the oropharynx (lidocain 
1%) and lidocain gel 20 mg/ml. FNA was performed with Cook Echotip 22G needles. 
Per nodal site, 3 to 4 passes were performed and at least two aspirates were 
smeared on slides. The remaining biopsies were suspensed in a conservation 
medium (Carbowax 2% [polyethyleenglycol 20 g in ethanol 96% methylated and filled 
up to 1000 ml with water]). If the slides showed no tumour cells, the remaining 
material was also analysed for tumour cells. If malignant cells were detected on the 
slides, the suspension in carbowax was used for immunohistochemical analysis to 
determine the subtype of NSCLC. 
 
Imaging 
PET-CT scans were performed on an integrated PET-CT scanner (GE Discovery ST 
PET-CT scanner; General Electric, Milwaukee, Wis). Patients were asked to fast for 6 
hours and than received 4 MBq/Kg body weight (min 252 and max 400 MBq) 
fluorodeoxyglucose intravenously followed by PET after 1 hour. Serum glucose had 
to be lower than 10 mmol/L. A reconstruction with CT attenuation correction was 
performed. An additional contrast enhanced helical CT-scan from head to pelvis was 
performed immediately after PET-CT scanning.  
Ratios of FDG uptake in the lymph nodes and background uptake as measured in 
the ascending aorta were calculated before and after the initial treatment.  
Metabolic response was scored according to criteria proposed by the European 
Organization for Research and Treatment of Cancer (EORTC)[18]. Progressive 
metabolic disease (PMD) was classified as an increase of 25% FDG uptake 
compared to baseline. Stable metabolic disease (SMD) was classified as an increase 
in FDG uptake of less than 25% or a decrease of less than 15%. Partial metabolic 
18
    restaging 
 
response (PMR) was classified as a reducion of more than 25%. Complete metabolic 
response (CMR) was classified as a complete resolution of FDG uptake. 
The response was judged as down-staged if there was at least a partial metabolic 
response in the metastatic lymph node. 
 
Treatments 
The patients were treated with various regimen consisting in most cases of 
concurrent chemo-radiotherapy and only a few patients received chemotherapy 
without concurrent radiotherapy. 
Restaging procedures were performed within 2 weeks after ending the induction 
regimen and involved at least an integrated PET-CT and EUS-FNA. The same 
mediastinal lymph node stations found to be positive at initial analysis were 
approached again for needle aspirations at restaging. 
If restaging with EUS-FNA showed no tumor cells, patients were considered as 
down-staged. Therapy proceeded with a thoracotomy including a lobe specific  
mediastinal lymph node dissection. During a right thoracotomy lymph node resection 
was performed for Naruke 4, 7, 10 and 11 for Right Upper Lobe lobectomy[19]. When 
possible Naruke 2 was resected as well. For the Right Lower Lobe lobectomy Naruke 
8, 9, 10, 11, and 7 were taken. As much as possible lymph node tissue was resected 
en bloc with the lobectomy. The same nodes were resected during left thoracotomies 
although Naruke 2 and 4 left were not always easy to retrieve due to preoperative 
treatment alterations.  
 





Table 1 shows the characteristics of the 28 patients included. 
The median number of nodal sites biopsied during initial staging procedures was 3 
(range 1-6). 
Six patients received chemotherapy and 22 patients concurrent chemo-radiotherapy 
as induction treatment. In thirteen of the patients who received concurrent chemo-
radiotherapy, two courses of full dose chemotherapy preceded chemoradiotherapy.  
Restaging EUS-FNA and PET-CT was performed within 2 weeks from last treatment 
date (median 10 respectively 6 days). In 3 patients the restaging PET-CT was 
performed in the last week of chemoradiotherapy. 
Four patients who were not down-staged were treated with additional radiotherapy 














Median age (range) (year) 60 (47-78) 
  
Gender  
            Male 22 
            Female 6 
  
Histology  
            Adenocarcinoma 6 
            Squamous cell carcinoma 15 
            Nonspecified NSCLC 7 
  
Induction treatment  
            Cb/Pac Q3wk 2x 1 
            G/C Q3wk 2x 4 
            G/C Q3wk 3x 1 
            G/Cb Q3wk 2x   followed by    C/D QW 6x + 59,4 Gy 1 
            G/C Q3wk 2x     followed by    C/D QW 6x + 66 Gy 12 
            C/D QW 6x + 66 Gy 2 
            C/D QW 6x + 60 Gy 1 
            C/D QW 6x + 45 Gy 6 
  
Mean interval between end of treatment and restaging 
(days) 
 
            Restaging PET 6   (range  4  –  172) 
            Restaging EUS 10 (range  6  –  196) 
  
Distribution of initial N2-disease  
            4L 12 
            7 12 
            4L + 7 2 
            8 1 
            5 1 
  
Table 1 
Patient characteristics (28 patients) 
NSCLC, non-small cell lung cancer, no histologic classification available at initial analysis 
Cb/Pac, carboplatin AUC 6  day 1 + paclitaxel 175 mg/m2 day 1; G/C, gemcitabin 1250 mg/m2 day 
1,8 + cisplatin 80 mg/m2 day 1; 
 
C/D, cisplatin 20 mg/m2 day 1 + docetaxel 20 mg/m2 day 1; Gy,Gray;  
EUS, endoscopic ultrasound; PET, positron emission tomography. 
20
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EUS-FNA of mediastinal nodes at restaging. 
During restaging a median number of 2 (range 1-3) nodal sites were approached with 
EUS-FNA. There were no complications of EUS-FNA procedures. Particularly, pain 
during the procedure was not mentioned by the patients. Fifteen out of 28 patients 
had a restaging EUS-FNA that showed no tumor cells in the mediastinal lymph nodes 
and in one patient pathology was not conclusive. In the other patients tumor cells 
were present. A thoracotomy was performed in 13 out of the 15 down-staged  
patients and in the patient with inconclusive pathologic results. Two patients who 
were down-staged were ultimately considered not operable. One patient because of 
a necrotizing reaction in the radiated tumor with probable secondary infection 
(recovering well after antibiotics) and the other patient was not operable due to 
insufficient pulmonary function tests. In one down-staged patient a left-sided 
pneumonectomy was performed but a lymph node dissection was omitted The 
predictive value of a negative restaging EUS for negative findings at surgical 
evaluation of resected nodes was 91.6 %.  
One patient had a lobectomy of the left lower lobe in spite of a tumor-positive 
restaging EUS-FNA but an almost complete diminished FDG-uptake. However, 
pathology confirmed small number of tumor cells in a mediastinal lymph node. The 
accuracy of EUS-FNA in restaging was 92.3%. 
 
FDG-PET response in mediastinal nodes at restaging. 
Table 2 shows the results of nodal restaging with FDG-PET. There were 7 patients 
with a complete metabolic response (CMR). Two of these patients had persistent 
nodal disease at restaging EUS and so were not operated according to the protocol. 
Four patients had pathologic down-staging confirmed with surgery. For one patient 
with a CMR there was no surgical verification of the nodal status because a lymph 
node resection was not performed during thoracotomy. 
Eighteen patients showed a partial metabolic response (PMR) of nodal disease with 
FDG activity decreases ranging from 26% to 98%. 
In this group 7 patients were tumor positive with EUS-FNA and their FDG activity 
decrease was between 42% and 98%. One patient was operated although the EUS-
FNA revealed persistant nodal disease and the nodal status was verified during 
operation. 
In 7 patients with PMR of the nodes, down-staging was confirmed with surgery. One 
patient had persistent nodal disease although the EUS-FNA showed no tumour 
anymore. For 2 patients PMR could not be verified. One patient had a bad general 
condition due to infection in a necrotic irradiated lung and one patient was in good 
condition but had insufficient pulmonary function tests. 
Two patients showed stable metabolic disease (SMD) matching persistent metastatic 
nodal disease with restaging EUS-FNA. Two patients had progressive metabolic 
disease (PMD). In one of them a thoracotomy confirmed pathologic down-staging as 
was suggested by EUS-FNA results. One patient demonstrated persistent nodal 
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1 4L Negative 103 CMR Pneumonectomy L NA 
2 7 Positive 76 PMR RT NA 
3 7 Negative -69 PMD Pneumonectomy L Negative 
4 7 Positive 98 PMR Lobectomy LLL Positive 
5 4L Positive 76 PMR CTRT NA 
6 5 Negative 26 PMR Lobectomy LUL Negative 
7 8 Negative 103 CMR Lobectomy LUL Negative 
8 7 Negative 95 PMR Pneumonectomy R Negative 
9 4L + 7 Positive -73 PMD None NA 
10 4L Inconclusive 90 PMR Pneumonectomy L Negative 
11 4L Negative 200 CMR Pneumonectomy L Negative 
12 4L + 7 Negative 91 PMR Pneumonectomy L Negative 
13 4L Negative 94 PMR Antibiotics NA 
14 7 Positive 3 SMD CTRT NA 
15 4L Positive -1 SMD WBRT  NA 
16 7 Negative 110 CMR Bilobectomy Negative 
17 4L Negative 89 PMR Lobectomy LLL Negative 
18 4L Negative 91 PMR Pneumonectomy L Negative 
19 4L Positive 74 PMR CT NA 
20 7 Positive 72 PMR Thoracic RT  NA 
21 7 Negative 108 CMR Pneumonectomy R Negative 
22 7 Negative 97 PMR None NA 
23 4L Negative 40 PMR Nodal dissection* Positive 
24 4L Positive 113 CMR Immunotherapy  NA 
25 7 Positive 78 PMR Immunotherapy NA 
26 7 Positive 113 CMR RT metastasis NA 
27 4L Positive 42 PMR None NA 
28 7 Negative 98 PMR Pneumonectomy L Negative 
 
Table 2 
Results of restaging evaluation and surgery of nodal disease 
CMR, complete metabolic response; PMR, partial metabolic response; PMD, progressive metabolic 
disease; SMD, stable metabolic disease; L, left side; R, right side; LLL, left lower lobe; LUL, left 
upper lobe; NA, not available; WBRT, whole brain radiotherapy; CTRT, concurrent chemo-
radiotherapy; CT, chemotherapy; EUS, endoscopic ultrasound; PET, positron emission tomography 
* Patient had a local mediastinal recurrence 2 years after a lobectomy left lower lobe 
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Relationship between pathologic and metabolic down-staging    
The relationship between pathologic down-staging and metabolic downstaging is 
shown in table 3. 
As all but one of the 12 patients with positive EUS-FNA at restaging were not 
operated according to protocol, verification of the metabolic results was not possible.  
In this group of cytologically non-down-staged patients, metabolic down-staging was 
observed in 9 subjects. One patient was operated although restaging EUS-FNA 
revealed persistent nodal disease. The decision for this was influenced by the 
convincing (partial) metabolic response this patient showed, Surgery verified the 
absence of pathologic down-staging.  
In 3 out of 14 patients with surgically verified restaging, the FDG-PET scan did not 










FDG-PET response in the primary tumor.  
The decrease in metabolic activity in the primary tumor in relation to the pathologic 
findings at surgery is demonstrated in table 4. One patient without metabolic down-
staging of the primary tumor was operated and pathologic analysis revealed vital 
tumor. Eleven patients treated with surgery showed decreases in metabolic rate 
regarded as PMR. In this group 6 patients showed a complete pathologic response 
(including one necrotizing tumour) and 5 still had vital cancer tissue in the resected 
specimen. 
There was one patient with a CMR who still had vital tissue in the resected specimen 





   
 No metabolic down-staging 
by PET (PMD and SMD) 
Metabolic down-staging  
by PET (CMR and PMR) 





(no vital tumor cells) 
1 15* 
   
Table 3 
Relation between down-staging with EUS-FNA and   FDG-PET 
EUS-FNA, endoscopic ultrasound-fine needle aspiration; FDG-PET, 18F-fluorodeoxyglucose- positron 
emission tomography; PMD, progressive metabolic disease; SMD, stable metabolic disease; CMR, 
complete metabolic response; PMR, partial metabolic response. 
* One patient had inconclusive cytology and a PMR of the mediastinal nodes. 
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Relationship between metabolic responses in primary tumor and lymph nodes 
When metabolic responses are devided in metabolic down-staging (CMR+PMR) and 
metabolic non-down-staging (SMD+PMD), the metabolic staging results matched for 
nodal disease and primary tumour in 24 patients. In 3 patients, the metabolic staging 
results did not match and for one patient the relation can not be studied because the 
primary tumour was resected 2 years before. 
 
Metabolic response in relation to treatment 
In 6 patients treated with chemotherapy, PMR was observed in the nodes of 5 
patients and SMD in 1 patient (metabolic downstaging in 83%). In 22 patients treated 
with chemo-radiotherapy there were 12 patients with PMR and 7 with CMR in the 
lymph nodes (86% with metabolic downstaging). 
The metabolic responses after chemotherapy in the primary tumor were classified as 
PMR in 4 patients, PMD in 1 patient and SMD in 1 patient ( metabolic downstaging in 
67% ). The metabolic response in 21 primary tumors treated with chemo-
radiotherapy were classified as PMR in 16 patients, CMR in 2 patients, PMD in 2 












     
1 96 PMR Pneumonectomy L CR 
3 73 PMR Pneumonectomy L CR 
4 99 PMR Lobectomy LLL Vital tumor + N2 metastasis ( N8/9 ) 
6 14 SMD Lobectomy LUL Vital tumor + N1 metastasis 
7 74 PMR Lobectomy LUL Vital tumor + N1 metastasis 
8 87 PMR Pneumonectomy R Vital tumor; no node metastasis 
10 85 PMR Pneumonectomy L CR 
11 86 PMR Pneumonectomy L Necrotizing tumor; no node metastasis 
12 48 PMR Pneumonectomy L Vital tumor + N1 metastasis 
16 77 PMR Bilobectomy R Vital tumor 
17 101 CMR Lobectomy LLL CR 
18 101 CMR Pneumonectomy L Vital tumor; no node metastasis 
21 93 PMR Pneumonectomy R CR 
28 97 PMR Pneumonectomy L CR 
     
FDG-PET, 18F-fluorodeoxyglucose- positron emission tomography; PMR, partial metabolic response; SMD, 
stable metabolic disease; CMR, complete metabolic response; CR, complete pathological response 
Table 4  
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patients and SMD in 1 patient ( metabolic downstaging in 86%). One patient had a 
resection of the primary tumor two years before. 
 
Follow up  
In figures 1 and 2, Kaplan Meier curves show overall survival and progression free 
survival respectively for down-staged patients and patients with persistent nodal 
disease . The down-staged patients had a median follow up time of 11.1.months 
(range 1.6 – 32.6.months). The patients with persistent nodal disease had a median 


























Figure 1. Kaplan-Meier curve of overall survival for patients with stage III non-small 
cell lung cancer after treatment with chemo(radio)therapy. 
Patients with or without down-staging at repeated endoscopic ultrasound guided fine-
needle aspirations or surgical exploration of mediastinal lymph node metastasis are 
depicted. (P=0.049). Follow-up time not downstaged (days) = 139(76-978); follow-up 













































Figure 2. Kaplan-Meier curve of recurrence free survival for patients with stage III 
non-small cell lung cancer after treatment with chemo(radio)therapy. 
Patients with or without down-staging at repeated endoscopic ultrasound guided fine-
needle aspirations or surgical exploration of mediastinal lymph node metastasis are 
depicted. (P<0.0002). Follow-up time not downstaged (days) = 126(31-886); follow-







In the group of 13 down-staged patients with surgical confirmation, 2 patients died. 
One suffered a post-pneumectomy syndrome after a right sided pneumonectomy and 
the other died of a pneumonia 3 months after a left pneumonectomy. Ten patients 
are alive without signs of tumor activity and one patient had a local recurrence. The 
two down-staged patient who were not operated did not show local recurrence or 
metastatic disease for 3 and 24 months after treatment. 
In the only patient operated in spite of a positive restaging EUS-FNA, a local 
recurrence was detected after 29 months of follow up. Of the remaining 11 patients 
with a positive restaging EUS-FNA, 7 developed metastatic disease and 1 developed 
local recurrence during follow up.  
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Endoscopic ultrasound-guided fine needle aspiration ( EUS-FNA ) is a mediastinal  
staging modality that has been developed in the last decade. High sensitivities and 
specificities have been reported in a large number of studies and in a recently  
reported meta-analysis[16]. Since resolution of ultrasound techniques is high and fine 
needle aspirations are performed in real-time, EUS and EBUS or combinations of 
both with FNA have higher diagnostic accuracies than blind TBNA and PET-CT. 
Therefore they will become the preferred restaging tool in near future.  
There are only two studies that compared pathologic findings in material obtained 
with EUS or EBUS  with changes in FDG uptake in restaging NSCLC patients after 
induction chemoradiotherapy[10, 11]. In one study patients restaged with TBNA after 
induction chemoradiotherapy showed false-positive PET-CT results in 5 out of 11 
patients. All five patients with a positive TBNA had a positive PET-CT result and the 
two negative PET-CT scans were truly negative[11]. A study in 93 patients 
demonstrated a diagnostic accuracy of PET-CT at restaging of 92% for stage 0 and 
89% for stage I but only 69% for persistent stage III disease[10].  
The predictive value of downstaging after induction therapy for stage III nodal 
disease is generally recognized. Patients are selected for surgical treatment based 
on restaging results although the role of surgery in stage III NSCLC after 
chemoradiotherapy is still under debate. Evaluation exclusively on PET-CT imaging 
is not reliable enough for evaluation of the mediastinum, therefore pathologic 
confirmation is warranted[9].  
Once a mediastinoscopy is performed during the initial diagnostic analysis, a 
remediastinoscopy should not be performed[8][3]. At the initial staging endoscopy is 
the procedure of choice in case a restaging after induction therapy is planned. 
Our study confirmed that restaging with EUS-FNA after induction chemotherapy or 
chemoradiotherapy is feasible. Twenty-two of the studied patients underwent EUS-
FNA after induction with concurrent chemoradiotherapy. There were no 
complications and no significant complaints of pain although most patients suffered 
various grades of radiation esophagitis.  
This study demonstrated that a negative EUS-FNA at restaging predicted down-
staging very well. In only one of the 14 patients with surgical confirmation of the N 
status the EUS-FNA result at restaging was false negative. A negative predictive 
value of 91.6% and a diagnostic accuracy of 92.3% were calculated. 
A recent study on 124 patients treated with induction chemotherapy– not 
chemoradiotherapy - for stage IIIA nodal disease reported that EBUS-TBNA is a 
sensitive, specific, accurate, and minimally invasive test for mediastinal restaging of 
patients with NSCLC. However, because of the low negative predictive value, tumor-
negative findings should be confirmed by surgical staging before thoracotomy. Our 
results on EUS-FNA are in line with EBUS-FNA with the exception of our high 
negative predictive value of 91.6%. False negative findings are a result of the 
vanishing vital tumor mass. Nests of vital tumor cells remain which can be missed by 
passes of fine needle aspirations. EUS-FNA seem to perform better in restaging after 
chemo-radiotherapy than blind and ultrasound guided TBNA’s.  
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The bigger tumor samples obtained with EUS-FNA or the lower pretest probability of 
residual tumor in the mediastinal nodes may be an explaination for this observation  
The patients undergo EUS very easy and in a quiet setting. Nodes can be identified 
very accurate due to obvious anatomical landmarks and a non-moving patient. To 
minimize the chance of missing vital tumor parts in nodal tissue, we try to pass the 
needle under suction at least four times per site and in different directions in the 
node. However, in some cases the initially positive nodes disappeared completely or 
turned out to be haze, hardly recognizable structures. In three cases the lymph 
nodes were rubbery structures and hard to biopsy.  
During EBUS the patients are coughing and are restless even with midazolam. The 
US image is moving accordingly. The patients are generally too restless to sustain a 
long procedure with many biopsies at different sites. Orientation is more difficult 
because of less evident landmark structures. These characteristics may account for 
the worse perfomance of EBUS in restaging studies. 
FDG-PET was performed in every patient before start of treatment and again at the 
end of induction treatment at the same time as restaging EUS. Metabolic down-
staging in 75% of patients with persistent nodal disease at restaging EUS-FNA was 
seen (table 3). When EORTC  criteria for metabolic response are used, pathologic 
verification is required. The criteria,as proposed by the EORTC for stable or 
progressive metabolic disease (defined as a decrease of less than 25% or an 
increase in FDG uptake), predicted the post-treatment lymph node state better but 
still require pathologic confirmation. 
Based on receiver operating characteristic (ROC) curves, the optimal time to perform 
a repeat PET-scan to predict the pathologic stage after chemo-radiotherapy, is about 
1 month. This conclusion was derived from a retrospective analysis of 93 patients 
who received at least 60Gy of radiotherapy[20]. In our study the interval between end 
of treatment and restaging PET-scan was much shorter (median of 6 days) which 
might have influenced the accuracy. Our timing derived from a treatment strategy 
proposed for the most early patients in the study. These patients were treated with 45 
Gy of concurrent chemo-radiotherapy. After restaging, the patients were operated 
when they were down-staged but proceeded with radiotherapy until 66Gy in case 
they had persistent nodal disease. To minimize the interruption of radiotherapy, the 
restaging tests were performed immediately after chemoradiotherapy. During the 
study the treatment strategy was changed and patients were offered 66 Gy of 
radiotherapy in a concurrent setting. At the end of treatment the patient were 
restaged with the same short interval as the former patients. 
Based on recent information, nowadays patients undergo restaging investigations 
with an interval of 1 month. 
A study reporting on the performance of repeated PET-scans after neoadjuvant 
chemo-radiotherapy, showed that a decrease of 50% of the maximum standardized 
uptake value (SUV) in the nodes was highly likely for down-staging with a likelyhood 
ratio of 7.9[10]. 
In this study, 21 patients showed a decrease of FDG-uptake in the nodes of at least 
50% but two thirds had no pathologic down-staging.  
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In our series there was just 1 patient without metabolic down-staging in the lymph 
node who had pathologic down-staging with EUS-FNA, verified by surgery. Local 
inflammatory reactions to radiotherapy in and surrounding the tumor can account for 
increased FDG uptake. This effect can influence data of respons when restaging 
PET-CT is performed shortly after radiotherapy as in this study. Regarding the 
decreases of FDG uptake in the nodal metastases for down-staged as well as non-
down-staged patients in our series, this effect seems to have little influence. The 
metabolic response in the nodes overestimates the pathologic response in this study. 
Whether surgery should be the consequence of mediastinal down-staging after 
induction treatment with chemo-radiotherapy is still controversial. As demonstrated in 
table 4,in just over half the number of cases remnants of vital tissue, recognizable as 
tumor tissue, were seen in the primary tumor and hilar lymph nodes. These remnants 
could still represent vital tumor parts able to grow out to local recurrences or dying 
tumor cells on their way to necrosis and disappearance.  
Decreases of maximum SUV in repeated PET-CT scans can predict the effects of 
chemo-radiotherapy on the primary tumor. It is highly likely that a patient has a 
complete pathological response when the maximum SUV decreases by at least 75% 
or a partial response ( nodal downstaging but no complete pathological response) 
when the maximum SUV decreased 55% or more[10]. 
In this study 6 patients had a complete pathological response of the primary tumor  
and in 5 of them the FDG uptake decreased by more than 75%. There was 1 patient 
with a decrease of 73% of FDG uptake and a complete pathological remission..  
In two thirds of patients with a partial pathologic response, the decrease of FDG 
uptake was more than 55%. The decreases in FDG uptake in these primary tumours 
varied even from 74% to 101%.  
It seems that treatment affects the extend of the metabolic response. Although the 
metabolic responses in the lymph nodes were comparable in patients treated with 
chemotherapy and chemo-radiotherapy, complete metabolic responses were only 
observed in the chemo-radiotherapy group. Metabolic downstaging of the primary 
tumor was observed more often in patients treated with chemo-radiotherapy and 
complete metabolic responses were only observed in the patients treated with 
chemo-radiotherapy. These observations might reflect the more aggressive local 
approach with chemo-radiotherapy. 
Based on metabolic data it is impossible to discriminate between complete pathologic 
remission or persisting vital parts in the primary tumor. Decisions of surgery or not 
can not be safely made on decreases in FDG uptake.  
The effects of the short interval between last radiotherapy dose and restaging PET-
CT as in this study seem to be limited .High decreases of FDG uptake were observed 
in the patients with a complete pathologic response as well as in the patients with a 
partial pathologic response . 
Studies have demonstated that tumor progression is more likely to happen at distant 
sites than locally[3, 5, 6]. For this moment it is still not proven that the more 
aggressive additional local therapy, as surgery is, will improve survival rate. 
The prognostic significance of nodal down-staging is illustrated in this study. The 
overall survival curve of the downstaged patients shows an initial drop caused by 
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postoperative mortality. The divergence of the curves of down-staged patients versus 
patients with persistent nodal disease is obvious but the follow up is still very short. 
The right sided paratracheal nodes can not be reached with EUS. This part of the 
mediastinum could be covered by EBUS. A study on the accuracy of EBUS as 
restaging tool after only induction chemotherapy reported a very low negative 
predictive value of 20%[14] and studies with EBUS-TBNA after induction chemo-
radiotherapy have to be awaited. It can be expected that EBUS-TBNA will be 
superior in this respect in comparison to blind TBNA as was demonstrated in patients 




In conclusion, EUS-FNA is very well tolerated in patients treated with induction 
chemo-(radio)therapy and negative cytologic results predict down-staging very well. 
The value of PET scanning in restaging is limited because metabolic responses 
scored with EORTC criteria do need pathologic confirmation. 
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INTRODUCTION 
 
In the workup of infectious spondylodiscitis (ISD), blood cultures and computed 
tomography (CT)-guided biopsies or open biopsies are performed to verify the 
diagnosis and isolate pathogenic microorganisms. Herein we report the use of 





A 64-year old man was analysed for fatigue, weight loss and back pain between his 
shoulders. He had no fever. He had a history of myocardial infarction one year before 
followed by 2 percutaneous transluminal angioplasty procedures 1 year and 5 
months before disease symptoms. Blood chemistry showed an elevated C-reactive 
protein (CRP) of 64 mg/L but no other abnormalities. 
A CT scan, ordered to rule out pulmonary embolism, showed no pulmonary embolus 
but a prevertebral mass with destruction of the ventral part of the endplates 
diagnostic for spondylodiscitis (Fig. 1).  
EUS-FNA showed an active inflammation with necrosis but no malignancy. 
Microbiological culture showed Staphylococcus aureus (S.aureus) susceptible to 
methicillin and flucloxacillin. 
The patient recovered after 6 weeks of intravenous flucloxacillin. 
 
  
Figure 1: The left panel shows a sagittal scan demonstrating classical extensive 
destruction of the ventral part of the endplates. A prevertebral mass that 
extended from Th4 up to Th7 is continuous with the intervertebral disc 
space at the level of Th5-Th6. The right panel shows an axial scan of 
the prevertebral mass. 
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Patient 2 
A 76-year old man had 3 acute admissions in 4 weeks for heart failure with atrial 
fibrillation. He had a history of chronic obstructive pulmonary disease (COPD) and 
longer existing back pain. There was no fever, physical examination was 
unremarkable. During the last admission an elevated CRP of 262 mg/L was noted for 
the first time. Abnormalities on standard chest radiography were suspect for 
malignancy. A CT of the chest without contrast (due to diminished renal function) 
revealed a prevertebral mass (Fig. 2). 
The aspirate obtained with EUS-FNA had a purulent aspect, with abundant grape-like 
cocci at cytology. Culture confirmed S. aureus susceptible to methicillin, penicilline, 
amoxicillin, and clindamycin. 
The patient recovered with amoxicillin administered intravenously for 2 weeks and 
subsequently clindamycin orally for 4 weeks. Endocarditis or skin infections were 
excluded as possible source of haematogenous spread. During treatment a 
persisting elevated erythrocyte sedimentation rate was analysed resulting in the 





Figure 2:  A sagittal scan shows a prevertebral mass. Note the preservation of the 
posterior elements, including facet joints, lamina, and spinous process 
in both cases. The mainly right-sided prevertebral mass is shown on an 
axial scan on the lower panel. The mass is in close contact with the 
collapsed and eroded vertebra Th8. There is a small region of ventrally 
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COMMENTS 
 
We have encountered 2 patients in whom ISD was diagnosed with needle aspiration 
under EUS guidance. 
ISD is an infection of the intervertebral disc space often with involvement of the 
adjacent vertebral bodies. The incidence is low and estimated at 2.4 per 100,000 
inhabitants and increases with age. The thoracic spine is affected in 30% of patients 
and the lumbar spine in 60%. 
The clinical course is often insidious with back pain as a predominant symptom. 
Fever is not always present and biochemical tests are non-specific [1]. Both our 
patients had no fever and were in fact referred because of a suspicion for 
malignancy. 
Hematogenous spread of bacteria from infections elsewhere in the body is the main 
cause of ISD. Sometimes ISD is a complication of local invasive spinal procedures or 
contiguous spread from adjacent tissue infection. In patient 1 probably repeated 
angiographic interventions initiated infection. The risk for developing ISD is affected 
by predisposing underlying conditions like diabetes, alcoholism or human 
immunodeficiency virus. The bad general condition and immune compromised state 
(multiple myeloma) of patient 2 possibly facilitated the development of ISD.  
The most sensitive and specific imaging test for spondylodiscitis is magnetic 
resonance imaging (MRI). T1-weighted images show narrowing of the disc space 
and low signals consistent with edema in the marrow of adjacent vertebral bodies. 
T2-weighted images show increased signals in both the disc space and the 
surrounding vertebral bodies. MRI is very useful in helping distinguish between 
tuberculous and pyogenic causes and neoplasia. Use of CT scanning adds to MRI, 
as it better discriminates between bone and soft tissue than MRI[2]. 
Although imaging helps in the differential diagnosis and is essential for localising the 
source of infection, verification of the primary process should be performed with 
biopsy and microbiological cultures. A microbiological diagnosis can be made with 
blood cultures (positive in about half the patients), CT-guided percutaneous biopsies 
are performed when blood cultures remain negative or when tuberculosis or 
malignancy is suspected. Positive cultures with known bacteria are identified in 60-
70% of patients with ISD. As in both our patients, S. aureus, is the most common 
causative microorganism accounting for 15-84% of non-tuberculous cases[3]. If 
repeated percutaneous biopsies do not provide a diagnosis or when the infection is 
not accessible with a percutaneous approach, a diagnostic yield of 75% is achievable 
with an open (surgical) procedure. 
Next to CT-guided biopsies EUS-FNA provides a more simple, quick and easy to 
perform procedure to obtain biopsies under direct vision. If lesions are in the vicinity 
of the esophagus, they can be located with a linear ultrasound device mounted at the 
top of an endoscope. Biopsy samples or needle aspirations can be derived via the 
working channel [4].  
This is the first report of two cases of ISD diagnosed by EUS-FNA with identification 
of pathogens. A former case report described EUS-FNA of a paraspinal abscess at 
the level of C7 and Th1 but no microorganisms were isolated [5].  
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Although one could argue that the isolated S. aureus strains are due to 
contamination derived from the passage through the throat and esophagus, we think 
this is very unlikely. First, the high number of colony forming units of S. aureus 
isolated from the samples outnumbering the normal contaminating flora is highly 
indicative for infection. Furthermore, the direct Gram stains of both aspirates showed 
Gram-positive cocci. Because of the low sensitivity of the Gram stain one would not 
expect to find abundant Gram positive cocci in case of contamination.   
EUS-FNA is very safe and easy to perform and offers the opportunity to approach 
vertebral infections from anterior. After cytologic exclusion of malignant causes and 
isolation of pathogenic microorganisms, an adequate antimicrobial therapy can be 
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Chapter 4 
 
Esophageal fistula after EUS-FNA in a patient treated with Bevacizumab for 
Non-small Cell Lung Cancer. 
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A 54-years old female patient is presented with a T1aN3M1b, EGFR wild type 
adenocarcinoma originating in the right lung.  
The patient was treated with 4 courses of carboplatin and paclitaxel combined with 
bevacizumab (15 mg/kg) followed by maintenance bevacizumab. 
A partial remission was observed, persisting until after 2 courses of maintenance 
bevacizumab . At that moment patient exhibited a skin metastasis but target lesions 
showed no progression and bevacizumab was continued. Since there was doubt if 
the skin metastasis should be regarded as disease progression, further treatment 
strategies were considered.  
To exclude the presence of an EML-ALK gene reallocation, new samples were 
required as the original cell blocks were used up. A paraesophageal metastasis as 
easiest accessible lesion was approached with endoscopic ultrasound (EUS) guided 
FNA. 
A 3rd and 4th bevacizumab course were administered 13 days before, respectively 8 
days after EUS. Four weeks after EUS, a CT scan showed a new liver metastasis 
and increase of brain metastases indicating disease progression. Also a small air 
configuration in the sampled node was perceived.  
In the meanwhile, the patient experienced mild, but gradually progressive retrosternal 
dyscomfort. Blood chemistry showed elevated C-reactive protein (CRP) of 284 mg/L. 
A CT scan (8 weeks after EUS), showed enlargement of the air space in the 
paraesophageal region. At esophagoscopy, an impression was observed with 2 
elongated fissures covered with blood clots. At inspiration, air bubbles escaped from 
the fissures.  
Tube feeding and antibiotics resulted in clinical and biochemical improvement of the 
patient. 
A final CT scan (10 weeks after EUS), showed a progressive air space originating 
from the paraesophageal mass with access to the esophageal lumen (figure 3). 
 
In this patient, a fistula developed between a necrotizing mediastinal mass and the 
esophagus within 4 weeks after EUS while on bevacizumab treatment. Although 
cavitating mediastinal nodes were not described in particular previously, formation of 
bronchoesophageal fistula after bevacizumab was reported before, especially in 
patients pretreated with (chemo)radiotherapy[1, 2]. 
In this case there seems a relation between fistula formation and EUS. The high 
CRP, normalizing during antibiotic treatment, suggests an infectious component.  
Normally EUS-FNA is a safe technique but infectious mediastinitis in necrotic lymph 
nodes, resulting in cavitation, was reported previously[3]. 
In our patient, optimal circumstances for fistula formation were created in the 
aspirated node by pretreatment with bevacizumab. Repeated needle passes in 
necrotic tissue caused longitudinal fissures. Delayed wound-healing and secondary 
infection resulted in fistula formation finally. 
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EUS-FNA is therefore not recommended in patients on treatment with bevacizumab. 
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Figure  
Computed tomography (CT) images 
showing a solid right paraesophageal 
lymph node metastasis after treatment 
with 6 courses of bevacizumab and 15 
days before endoscopic ultrasound- 
guided fine needle aspirations (EUS- 
FNA) (panel A). 
  
The same node 10 weeks after EUS- 
FNA and after 8 courses of  
bevacizumab showing extensive  
cavitation and a breakthrough to the 
esophageal lumen (panel B). 
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Chapter 5 
 
Percutaneous Ultrasound-Guided biopsies in the evaluation of Thoracic 
Tumours after PET-CT 
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Lesions detected by PET-CT during the analysis of thoracic tumours are often 
impalpable at physical examination and subsequent ultrasound (US) may aid in 
finding these lesions for pathologic evaluation. 
Objectives 
The success rate of percutaneous US-guided biopsies of palpable and non-palpable 
lesions and the impact on tumour stage was studied prospectively. 
Methods. 
Lesions, significant for diagnosis and disease stage, with metabolic activity on PET-
CT and presumed appropriate for percutaneous approach under ultrasound guidance 
were selected for cytologic aspiration or tissue core biopsies.  
Results 
In 127 patients 134 lesions (subdivided in 24 local thoracic, 74 supraclavicular and 
36 distant metastatic lesions) were biopsied percutaneously under ultrasound 
guidance. Malignancy, benign disease and inadequate biopsies were found in 
80%(106/134), 14%(19/134) and 7%(9/134) respectively.  
In 55%(56/102) of patients, biopsies confirmed disease stage. 
Fifty-one percent (18/35) of distant lesions and 54%(43/68) of supraclavicular lesions 
were impalpable on physical examination.  
Conclusions 
US guided biopsies in patients with suspected thoracic malignancy on PET-CT 
provides an excellent tool for obtaining a pathological diagnosis, leading to a 


























2-Fluoro-2-deoxy-D-glucose  positron emission tomography (FDG-PET) integrated 
with computed tomography (CT) provides both anatomic and metabolic information, 
making it an extremely important tool in characterizing both local thoracic as well as 
metastatic disease. It has been demonstrated to have a higher diagnostic accuracy 
than PET or CT alone[1-4]. Therefore it can be considered the most important 
imaging tool in the analysis of thoracic tumors. Nevertheless, due to the low 
specificity of PET, pathological confirmation is necessary to establish a definitive 
diagnosis and/or to provide a tumor stage [5]. 
While a careful physical examination is considered standard of care, metastatic 
lesions are often missed and discovered only on PET. The visualization of both 
palpable and non palpable lesions by ultrasound (US) allows for real-time biopsy. 
This technique enables safe pathologic sampling with fine needle aspiration (FNA) or 
tissue core biopsies (TCB) of thoracic tumors in contact with the thoracic cage but 
also supraclavicular metastatic disease and various sites of distant metastatic 
disease.  
Pulmonologists in Europe have become increasingly familiar with US imaging as 
endoscopic ultrasound (EUS) and endobronchial ultrasound (EBUS) are nowadays 
established procedures in the diagnosis and staging of lung cancer. Although US 
guided percutaneous biopsy and aspiration in the diagnosis of pleural disease are 
broadly practised by pulmonologists, the technique is seldom applied to other 
thoracic indications. A recent guideline of the American College of Chest Physicians 
(ACCP) recommends confirmation of a suspected lung cancer by obtaining tumour 
cells or tissue with FNA or biopsy if feasible[6]. If pulmonologists become proficient in 
US guided biopsy they can expand their role in lung cancer diagnosis and staging..  
This study is a prospective analysis of the value of percutaneous US guided FNA and 
TCB in patients with PET-CT suspected thoracic neoplasms as performed by 
pulmonologists. The evaluating and procedural pulmonologist determined the lesions 
to be sampled based on their accessibility and visibility by US guided biopsy and 
their importance in diagnosis and/or staging. It was hypothesized that US accessible 
lesions (no matter if palpable or not) detected on PET-CT will provide a definitive 
pathological diagnosis and pathological proof of disease stage.  
 
PATIENTS AND METHODS 
 
Study population 
Patients that were selected for US guided sampling all had undergone PET-CT scans 
for suspected thoracic tumours. Selection was discussed in meetings of nuclear 
physician and pulmonologist and was based on PET-CT results. 
The lesions observed on PET-CT, that were approached for pathologic US guided 
sampling, had to fulfill three criteria : 
First they were judged by a pulmonologist to be accessible by US guided FNA or 
biopsies (for instance adjacent to the thoracic wall or located in the supraclavicular or 
axillary region). 
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In the second place only lesions with increased FDG uptake were selected. 
In the third place the lesions had to be significant for tumour staging. Preferably the 
obtained material delivered a pathological diagnosis and stage verification at once. 
If PET-CT showed obvious and extensive metastatic disease there were occasional 
deviations from this principle. In these cases the easiest accessible lesions were 
approached (for example, some widespread metastasized stage IV tumours were 
diagnosed according to this strategy with supraclavicular aspirations). 
The diagnostic strategy was based on recommendations in the guidelines on the 
initial diagnosis of lung cancer of the ACCP.  
According to legal criteria for medical research our Institutional Review Board stated 
that approval was not necessary for this study. 
 
Methods 
PET-CT scans were performed on an integrated PET-CT scanner (GE Discovery ST 
PET-CT scanner; General Electric, Milwaukee, Wis).  
Percutaneous US guided FNA was performed by a pulmonologist with a Hitachi 
probe (EUP-C532) with a EZU-PA532 Hitachi Biopsy attachment and a Hitachi EUB-
5500 processor. TCB and FNA was obtained under direct vision. 
Needles used were Spinocan 0,9 x 88 mm / 20G x 8 cm for cytology. For histologic 
biopsies Bard core tissue biopsy needles 14G x 13 cm. were used with a Bard 
magnum biopsy instrument (figure 1). 
A local physical examination was performed, before the application of US, to 
determine if lesions were palpable or not. 
All biopsies and aspirations were performed under local anaesthesia of the skin with 
lidocaine 2%. For local thoracic tumours, specimen were preferentially obtained with 
core tissue biopsy needles for histologic analysis. Two or 3 core tissue biopsies were 
taken as a rule for histologic sampling. Supraclavicular and distant metastatic lesions 
were usually approached with FNA. Specimen obtained with FNA were smeared on 
slides for morphologic analysis and deposited in fixative for immunohistochemical 
staining in cases were subtyping was necessary. Two to 4 needle passes into each 
lesion were taken. There was no on-site evaluation of the samples by a pathologist. 
The numbers of adequate (enough tissue or material to make a diagnosis as 
assessed by a pathologist after microscopy) and inadequate biopsies (not enough 
tissue or material or not accessible tumour or lymph node by US) were counted. In 
case of inadequate aspirates or biopsies, CT guided biopsies, endoscopic biopsies or 
surgical procedures were performed. When these additional investigations had to be 
performed this was considered as a failure of the US procedure. In case such an 
approach was not feasible clinical follow-up data were available to substantiate the 
diagnosis. 
Stage categories as defined by the American Joint Committee on Cancer Staging 
(AJCC)[7] and the sixth edition of the Union Internationale Contre le Cancer 





  percutaneous ultrasonography 
  
 
Figure 1 Devices used for ultrasound guided aspirations and core tissue 
biopsies. Left panel : biopsy attachment with 20G needle mounted on 







Between March 2006 and May 2009 a total number of 127 patients out of 1056 
patients(12%) in whom PET-CT was performed to image suspected thoracic 
malignancies, were considered suitable for US guided biopsies.  
In these patients a total number of 134 lesions were approached for US guided 
biopsies (FNA, n=107; TCB, n=22; not detectable with US, n=5). In 5 patients US 
guided biopsies were performed on more than one lesion (one patient had 3 biopsies 
on different lesions and 4 patients had 2 biopsies on different lesions). Table 1 shows 
the distribution of FNA and TCB in the subcategories local thoracic, supraclavicular 
and distant lesions (distant lesions are metastatic lesions other than mediastinal or 
supraclavicular lesions). 
Successful US guided biopsies were performed in 93% of lesions (125/134).  
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Seven percent (9/134) of US guided biopsies were considered inadequate either 
because PET-CT observed lesions could not be detected by US (n=5) or biopsies 
contained inadequate material (n=4) (table 2).  
 
Palpation 
At physical examination (performed after PET-CT) palpation of lesions was recorded 
in 92%(68/74) of patients with supraclavicular lesions and 94%(34/36) of patients 
with distant lesions. Table 1 shows that 54% of examined supraclavicular and 51% of 
examined distant lesions were not palpable (as expected, local thoracic disease was 

















































































































US guided aspirations and biopsies from PET-CT observed lesions 
 
Figures in parentheses are percentages. 
  
US, ultrasound; PET-CT, positron emission tomography integrated with computed tomography; FNA, fine-
needle aspiration; TCB, tissue core biopsy; NA, not applicable 
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Malignancy by US guided biopsies 
Overall, malignancy was confirmed in 80% (106/134) of US guided biopsies in PET-
CT positive lesions with a predominant representation of NSCLC (51% (68/134)) as 
shown in table 3. Subtypes of NSCLC in FNA and TCB are shown in table 4.  In 3 
FNA and 1 TCB subtyping was not possible and in 2 FNA subtyping was not carried 
out because a histological diagnosis was already available. Local thoracic US guided 
biopsies were positive for malignancy in 71% (17/24) of lesions, supraclavicular US 
guided biopsies in 86% (64/74) of lesions and distant US guided biopsies in 69% 
(25/36) of lesions (table 2). Positive predictive values to find malignancy by US 
guided punctures in thoracic, supraclavicular and  distant lesions observed with PET-
CT were 77%, 90% and 69%, respectively.  
 
Benign disease  
Benign diagnoses were obtained in 14%(19/134) of PET-CT positive lesions. In 8% 
(2/24) of local thoracic lesions a benign diagnosis was derived. Supraclavicular US 
guided biopsies showed benign disease in 10%(7/74) of biopsied lesions and distant 
US guided biopsies showed benign disease in 28%(10/36) of lesions. Benign 









































































Pathologic results of US guided aspirations and biopsies from PET-CT observed lesions 
* Inadequate biopsies are failures to find PET-CT observed lesions by US and biopsies without 
adequate material  
as assessed by the pathologist. 
** Percentage of malignant lesions that determine the tumour stage. 
‡
 106 lesions containing malignant tissue were biopsied in 102 patients. In 4 patients, 2 malignant 
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The overall rate of inadequate US guided biopsies was 7% (9/134) as demonstated 
in table 2. Inadequate US guided biopsies were performed in 21%(5/24) of  local 
lesions. One patient had a clinical follow-up of local pleural broadening after 
pneumonectomy during 18 months without any sign of progression. Two lesions were 
biopsied subsequently by surgery ( 1 mesothelioma and 1 malignant lymphoma), 1 
lesion was biopsied under CT guidance (bronchoalveolar carcinoma). In 1 patient a  
thoracic tumour could not be detected with percutaneous US but a diagnosis was 
obtained by a US guided biopsy of the left adrenal gland (NSCLC).  
Inadequate US guided biopsies were performed in supraclavicular regions in 
4%(3/74) of lesions and in 3%(1/36) of distant lesions. During a median clinical follow 
up of 1 year (range 7-41 months) of the 3 supraclavicular non-successfully biopsied 





















NSCLC 7           45 16 
SCLC 0           13 2 
LCNEC 1            2 1 
Sarcoma 1            2 0 
Mesothelioma 5            0 1 
Non-pulmonary metastasis 1            1 0 
Malignant Lymphoma 0            1 5 
Thymoma 2            0 0 
Total 17           64 25 
Table 3 
Ultrasound guided aspirations and biopsies from 106 PET-CT observed lesions 
in 102 patients that lead to pathologically confirmed malignant diagnoses 
 












Staging of disease 
In 58%(61/106) of lesions with a malignant diagnosis, this result confirmed the 
tumour stage. For local thoracic malignant lesions, supraclavicular malignant lesions 
and distant malignant lesion these rates were 53%(9/17), 50%(32/64) and 
80%(20/25) respectively (table 2). 
       




    
Local thoracic lesions Adenocarcinoma 2 0 
Squamous cell ca. 2 1 
 Not differentiated 1 1 
    
 subtotal 5 2 
    
Supraclavicular lesions Adenocarcinoma 30 0 
Squamous cell ca. 11 0 
 Large cell carcinoma 1 0 
 Not differentiated 1 0 
 Not applicable* 2 0 
    
 subtotal 45 0 
    
Distant lesions Adenocarcinoma 10 2 
 Squamous cell ca. 3 0 
 Not differentiated 1 0 
    
 subtotal 14 2 
    
 total 64 4 
    
ca, carcinoma  
*  : 1 patient was known with a pulmonary adenocarcinoma 2 years before and in 
 1 patient bronchial biopsies already showed a primary adenocarcinoma 
Table 4  
Subtyping results of  NSCLC in fine-needle aspirations and tissue core biopsies based 
on morphologic and immunohistochemical analysis 
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A total number of 106 lesions with malignancy was found in 102 patients (2 different  
malignant lesions were biopsied in 4 patients). A pathological confirmation of tumour 
stage was achieved in 55%(56/102) of patients with malignancy. In 45%(46/102) of  
patients the biopsy provided a diagnosis but the lesions were not confirmative for 
disease stage. Ten percent of patients with malignancy (10/102) needed additional 
invasive investigations to confirm disease stage or subtyping of the tumour. The 
procedures were lymph node excisions and thoracoscopy by surgery (n=4) and EUS 
with histologic biopsies for immunohistochemical subtyping of malignant lymphomas 
(n=1), EBUS for mediastinal node metastasis (n=1) and 4 FNA’s (in left adrenal 
gland, in a coeliac and axillar lymph node, and a cutaneous metastasis, respectively).  
For the other 36 patients additional biopsies were not required. In 26 patients (25%), 
PET-CT showed obvious extensive metastatic disease, where confirmation of 
malignancy seemed not appropriate, 5 patients had mesothelioma, 4 patients had 
brain metastases, and for 1 patient the biopsy was obtained to differentiate between 
progression of two different recurrent malignant diseases. 
 
Complications 
There were 2 (1.5%) complications registered. Both occurred after tissue core 
biopsies of a local thoracic lesion. One of the histologic biopsies was complicated by 
a severe hemoptysis leading to intubation. One of the tissue core biopsies contained 
also spleen tissue on pathologic examination without adverse events after the biopsy. 



























Non-specific reactive lymph nodes 0 6 7 
Organizing pneumonia 2 0 2 
Whartin’s tumour 0 0 3 
Sarcoidosis 0 1 0 
Total 2 7 10 
Table 5 
Ultrasound guided aspirations and biopsies from PET-CT observed lesions that lead 
to pathologically confirmed benign diagnoses 
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This study shows that percutaneous US guided biopsies in the diagnosis and staging 
of thoracic tumours, have a high diagnostic success rate after localization with PET-
CT.  The quality and quantity of cytologic specimen allowed pathologists to specify 
subtypes of NSCLC in almost all patients. 
The high resolution of US for lesions within about 5 to 10 cm distance from the skin 
brings many lesions within the scope of US guided biopsies. For intrapulmonary 
lesions this may not be the case due to positional alterations by gravity when CT 
images in prone position are used to select lesions for US guided approach in supine 
position (figure 2). Other failures of US guided punctures were due to inaccurate 
interpretations of PET-CT like brown fatty tissue located at supraclavicular locations 
and inaccurate pathologic sampling. 
 
Thoracic lesions 
Although US is a relatively underused diagnostic modality, it provides an accurate 
localisation of chest abnormalities if not surrounded by aerated lung[9]. In this study, 
the most prominent reason for test failure in local thoracic disease was indeed the 
inability to image lesions through aerated lung by US. Former studies already 
demonstrated the benefit of US guided biopsies after CT imaging. Percutaneous 
biopsies of pulmonary, pleural or mediastinal lesions in contact with the chest wall 
under US guidance yielded a diagnosis in 90% of patients with a malignancy and in 
67% of patients with benign lesions in a study of 124 patients[10]. A high efficacy of 
US-guided biopsies  was reported in 31 out of 34 lesions in the analysis of thoracic 
tumours[11]. Recently a diagnostic yield of over 93% was reported in a single-
session sequential approach of mediastinal masses with US-assisted transthoracal 
FNA (with rapid on-site evaluation) eventually followed by TCB[12]. 
Even centrally located tumours with post-obstructive collapse or pneumonitis can be 
safely biopsied with deep passes and an acceptable diagnostic yield of 74%[13]. 
Evaluation of local thoracic disease with PET scans has the important advantage to  
discriminate between active metabolic diseases (inflammatory and malignant) and 
diseases without increased metabolic activity such as atelectasis, loculated fluid or 
scar tissue. Lesions without FDG uptake are probably benign and justify a wait and 
see attitude. Lung cancer is generally characterised by high FDG uptake but for 
assessment of the T-stage PET scans have limited value[14]. The variety of possible 
alternative diagnoses of PET-CT positive solitary thoracic tumours account for the 
need for tissue. This is demonstrated by the high number of benign and non-primarily 
pulmonary malignancies found in this study (11 out of 19 diagnoses).  
 
Supraclavicular lymph nodes 
Supraclavicular nodes are frequently involved in lung cancer and define stage IIIB 
disease. In this study we focused on PET-CT positive supraclavicular findings and 
demonstrated malignancy in the majority of patients suspected to have a thoracic 
neoplasm especially NSCLC. PET-CT has a diagnostic accuracy of 71% in detecting 
non-palpable supraclavicular lymph node metastasis as was demonstrated in a group 
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of 32 patients with NSCLC[15]. In our study accuracy was 85%. The sensitivity of 
palpation of supraclavicular node metastasis in lung cancer is significantly lower than 
with US or CT. This was illustrated by a study that demonstrated malignancy with US 
guided FNA in 8% of patients with suspected and potentially operable lung cancer 
without palpable lymph nodes[16]. A study of 117 patients analysed for lung cancer 
confirmed this low sensitivity of palpation compared to US or CT and demonstrated 
that only markedly enlarged metastases were palpable[17].  
In patients with proven N2 or N3 disease, enlarged but non-palpable supraclavicular 
lymph nodes (on CT) contained  metastatic disease in even 45.5% of patients[18]. 
This study confirms the added value of US in detecting enlarged but non-palpable 




Figure 2 Effect of body position on ultrasound visibility of an intrathoracic lesion. 
Example of problems encountered with the use of ultrasound. 
Left panel, patient in prone position. Lesion in dorsal left lung adjacent 
to thoracic wall. Right panel, same patient lying in supine position for 
biopsy. The lesion is no longer adjacent to thoracic wall and becomes 




Distant metastatic disease 
An  important feature of FDG-PET is the ability to detect distant metastatic disease. 
In about 8-10% of resectable patients with NSCLC and in 18% and 24% of stage II 
and III patients who were staged conventionally (with CT-scan, bone scans and 
ultrasonography), PET scan detected distant metastatic disease[19-21]. 
With US many metastatic sites can be reached percutaneously if lesions are not  
surrounded by air or covered by bony structures. The ability to visualise lesions is 
furthermore dependent on size of lesions, tissue characteristics and interfaces, 
distance to transducer and sensitivity of equipment.  
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In this study US guided biopsies were performed in axillary, retromandibular, 
retroauricular, intercostal, soft tissue, skin, and osseous lesions.   Half the patients 
(51%) had non-palpable lesions, the value of US guidance to obtain material for 
pathologic verification of PET-CT positive lesions is emphasized in this study.  
 
Staging with US guided biopsies. 
For more than half of the patients with malignancy in this study, the minimally 
invasive approach with an US approach confirmed diagnosis and disease stage at 
one time. Endoscopic investigations, often performed as a routine practice in the 
analysis of thoracic tumours, are generally considered unpleasant and can be 
omitted if percutaneous US guided biopsies confirms malignancy. 
Diagnostic tests to obtain pathologic specimen should be chosen with a minimal 
burden to the patient but with maintenance of high quality diagnostic 
characteristics[5]. US guided biopsies match these qualities as was demonstrated in 
this study.  
 
Palpation of lesions.  
A careful physical examination is one of the first parts of the diagnostic work up of 
patients with a suspected thoracic malignancy. In this study more than half the 
lesions were not palpable although the physician was aware of the results of the 
PET-CT. With the use of US guidance, the lesions could be detected and biopsied 
very effectively. On the contrary, when lesions are palpable, the use of ultrasound 
guidance diminishes the chance of inadequate biopsies in thyroid nodules when 
compared with palpation guided biopsies[22]. Therefore the use of ultrasound is 
recommended in both situations. 
 
Limitations 
Although the study is a prospective analysis of US guided biopsy results, there was 
no well-defined selection of patients according to protocol criteria. Patients were 
selected on clinical criteria that work sufficiently in daily practice but influence the 
outcome of results unequivocally. At the start of a new technique there is a tendency 
to select lesions with high pretest probability for successfull biopsies. When 
experience increases, biopsies of more difficult lesions will be attempted but will also 
lead to increasing failure rates.  
A criterion to select lesions for percutaneous US guided biopsies was uptake of FDG. 
Small lesions, which do not have enough tracer to be seen on PET-CT were not 




In conclusion this study demonstrates that US guided percutaneous biopsies 
increases the pathological outcome in the work up of thoracic tumours after PET-CT. 
PET-CT in combination with subsequent US guided biopsy provides a definitive 
diagnosis and tumour stage in the majority of patients and can be performed safely. 
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Percutaneous US guided biopsies expand the diagnostic capability of pulmonologists 





[1] Antoch G, Stattaus J, Nemat AT, et al. Non-Small Cell Lung Cancer: Dual-
Modality PET/CT in Preoperative Staging. Radiology 2003;229:526-33.  
[2] Cerfolio RJ, Ojha B, Bryant AS, Raghuveer V, Mountz JM, Bartolucci AA. The 
accuracy of integrated PET-CT compared with dedicated PET alone for the staging 
of patients with nonsmall cell lung cancer. Ann Thorac Surg 2004;78:1017-23.  
[3] Lardinois D, Weder W, Hany TF, et al. Staging of Non-Small-Cell Lung Cancer 
with Integrated Positron-Emission Tomography and Computed Tomography. N Engl 
J Med 2003;348:2500-7.  
[4] Shim SS, Lee KS, Kim BT, et al. Non-Small Cell Lung Cancer: Prospective 
Comparison of Integrated FDG PET/CT and CT Alone for Preoperative Staging. 
Radiology 2005;236:1011-9.  
[5] Silvestri GA, Gould MK, Margolis ML, et al. Noninvasive Staging of Non-small Cell 
Lung Cancer: ACCP Evidenced-Based Clinical Practice Guidelines (2nd Edition). 
Chest 2007;132:178S-201.  
[6] Rivera MP, Mehta AC. Initial Diagnosis of Lung Cancer: ACCP Evidence-Based 
Clinical Practice Guidelines (2nd Edition). Chest 2007;132:131S-148.  
[7] FL G, CC C, AG F, JP S, DP W, editors. American Joint Committee on Cancer 
Staging Atlas. 2006:167-76.  
[8] LH S, CL W, editors. UICC: TNM classification of malignant tumors, 6th ed. 2002.  
[9] Middleton WD, Teefey SA, Dahiya N. Ultrasound-guided chest biopsies. 
Ultrasound Q 2006;22:241-52.  
[10] Ikezoe J, Morimoto S, Arisawa J, Takashima S, Kozuka T, Nakahara K. 
Percutaneous biopsy of thoracic lesions: value of sonography for needle guidance. 
Am J Roentgenol 1990;154:1181-5.  
[11] Sheth S, Hamper UM, Stanley DB, Wheeler JH, Smith PA. US Guidance for 
Thoracic Biopsy: A Valuable Alternative to CT. Radiology 1999;210:721-6.  
[12] Koegelenberg CF, Diacon AH, Irusen EM, et al. The diagnostic yield and safety 
of ultrasound-assisted transthoracic biopsy of mediastinal masses. Respiration 
2011;81:134-41.  
56
  percutaneous ultrasonography 
  
[13] Koegelenberg CF, Bolliger CT, Irusen EM, et al. The diagnostic yield and safety 
of ultrasound-assisted transthoracic fine-needle aspiration of drowned lung. 
Respiration 2011;81:26-31.  
[14] Vansteenkiste J, Fischer BM, Dooms C, Mortensen J. Positron-emission 
tomography in prognostic and therapeutic assessment of lung cancer: systematic 
review. Lancet Oncol 2004;5:531-40.  
[15] Sung YM, Lee KS, Kim BT, et al. Nonpalpable Supraclavicular Lymph Nodes in 
Lung Cancer Patients: Preoperative Characterization with 18F-FDG PET/CT. Am J 
Roentgenol 2008;190:246-52.  
[16] Sihoe AD, Lee TW, Ahuja AT, Yim AP. Should cervical ultrasonography be a 
routine staging investigation for lung cancer patients with impalpable cervical lymph 
nodes? Eur J Cardiothorac Surg 2004;25:486-91.  
[17] van Overhagen H, Brakel K, Heijenbrok MW, et al. Metastases in 
Supraclavicular Lymph Nodes in Lung Cancer: Assessment with Palpation, US, and 
CT. Radiology 2004;232:75-80.  
[18] Kumaran M, Benamore RE, Vaidhyanath R, et al. Ultrasound guided cytological 
aspiration of supraclavicular lymph nodes in patients with suspected lung cancer. 
Thorax 2005;60:229-33.  
[19] MacManus MP, Hicks RJ, Matthews JP, et al. High rate of detection of 
unsuspected distant metastases by pet in apparent stage III non-small-cell lung 
cancer: implications for radical radiation therapy. Int J Radiat Oncol Biol Phys 
2001;50:287-93.  
[20] Pieterman RM, van Putten JWG, Meuzelaar JJ, et al. Preoperative Staging of 
Non-Small-Cell Lung Cancer with Positron-Emission Tomography. N Engl J Med 
2000;343:254-61.  
[21] Stroobants SG, D'Hoore I, Dooms C, et al. Additional value of whole-body 
fluorodeoxyglucose positron emission tomography in the detection of distant 
metastases of non-small-cell lung cancer. Clin Lung Cancer 2003;4:242-7.  
[22] Can AS, Peker K. Comparison of palpation-versus ultrasound-guided fine-needle 














   
Chapter 6 
 
Analysis of “dry” mesothelioma with ultrasound guided biopsies. 
 
Lung Cancer 2012; 78:229-233 
 
 







































chapter 6   
ABSTRACT 
 
Background: Image-guided sampling of the thickened pleura is a sensitive approach 
in patients with malignant pleural mesothelioma with pleural effusion. Malignant 
pleural mesothelioma presenting without effusion however is more of a diagnostic 
challenge. In this study we report the diagnostic yield and complications of 
ultrasound-guided cutting needle biopsies in this particular category of patients. 
Methods: A retrospective database analysis from September 2007 until January 
2012 was performed in 56 patients with malignant pleural mesothelioma. Clinical 
characteristics and results of diagnostic evaluations were analysed. 
Results: Of the 56 patients with malignant pleural mesothelioma, 20 patients 
presented without pleural effusion of with locular effusion. Ultrasound-guided cutting 
needle biopsy was performed in 14/20 patients with a diagnostic accuracy of 80%. 
Only 1 patient had mild hemoptysis immediately following biopsies. 
Conclusion: Diagnosing patients with pleural thickenings suspect for malignant 
mesothelioma without pleural effusion or with loculated pleural effusion is effective 
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INTRODUCTION 
 
Malignant pleural mesothelioma MPM is the most common primary pleural 
malignancy. There is a close relationship with asbestos exposure with a long latency 
period of up to 40 years before disease develops. The diagnosis is likely in patients 
with a history of asbestos exposure and clinical symptoms of chest pain, dyspnea 
and pleural effusion. Imaging supports the diagnosis but pathologic verification on 
pleural biopsies is almost invariably necessary. 
Initially in most patient presenting with a pleural effusion a thoracentesis is 
performed. Although immunohistochemical staining of embedded cytologic specimen 
or electron microscopy is sometimes very suggestive for MPM, the obtained tumour 
cells in pleural aspirations are often too minimal to enable this pathologic elaboration. 
MPM has a wide range of morphological appearances that makes it difficult to 
discriminate from other malignancies especially adenocarcinoma. There are no 100% 
sensitive pathologic markers for MPM and so a panel of markers is used for optimal 
identification[1]. The acquisition of histologic material is practically obligatory in daily 
practice to establish the diagnosis of MPM. 
Several biopsy techniques have been compared. It was demonstrated that obtaining 
biopsies under image-guidance provides a higher diagnostic yield than blind biopsies 
but are still slightly inferior when compared with thoracoscopic biopsies[2]. 
Abrams needle pleural biopsies (ANPB) performed without image-guidance were 
inferior compared to CT-guided pleural biopsies[3]. However a comparison of ANPB 
under CT-guidance (CT-ANPB) with thoracoscopy did not show any difference[4]. For 
both studies it has to be mentioned that all patients had pleural effusion.  
Thoracoscopy has the advantage of immediate evacuation of the pleural effusion 
during the intervention relieving obviously dyspnea sensations in many patients and 
enabling adequate pleurodesis at the same time[5].  
In a substantial amount of patients however, MPM presents with pleural thickening 
without effusion. For this category, medical thoracoscopy is hardly possible to carry 
out and ANPB is impossible. For those cases, image-guided percutaneous 
approaches with CT or US are appropriate methods to obtain adequate tissue. 
There are no direct comparative studies for both modalities in MPM[6]. In a study of 
21 patients with MPM the diagnosis was obtained with image-guided cutting needle 
biopsies (CNB) with CT guidance in 15 patients and with US guidance in 6 
patients[7]. In 7/21 patients there was no pleural fluid but unfortunately the study did 
not specify if the diagnoses were obtained with CT or US guidance. 
The largest published series of US-guided biopies in MPM  consists of 52 patients. A 
sensitivity and specificity of 77% respectively 88% was reported. Unfortunately the 
radiologic appearance with respect to the presence or absence of pleural effusion 
was not described[8].        
In this study we focus on the role of US-guided biopsies as a diagnostic modality 
especially for MPM presenting without pleural effusion. To that end we characterized 
all MPM patients by radiologic appearance and assessed retrospectively the way the 
pathologic diagnosis was obtained in the subset of patients without effusion or with 
loculated effusion.             
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PATIENTS AND METHODS 
 
This is a single centre study that analysed the diagnostic procedures in 56 
consecutive patients over a period of 4 years with a diagnosis of MPM. For this 
retrospective analysis there was no ethical approval required. All diagnostic 
interventions performed to acquire material in the analysis of MPM and all final 
interventions resulting in the diagnosis of MPM were recorded as well as the 
radiological appearance of pleural disease.  
The results of all US-CNB or attemps to biopt pleural thickenings were recorded as 
well as gender, age, side of pleural disease, radiologic presentation and histology.  
Unfortunately, the pleural thickening was not measured with US during the biopsy 
procedures. The pleural thickness was determined retrospectively by reviewing the 
contrast-enhanced CT scans and measuring the maximum thickness at the site 
described in the US guided biopsy reports.  
All US-CNB were performed by pulmonologists after informed consent and under 
local anaesthesia with lidocain 2%. Biopsies were obtained under direct vision with a 
Hitachi probe (EUP-C532) and a Hitachi EUB-5500 processor. Figure 1 shows an US 
image of a tissue core needle sampling a mesothelioma and a corresponding CT 
image.  
Bard core tissue biopsy needles 14G x 13 cm. mounted on the US probe with a EZU-
PA532 Hitachi Biopsy attachment were used with a Bard magnum biopsy instrument 
















Figure 1.  The left panel shows the ultrasound image of a tissue core needle 
biopsy (14G) from a malignant pleural mesothelioma. The long arrow 
shows a dark 11 mm thick pleural broadening and the short arrow 
indicates the needle. Note the local extension of the pleural 
broadening protruding into the lung. At the left side a rib causes a 
downward zone of absent ultrasound imaging. 
  The right panel shows the corresponding CT image.  
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Pathologic examination was performed using Haematoxylin-Eosin stained step 
sections, in addition with immunohistochemical staining of Cytokeratin AE 1/3, CK5, 
CK 7, CEA, Calretinin, Ber-EP4, WT-1, CD15, D2-40, TTF-1, MOC-31. Figure 2 
shows examples of pathologic slides obtained with 14G needles.  
If MPM was certain or suspected, confirmation was requested at the Dutch 









Pathologic slides of tissue core needle 





Panel A: Calretinin 
immunohistochemistry showing 
positive nuclei and cytoplasm as 









Panel B: Hematoxin and Eosin stained 
slide showing deaply infiltrative 
epithelial type mesothelioma. 10x.  










Panel C: Hematoxin and Eosin slide 
with epithelial type mesothelioma 
infiltrating thoracic muscles (arrow). 
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RESULTS 
 
Diagnostic interventions in mesothelioma 
From September 2007 until January 2012 the diagnosis of MPM was made in 56 
patients. Table 1 shows the diagnostic interventions that provided the diagnosis and 
the pathological subtypes. 
The patients are classified in 36 patients with a massive pleural effusion and 20 
patients with pleural thickenings with or without loculated pleural fluid.  
Thoracoscopy provided the diagnosis in patients with massive pleural effusion in 
23/36 patients. In 41 patients at least one thoracocentesis was performed but in only 
2 patients the results were considered appropriate for the definitive diagnosis. In all 
other cases, histologic confirmation followed. In only 3/36 patients a surgical 
diagnostic procedure was performed after negative cytology in aspirated pleural fluid. 
In 2/3 patients it remains unclear why patients were not analysed with a 
thoracoscopy and in 1/3 patients there was a hydropneumothorax with lots of 
adhesions impelling a surgical intervention.  
When pleural effusion was not prominent there was a marked predominance of US-
CNB (12/20) as provider for the diagnosis of MPM (table 1). 
 
Ultrasound-guided core tissue biopsies in mesothelioma 
Table 2 demonstrates the characteristics of 20 out of the total of 54 patients that 
were analysed with US-CNB. There were 14 patients with only thickened pleura or 
thickened pleura with loculated effusion who underwent US-CNB and 6 patients with 
massive pleural effusion. Pleural thickness varied from 7 to 51 mm.  
Biopsies resulted in 17/20 in a definitive diagnosis of MPM. In 2 patients a second 
US-CNB was performed when the first attempts were unsuccessful (table 2).  
Non-diagnostic US-CNB was performed in 3/20 patients. In 1 patient (with a 
circumferential pleural thickening without effusion) the needle could not be forwarded 
into the pleura although the broadened pleura was visible very well. In 1 patient with 
massive effusion there was no CT scan available and with US, solid structures for 
biopsy were not detected. The third patient had US guided cytologic aspiration of a 
loculated effusion. Pleural thickening could however not be seen and CT scan 
showed a large MPM mass in a paravertebral location not reachable with CNB. 
 
Ultrasound-guided core tissue biopsies in patients without massive effusions 
Table 3 focusses on the subgroup of patients characterised by the absence of 
massive pleural effusion. In some patients pleural effusion was present but only 
loculated in a clinical picture dominated by solid pleural thickening. 
In 4/20 patients the mesothelioma grew through the intercostal space and was 
palpable at the outside of the thoracic cage. Upfront diagnostic surgery was  
performed in 2/4 patients although image-guided biopies should have been easy to 
perform in both patients afterwards. A palpable chest tube track metastasis was 
diagnosed with US-CNB in 1 patient after failure of VATS and mediastinoscopy.  
The fourth patient with a palpable tumour in the right axilla was diagnosed with 
upfront US-CNB. 
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In 11/20 patients the initially non-diagnostic investigations were performed in the 
presence of abundant effusion (one or more thoracenteses, ANPB or thoracoscopy). 
After that the pleural effusion was absent because of chest tube drainage and 
pleurodesis. These patients proceeded to image-guided CNB with CT (2/11) or US 
(6/11) or diagnostic surgery (3/11).  
Image-guided CNB as initial diagnostic mode was performed in 8/20 patients. 
Biopsies under CT-guidance in 1/8 and under US-guidance in 7/8. 
 








Diagnostic test    
    
Thoracoscopy 23 0 23 
CT-guided biopsies 2 2 4 
US-guided biopsies 5 12* 17 
Cytologic aspiration 2 0 2 
VATS 1 2 3 
Minithoracotomy 1 2 3 
Abrams biopsy 1 0 1 
Surgical biopsy 1 2§ 3 
    
Total 36 20 56 
    
Histologic diagnosis    
    
Epithelioid 27 13 40 
Sarcomatoid 5 4 9 
Mixed epithelioid/sarcomatoid 4 3 7 
    
Total 36 20 56 
CT, computed tomography; US, ultrasound; VATS, video-assisted thoracoscopic surgery 
*: including 2 palpable tumours; 
§
: 2 palpable tumours 
Table 1 
Diagnostic tests providing the diagnosis of malignant pleural mesothelioma and results 
of pathological classification in 56 patients with massive pleural effusion or pleural 
thickening/loculated pleural effusion. 
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Complications 
A total number of 22 US-CNB was performed in this series. Only 1 patient (the 
patient with the thinnest circumferential broadening of maximum 7 mm) suffered a 
single slight hemoptysis. Patients experienced no significant pain and pneumothorax 












   
Gender male: female 19:1 
Age  median(range) years 66(57-84) 
Side of biopsy  right:left 13:7 
Width of biopsied pleura Median(range) in cm. 17(7-51) 
   
Radiological appearance Circumferential thickening 5 
 Circumferential thickening with loculated effusion 3 
 Circumferential thickening and extrathoracic growth 1 
 Located pleural thickening 2 
 Located pleural thickening with loculated effusion 2 
 Located pleural thickening and extrathoracic growth 1 
 Massive pleural effusion 6* 
   
Histology Epithelioid 13 
 Sarcomatoid 4 
 Mixed epithelioid/sarcomatoid 3 
   
Results US-guided 
biopsies  
Diagnostic CNB 17§ 
 Non-diagnostic/no biopsies 5‡ 
   
Complications hemoptysis 1 
   
Table 2  
Characteristics of patients, radiologic appearance and histology in 20 patients analysed 
with ultrasound-guided tissue core biopsies 
 
CT, computed tomography; US, ultrasound; CNB, core needle biopsy 
*: 1 patient without CT scan. 
§: 2 patients had a repeated US-TCB.  
‡: non-diagnostic (attempts for) US-TCB followed by repeated US-TNB in 2 patients or by diagnostic surgical procedures 
in 3 patients. 
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Diagnosing malignant pleural mesothelioma is often a challenge in daily practice 
especially when the disease  presents with diffuse or localised pleural thickening 
rather than pleural effusion. 
Pleural thickening without effusion is sometimes the first clinical presentation or 
remains as the final situation after former diagnostic interventions with relieving chest 
tube drainages. This study describes the experience with US-CNB in this particular 
subset of patients with MPM. 
A diagnostic accuracy of 80% was demonstrated for US-CNB in patients with MPM. 
In only 2/14 patients, US-CNB was non-diagnostic (although in 1/14 patients US-
CNB had to be repeated). These 2 patients were diagnosed with VATS and 
minithoracotomy. A diagnostic accuracy for US-CNB of also 80% was described in a 
study of 70 patients suspected for MPM[8]. This study is however incomparable to 
our report because it did not focus on the subgroup of patients without massive 
    
gender male: female 19:1  
age  median(range) 71(56-84)  
side of biopsy  right:left 12:8  
Width of biopsied pleura median(range) in 
mm. 
17(7-51)  
    
 Number of patients Non-diagnostic  Diagnostic 
    
Pleural fluid aspiration* 10 15 0 
Abrams biopsy* 3 3 0 
Thoracoscopy* 3 3 0 
EUS-FNA 2 2 0 
CT-TCB 3 2 1 
US-TCB 14§ 3 12 
Surgical biopsy 3 1 2 
VATS 3 1 2 
(Mini)thoracotomy 2 0 2 
Mediastinoscopy 1 1 0 
    
EUS-FNA, endoscopic ultrasound-guided fine needle aspiration; CT-TCB, computed tomography-
guided tissue core biopsy; US-TCB, ultrasound-guided tissue core biopsy; VATS, video-assisted 
thoracoscopic surgery 
*: performed in loculated effusion or initially in massive pleural effusion before pleurodesis 
§: in 1 patient 1 non-diagnostic US-TCB was followed by a second diagnostic US-TCB  
Table 3 
Patient characteristics and biopsy results of all performed diagnostics in 20 patients 
with a final diagnosis of malignant pleural mesothelioma without massive pleural 
effusion at time of diagnosis. 
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effusion. In a study of 33 patients with a suspected malignant effusion, in 21 patients 
a definitive diagnosis of MPM was obtained with image-guided CNB. A diagnostic 
accuracy of 86% was reported but concerned CT-CNB as well as US-CNB[9]. This 
result is neither comparable with ours because two thirds of patients had pleural 
effusions and only 6/21 had US-CNB[10]. 
In retrospection, 2 out of 4 upfront surgical diagnostic procedures in our series could 
have been precluded when US-CNB was tried before. Both patients had MPM 
locations palpable on the outside of the thorax and were analysed before imaging. 
For the 2 other patients US-CNB was less suitable. In 1 patient a non-diagnostic CT-
CNB was performed and 1 patient had a pleural thickening of maximum 8 mm. 
considered too small by the treating physician for image-guided biopsies. 
In 2/20 patients a successful CT-CNB was the chosen diagnostic investigation but for 
both the diffuse pleural thickenings could have been approached with US-CNB as 
well. 
The advantages of US guidance over CT-guidance is its ready availability and lack of 
radiation exposure but above all the possibility of real-time sampling which reduces 
the chance of lung perforation and perforation of larger blood vessels. The direction 
of the needle and the depth of the biopsy can be established very well with the help 
of US. In 2 patients diagnosed with US-CNB the MPM was palpable at the outside of 
the thoracic cage. Although US-guidance is less essential in this situation, it still 
assists the clinician by determining the needle track and visualizing surrounding 
structures.  
US-CNB was also performed in 6 patients with a massive pleural effusion. All but one 
of these US-CNB were successful and the failure was repeated successful under US-
guidance at another moment. Although very feasible and patient-friendly, CNB is only 
diagnostic and does not treat patients as does thoracoscopy. So for patients with 
massive pleural effusion thoracoscopy is the diagnostic procedure of choice. 
The technique of US-CNB is safe. In this study only 1 patient had mild hemoptysis. 
This corresponds to the small numbers of complications reported in literature. 
Studies in 53, 6 and 5 patients with MPM (diagnosed with US-CNB) reported 
complications in 2, 1 respectively 0 patients[8, 10, 11]. The 3 patients had mild 
hemoptysis, local chest pain and a chest wall hematoma. 
The problem of needle track seeding was studied in 100 patients with MPM who 
were diagnosed with image-guided CNB or surgical biopsies (thoracoscopy or 
thoracotomy). In 22/100 patients CNB was performed (1/22 patients with US-
guidance) and only 1 patient developed a needle track seeding. This contrasted to 
the 22% of needle track seedings that were found in patients diagnosed with surgical 
procedures[12]. Unfortunately, we did not monitor for this disease manifestation in our 
study. In fact 2 of our patients were diagnosed primary on needle track metastases; 1 
after former surgical procedures and 1 patient a year after a negative 
thoracocentesis. 
Limitations of this study are its retrospective nature and its small number of patients. 
The limited number of CT-guided biopsies do not allow a comparison between US 
and CT as guiding modality. Nevertheless this particular category of so called “dry” 
MPM patients and the diagnostic capacity and suitability of US-CNB for these 
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patients deserves attention. US-CNB can eventually prevent more aggravating 
surgical procedures. 
In conclusion, this study demonstrates the safety and high diagnostic accuracy of 
US-CNB for patients with MPM presenting  without massive pleural effusion. 
Percutaneous biopsies and aspirations with US for indications such as pleural fluid or 
pleural pockets are broadly applied by pulmonologists nowadays so it seems a 
logical and small step to expand the use of this technique to solid pleural thickenings 
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ABSTRACT 
 
Introduction: Incidental mediastinal lymphadenopathy challenges pulmonologists to 
decide on eventual further diagnostic steps. The aim of this study was to characterize 
unexpected mediastinal findings by imaging and pathologic analysis.  
Methods: Entry criterion for this prospective explorative study was mediastinal 
lymphadenopathy as an incidental finding on CT scans made for indications other 
than the analysis and staging of neoplasms.  
Lymph node dimensions were measured on CT. Subsequent diagnostic 
investigations were positron-emission tomography (PET), endoscopic ultrasound 
(EUS) or endobronchial ultrasound (EBUS) guided punctures and clinical follow up.  
Results: 83 patients from 8 hospitals met the entry criteria. The median number of 
Naruke stations with enlarged nodes was 7 (range 3-9). The median size of all nodes 
measured, varied between 6 and 14 mm. The median number of lymph node stations 
with nodes of at least 10 mm was 3 (range 0-8). 
Hilar node enlargement was detected in 77% of patients.  
No definitive diagnosis was obtained in 7/83 (8%) of patients. Lymphocytes were 
found in 55/83 (66%) and sarcoidosis in 18/83 (22%) of aspirates. 
PET showed metabolic activity in 87% of patients.  
Follow up CT scans were available in 36/62 (58%) of patients without a classifying 
diagnosis. Two patients developed lung cancer 2 years after initial analysis.  
Conclusion:  Incidental mediastinal lymph nodes on CT are characterized by 
multiplicity, relative small sizes and coexistence with hilar lymphadenopathy in the 
majority of patients. These nodes often display increased metabolic activity. 
The low predictive value for malignancy justifies a restrictive attitude towards invasive 
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INTRODUCTION 
 
Enlarged mediastinal lymph nodes may be detected incidentally on computer 
tomography (CT) of the chest and often raise the question whether further analysis is 
indicated. Nowadays CT is easily accessible and made for a broader range of 
indications including pulmonary embolism and coronary artery imaging. Thus, 
incidentally enlarged mediastinal nodes will be found in incremental numbers 
challenging the pulmonologist to make decisions about further diagnostic approach. 
Incidental findings are defined as imaging abnormalities not related to the indication 
for which the CT is requested.  
Prevalences of incidental mediastinal lymphadenopathy are reported between 0.15% 
and 3%, but a systematic pathological analysis of these findings has not been 
described so far[1-9] 
Several studies describe pathologic results of mediastinal masses in patients of 
unknown etiology[10-13] The rates of malignancy ranged in these studies from 29% 
to 65% with entry criteria that varied significantly. A meta-analysis showed that larger 
nodes have a higher chance of containing malignancy[14]. The prevalence of 
malignancy will be lower when nodes are small as is usually the case when detected 
by incidence on CT. 
This prospective study with patients referred from eight different hospitals describes 
the extend, size, metabolic activity and pathological findings of incidentally detected 
mediastinal lymph nodes.  
 
PATIENTS AND METHODS 
 
Study entry criterium 
Patients with at least one enlarged mediastinal lymph node (shortest diameter of ≥ 10 
mm) were selected for the study when this incidental finding was detected on CT of 
the thorax made for a wide range of indications other than the analysis or staging of 
any neoplasm. One patient was analysed although the shortest diameter of nodes 
did not reach 10 mm. Excluded were patients with a poor performance score 
precluding the consequences of further diagnostic analysis. 
 
Imaging and evaluation of nodal disease 
Patients were referred from eight different hospitals. CT of the thorax was performed 
according to local protocols. One of the authors (JS) reviewed all CT scans and all 
visible mediastinal nodes were measured along the shortest axis and the mediastinal 
position was classified according to the International Association for the Study of 
Lung Cancer (IASLC)[15].  
In only a limited number of patients a positron-emission tomography (PET) was 
performed with fluoro-2-deoxyglucose (FDG) in the mediastinal nodes was 
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Ultrasound guided biopsies and pathologic analysis 
Mediastinal lymph nodes were approached with EUS or EBUS for a diagnostic 
aspiration or biopsy. EUS and EBUS was performed with Pentax ultrasound 
endoscopes with a Hitachi EUB-5500 processor. The fine needle aspiration (FNA) 
biopsies were performed under conscious sedation with midazolam and with local 
anaesthesia that was sprayed in the oropharynx (lidocain 1%) and lidocain gel 20 
mg/ml. Per nodal site, three to four needle passes were performed and at least two 
aspirates were smeared on slides. Remaining aspirate was deposited  in a fixative 
medium (Carbowax 2% [polyethyleenglycol 20 g in ethanol 96% methylated and filled 





From August 2005 until December 2010, 83 out of 1530 patients met the inclusion 
criteria of our study. They underwent EUS or EBUS for analysis of incidentally 




Table 1 shows the characteristics of 83 patients (61 men and 22 women) with a 
median age of 59 years (range 27-87).  
All patients were referred for EUS-FNA (81) or EBUS-TBNA (2) of incidentally 
detected lymph nodes on CT scans for a variety of indications (table 1). Most CT 
scans were angio-CT scans made in the work up of pulmonary embolism (43). Other 
indications were pulmonary infiltrative disease (5), pleural disease (8), 
parenchymatous disease (3), health screening scans (2), coronary angiography (2) 
and a remaining group with other indications (20). 
 
Numbers and sizes of mediastinal nodes  
In our patients nodes of all sizes were visible on CT-scans in at least 3 levels 
(according to the Naruke classification) and in some patients lymph nodes were 
visible on CT at all sites. The median number of sites with visible nodes was 7 (range 
3-9). The median number of lymph nodes of at least 10 mm was 3 (range 0-8). 
Table 1 shows the numbers of patients with different lymph node sizes at any 
mediastinal site. The median number of involved mediastinal sites is also described 
in table 1. In 64 patients hilar lymphadenopathy was also evident. In 19 patients hilar 
node enlargement was absent.  
Table 2 demonstrates the nodal size, subdivided in several size categories, for 
specified mediastinal sites.  
 
FDG uptake in mediastinal nodes 
PET scans had been performed in 29 patients. Increased FDG-uptake in mediastinal 
nodes was demonstrated in 25 patients (3 inadequate aspirates, 16 reactive 
lymphoid change, 5 granulomatous inflammation compatible with sarcoidosis and 1  
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 N Median 
(Range) 




Age (yr)  59 (27-87) 
   
Gender   
              Male 61  
              Female 22  
   
Indications for CT scan 
 
  
              Suspected pulmonary embolism                                      43  
              Pleural disease on chest X-ray  8  
              Suspected interstitial pulmonary disease   8  
              Persistent pulmonary infiltrate on chest X-ray  5  
              General Internal analysis  5  
              General Pulmonologic analysis  3  
              Imaging of benign pulmonary abnormalities  3  
              Commercial screening  2  
              Coronary angiography  2  
              Analysis ascending aorta  2  
              Other*  2  
   
Mediastinal locations    
   
         All measurable nodes 83 7 (3-9) 
         Nodes of at least 10 mm. 82 3 (0-8) 
              10-15 mm 79 3 (1-6) 
              16-20 mm 38 1 (1-4) 
              21-30 mm 21 1 (1-3) 
              > 30 mm  2 1 
   
Hilar nodal enlargement   
         Yes  64  
         No  19  
Tabel 1 
Patient characteristics of 83 incidentally encountered mediastinal 
lymphadenopathy 
 
*: mediastinal lymphadenopathy as incidental finding on MRI for cervical radicular syndrome and 
exclusion  of a primary malignancy in the workup of an abnormal cerebral MRI . 
MRI, magnetic resonance imaging; CT, computed tomography.  
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granulomatous inflammation staining positive for mycobacteria) In four patients there 
was no increased FDG uptake observed (all reactive lymphoid change). 
 
Pathologic analysis 
Table 2 describes the results of pathological analysis. Cytologic aspirates were 
derived from 80 patients. In two patients introduction of the endoscope failed and in 
one patient, nodes were not detected with ultrasound. In four patients the aspirates 
were considered inadequate for pathologic analysis. 
Guided by ultrasound, subcarinal nodes were biopsied in 67 patients, the aortic 
window (locations 4L and 5) 34 patients, location 8 in two patients and locations 2L 
and 4R  both in one patient. In 76/80 patients the quality of aspirated material 
allowed an adequate pathological analysis. 
In 55 patients the aspirates showed many lymphocytes and were considered reactive 
without a classifying diagnosis. Eighteen patients had a granulomatous inflammatory 
reaction compatible with sarcoidosis. One patient also had a granulomatous disorder 
and acid-fast mycobacteria with Ziehl-Neelson stain. Conventional culture and a 
polymerase chain reaction for Mycobacteria were negative. One patient had a 
bronchogenic cyst. 
In a patient with a history of breast cancer, a CT was made to analyse loculated 
pleural fluid without pathological evidence of a malignancy. The enlarged mediastinal 
nodes, not visible on normal X-ray, contained metastatic disease of her breast 
cancer. 
In a subset of 21 patients with conditions frequently associated with mediastinal 
lymphadenopathy (pleural disease, interstitial disease and infiltrative disease) 
lymphocytes were present in 81%, and a granulomatous inflammatory pattern in 14% 
compared to 61% and 24% for all other patients, respectively. 
 
Follow up 
A classifying diagnosis was obtained with EUS in 21 out of 83 patients. In the 62 
patients with no classifying diagnosis, follow up data were analysed. This group 
consisted of 55 patients with adequate aspirates, 4 patients with inadequate 
aspirates, 2 patients in whom introduction of the echoscope failed and 1 patient in 
whom no enlarged lymph nodes were detected with ultrasound. 
Follow up CT scans were available for 36/62 patients (58%). The scans were made 
after a median interval of 118 days (range 10-692 days). Decisions for follow up were 
made at the discretion of patients own treating physician. Eleven patients were 
referred from other hospitals and lost to follow up and for 16 patients in our own 
practice, no follow up CT scans were requested.  
In 9 patients the lymphadenopathy had reduced spontaneously. In 24 patients the 
lymphadenopathy remained unchanged and in 2 patients the lymphadenopathy 
progressed both in size and in number. In both patients with progressive 
lymphadenopathy detected on CT scans after 20 and 23 months of follow up, the 
initial EUS-FNA contained adequate samples without malignant cells.In one patient, 
a repeat EUS-FNA after 21 months in subcarinal lymph nodes showed malignant 
cells and this patient was diagnosed with stage IV NSCLC. In the other patient, 
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metastatic lung cancer was demonstrated by a liver biopsy 22 months after initial 
EUS-FNA. In this patient with obvious progression of mediastinal lymphadenopathy, 
metastatic disease was not verified as a repeated EUS was not performed. Revision 
and comparison of CT scans suggests progression of already existing 
lymphadenopathy but an evident primary tumour was absent on the initial scans.  
When the number of enlarged nodes and the sizes of enlarged nodes for the patients 
with malignancy (developing during follow up or at initial analysis) are compared with 










     
Radiologic distribution of mediastinal nodes 
(according to IASLC) 
Size of Nodes 
(mm)  Median 
(Range) 
       











       
 2R       41      18       9       1      0 8      (4-26) 
 4R       26      37      15       4      0 13     (4-27) 
 2L       39       9       0       0      0 6      (3-15) 
 4L       35      34       2       0      0 10     (4-16) 
  5        25      37       8       0      0 11     (5-19) 
  6      46      18       4       0      0 8      (3-20) 
  7          8      35      16     18      2 14     (6-35) 
  8      10      18       6       1      0 11     (4-28) 
  9          14       7       0       0      0 8      (5-15) 
       
Pathologic results 
 
Lymphocytes  55 
Sarcoidosis  18 
Metastasis mammacarcinoma  1 
Granulomatous inflammation, ZN positive stains  1 
Bronchogenic cyste  1 
Inadequate needle aspirate  4 
No aspirate acquired   3 
    
Table 2 
Nodal distribution and pathological results of EUS and EBUS 
EUS, endoscopic ultrasound; EBUS, endobronchial ultrasound;IASLC, International Association 
for the Study of Lung Cancer; L,left; R,right; ZN, Ziehl-Neelsen  
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In this study a group of 83 patients referred for suspected pulmonary malignancy 
were described who had in common that mediastinal lymphadenopathy was detected 
incidentally on CT performed for a variety of indications other than the analysis of 
malignancy.  
The most characteristic feature of these enlarged mediastinal lymph nodes is their 
presence in multiple Naruke stations, its variable but relatively small size and the 
concomitant hilar involvement in most patients. There was one patient in whom the 
largest nodes measured less than 10 mm. In 46% (38/83) patients the largest 
measured nodes were between 10 and 15 mm followed by 26% (22/83) patients with 
maximum nodes of 16-20 mm, 24% (20/83) patients with largest nodes of 21-30 mm 
and 2% (2/83) with nodes measuring more than 30 mm. 
The size of mediastinal nodes is predictive for the final pathologic diagnosis as has 
been demonstrated in a study where benign nodes were significantly smaller than 
malignant nodes[16]. However the nodes of the patient in this study with breast 
cancer metastasis and the two patients that developed NSCLC during follow up did 
not differ in size from the other patients.   
Incidental mediastinal findings are described in screening studies for coronary artery 
disease but information on extend and size of these findings is scarse[1, 2, 4-7].  
Lung cancer screening studies also report prevalences of nonpulmonary incidental 
findings but details of mediastinal incidental findings are limited or absent[3, 8, 9]. 
If imaging was expanded with FDG-PET, the majority of patients demonstrated 
increased FDG uptake in their nodes.  
It is debatable whether PET is indicated in patients without radiologic evidence of  
primary lung tumours. All but one of 29 patients in whom PET was performed had at 
least 1 lymph node measuring 10 mm or more in short-axis diameter. Remarkably, 
the only patient with nodes smaller than 10 mm developed lung cancer with 
confirmed subcarinal metastatic disease.  
PET offered in our study no added value to CT in incidentally detected mediastinal 
nodes since reactive inflammatory diseases also showed metabolic activity and 
hence did not discriminate from malignant disease. 
 
Pathology 
In our study, the majority of incidental mediastinal findings showed a reactive 
inflammatory pattern on pathological analysis sometimes compatible with sarcoidosis 
as might be expected from imaging results. Granulomatous inflammatory reactions 
could be expected relatively more often in patients with conditions with pleural, 
interstitial or infiltrative disease.In a screening study in asbestos workers in 1% of 
patients mediastinal lymphadenopathy was reported and all lesions were proved to 
be benign[9]. The size of the detected mediastinal nodes was not provided but since 
this was a screening study, the lesions were presumably small in size. 
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In a study of 1520 lung cancer screening participants, incidental mediastinal findings 
(2 lymphomas) were reported but the prevalence of incidentally detected mediastinal 
lymphadenopathy was not described[8]  
Malignancy was found in only one patient in our study. This patient had a history of 
breast cancer and so this finding was not unexpected. In all other patients, 
malignancy was not observed. These findings conflict with the high pretest probability 
of malignancy in patients with mediastinal lymphadenopathy of unknown aetiology in 
former series[10-13]. Critical is how patients are selected. In a study of isolated 
mediastinal lymphadenopathy, EBUS-TBNA resulted in a diagnosis of malignancy in 
60% (33/55) patients[12]. All patients in this study had suspected lymphoma, 29% 
(16/55) patients had a history of malignancy and excluded were patients with typical 
clinicoradiologic features of sarcoidosis. This study did not specify the size and 
number of mediastinal nodes. Neither were these features described in two studies 
reporting malignancy in 29% (40/140) and 65% (22/34) of patients[10, 13]. Finally, in 
61% (46/75) of patients malignancy was observed in subcarinal nodes but these 
were at least 25 mm[11]. In a subgroup of patients analysed for isolated mediastinal 
lymph nodes with typical clinicoradiological features suggestive for sarcoidosis this 
diagnosis was confirmed in 93% (26/28) patients but 1/28 had malignancy[17]. 
Our study population cannot be compared with the patients in these studies due to 
different entry criteria and lacking information on number and size of mediastinal 
nodes. 
Regarding our own results in patients with high rates of hilar lymphadenopathy and 
multiple mediastinal nodes the number of patients with a granulomatous 
inflammatory reaction seems small. The difference of these results with our findings 
can be explained by the fact that the incidental nodes in our study were relatively 




In the literature there are no follow up data of incidental mediastinal findings. In our 
study  with a deliberate follow up, determined by the treating physicians, follow up CT 
was available in more than half the patients without a classifying diagnosis of 
incidental mediastinal findings. Two out of 62 patients (3%) developed lung cancer in 
nodes that had been evaluated initially with EUS-FNA. The interval of detection of 
lung cancer was almost 2 years in both patients. Based on follow up findings in this 
study, the need for regular monitoring of incidentally detected lymphadenopathy with 
CT scans is debatable.  
Regarding the pathologic diagnoses in this study, the probability to detect a disease 
that needs treatment is very low (although an exception could be made for patients 
with a history of malignancy). This counterweights the low threshold to apply modern 
endosonographic techniques due to their favorable safety profile and high diagnostic 
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CONCLUSION 
 
Incidentally detected lymphadenopathy often worries pulmonologists leading to 
further diagnostic procedures. This explorative study demonstrates that incidentally 
detected mediastinal findings are mainly a manifestation of reactive inflammatory 
origin in mainly multiple, slightly enlarged mediastinal lymph nodes. Our study does 
not support a very aggressive diagnostic approach of these nodes except for patients 
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ABSTRACT 
 
Background: A standardized diagnostic program, initiated to reduce the length of 
the diagnostic track and to improve application of diagnostic tools for patients 
referred with suspicious abnormalities on standard chest radiographies, was 
evaluated.  
Methods: The findings on integrated PET-CT determined the choice of invasive 
investigations to be performed the same day. Diagnostic results, time courses and 
number and sorts of applied invasive investigations were assessed.  
Results: In 297 eligible patients, malignant disease was diagnosed in 72% and 
benign disease in 26% of patients. One percent of the patients had no abnormalities 
at all. 
For 85% of patients with a malignancy, investigations were rounded off in one day 
resulting in a diagnosis and definitive clinical disease stage.  
The median time from start of the analysis to informing the patient about diagnosis   
and tumour stage was 7 days. 
One invasive investigation was performed in 53% of patients in the study group and 
at least 2 investigations were performed in 33%. Bronchoscopies formed a part of the 
diagnostic process in 59% of patients. Surgical diagnostic procedures were 
performed in 8% of patients.  
Conclusion: The diagnostic program resulted in a short time to diagnosis with 
finalization of invasive investigations on one day in the majority of patients. The 
imaging-based choice of invasive investigations precluded bronchoscopies in a 























  diagnostic program 
INTRODUCTION 
 
Patients have to undergo a variety of diagnostic tests for the analysis of suspicious 
abnormalities on standard chest radiographies to obtain information on pathology 
and extend of disease. In case of malignancy, tumour stage, resectability, operability 
and comorbidity are important issues to assess for optimal patient management.  
A short diagnostic track may lead to more satisfaction for patients and physicians 
although a relationship between hospital waiting time and survival or recurrence rates 
in lung cancer patients has never been demonstrated[1-7].  Diagnostic time is 
considered as an indicator for quality and recommendations on this issue are 
published in guidelines. 
Former publications on fast-track diagnostic programs used bronchoscopy after 
positron-emission tomography (PET) and /or computerized tomography (CT) as 
standardized work-up[8, 9]. The diagnostic accuracy of bronchoscopy for mediastinal 
staging however is limited and distant metastatic disease still needs verification. So 
for many patients in these programs, further diagnostics are required. 
Our diagnostic program was designed to perform all tests, needed to diagnose 
suspicious abnormalities, on one single day (including confirmatory tests for disease 
stage in case of malignancy). PET-CT, as superior imaging modality for lung cancer 
suspects, guided the choice of further investigations[10-12]. Relevant findings on 
PET-CT were confirmed by bronchoscopy, ultrasound (US) guided punctions, 
endoscopic ultrasound with fine-needle aspiration (EUS-FNA) or endobronchial 
ultrasound with transbronchial needle aspiration (EBUS-TBNA) or combinations.  
We hypothesized that the sequence of investigations and the choice from a variety of 
immediate available biopsy techniques should lead to a high rate of finalized 
diagnostic work-ups at one diagnostic day. We expected that this would result in a 
short time to analyze patients with suspected lung cancer. We also expected that 
many patients would be diagnosed with ultrasound guided biopsies (either 
endoscopic or percutaneous) that would be sufficient for a proper diagnosis including 
tumour stage. This would demonstrate consequently that a diagnosis of thoracic 
malignancy not automatically requires a bronchoscopy. 
 
PATIENTS AND METHODS 
 
Study population 
The target population consisted of consecutive patients with abnormalities suspicious 
for lung cancer on standard chest radiographies referred to the outpatient clinic of the 
Chest Unit by a general practitioner or medical specialist from February 2006 until 
January 2010. 
After the radiographs and referral notes were reviewed by the author (JS), patients 
were invited to enter the study after answering a questionnaire by telephone. The 
questionnaire was used to inform and invite patients to participate in the program and 
to obtain information on basic patient characteristics, demographics, comorbidity and 
medication use. The study was approved by the Medical Ethical Committee of the 
Isala Clinics in Zwolle, the Netherlands and informed consent was obtained from all 
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patients. Patient information forms and a time table for the diagnostic day were 
provided by mail or email. 
A cost analysis was not performed. 
 
Diagnostic workup 
The program was designed to enable the analysis of three patients on a fixed day 











During the diagnostic day in the clinic the patients were accompanied by a nurse. 
Routine laboratory tests were performed before PET-CT scanning. EKG and 
pulmonary function tests were performed in the morning hours. Every week, 3 PET-
CT slots were reserved for the program. The slots were reallocated 48 hours before 
the time slot to the general hospital when less than 3 patients entered the study in 
that week.  PET-CT was performed on an integrated PET-CT scanner (GE Discovery 
ST PET-CT scanner; General Electric, Milwaukee, Wis) and reviewed by the author 
Figure 1.Time table of activities and investigations for 3 patients (maximum) during 
the day of the diagnostic program. 
 
PET-CT, positron emission tomography/computed tomography; EUS, endoscopic ultrasonography;  
EBUS, endobronchial ultrasonography 
 
:stay at the ward 
:PET-CT 
:pulmonary function tests 
:light meal 
:review imaging 
:consultation with the patient 
:invasive non-surgical investigations (ultrasonographically guided aspirations, 
EUS, EBUS and bronchoscopy) 
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(JS) and a nuclear physician (AO). All CT scans were contrast CT scans except for 
patients with renal insufficiency. Afterwards patients consulted a pulmonologist for 
history, short physical examination, explanation of test results so far and forthcoming 
invasive investigations in the afternoon. The choice of these invasive non-surgical 
investigations was guided by a flow-chart (figure 2) and consisted of bronchoscopy 
(eventually with blind TBNA), US guided FNA (US-FNA) or US guided core tissue 
biopsies and EUS. Navigational bronchoscopy for peripheral lesions was not 
performed in this study. EBUS became available halfway the study. The invasive 















Histologic and cytologic specimen were analysed on a routine base. The time for 
pathologic analysis varied between one day in case of high clinical priority to 
maximally five working days. In cases with only cytologic specimen, NSCLC subtype 
determination was performed by using immunohistochemical stained slices of 
paraffin embedded cell suspensions. Molecular analysis was routinely implemented 
halfway 2009 in patients with stage IV adenocarcinoma. 
At the end of the diagnostic day, the patients left the hospital with an appointment for 
a final consultation one week later to be informed about the diagnosis and treatment. 
Figure 2. Diagnostic flow chart. 
 
§ :lymph nodes on Naruke 2L, 4L, 5, 7, 8 and 9, very large nodes on 2R and 4R 
‡ :lymph nodes on Naruke 2L, 4L, 2R, 4R, 7 and hilar masses 
⃰   :when PET-CT shows multiple pulmonary, osseous or hepatogenic lesions that are not easy 
accessible and demonstrate obvious metastatic disease 
 
PET-CT, positron-emission tomography; US, ultrasound; EUS-FNA, endoscopic ultrasound-guided 
fine needle aspiration; EBUS-TBNA, endobronchial ultrasound-guided transbronchial needle 
aspiration 
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If additional investigations were needed (particularly exercise tests, perfusion scans 
or preoperative evaluations by other consultants), appointments were made. Brain 
MRI was not part of the diagnostic process so this was performed on separate days 
(within a week) in patients with clinical stage III disease or clinical suspicion of brain 
metastasis. 
 
Evaluation of results  
Numbers of patients with benign and malignant disease and patients in whom PET-
CT revealed no abnormalities at all, was evaluated. Malignant and benign disease 
was subdivided in clinical diagnoses and pathologically confirmed diagnoses. 
The percentage of patients with a definitive diagnosis (including disease stage) 
obtained during the diagnostic day was determined. Version 7 of the International 
Association for the Study of Lung Cancer (IASLC) was used for staging of 
NSCLC[13]. 
The number of days (including weekend-days), from initial abnormal chest 
radiography to first visit at the pulmonary department was assessed as well as the 
time from start of analysis to the final consult (the moment patients were informed 
about the definitive diagnosis including disease stage and proposed therapy) and the 
time from final consult to start of treatment. 
The numbers of invasive tests (bronchoscopy, EUS-FNA, EBUS-TBNA and 






A total of 303 patients were enrolled in the program from February 1st 2006 until 
January 1st  2010. Six patients were ineligible for analysis (4 patients already had CT-
scans performed before the study day, one patient had no PET scan at the planned 
diagnostic day and one patient underwent a supraclavicular biopsy before inclusion). 
Of 297 patients included, 72%(215/297) had malignant disease ( 202/215 patients 
with a pathologically confirmed diagnosis and 13/215 patients with a clinical 
diagnosis). Benign disease was diagnosed in 26%(78/297) patients (9/78 patients 
with a pathologic diagnosis and 69/78 patients with a diagnosis based on imaging). 
No abnormalities at all were detected on PET-CT scans in 1%(4/297) of patients. In 
these patients, supposed lesions on chest radiography appeared to be superposed 
normal structures (table 1). 
 
Benign diagnoses  
Table 2 shows characteristics for 78 patients with a benign diagnosis with a 
preponderance of infectious diseases (52%). Metabolic activity was seen in most 
patients with an infectious etiology and in all patients with sarcoidosis and pulmonary 
embolism. The diagnosis was based on pathology in 12%(9/78) and on imaging in 
88%(69/78) of patients. 
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A median time of 9 days passed from the day the abnormal radiograph was made 
until the patient entered the diagnostic program (range 2-33 days). Most patients 
were informed about their benign diagnosis immediately at their first contact with the 
pulmonologist when conclusions were based on imaging with PET-CT. Treatments 
with antibiotics (11), anticoagulation (3) and tube thoracostomy (2) were initiated the 
same day. One patient was scheduled for rigid bronchoscopy on a separate day. 

























For the patients with a diagnosis based on imaging (69/78), radiological follow up 
data were collected in 71%(49/69) of patients (11 with CT and 38 with chest 
radiographs). During a median follow up of 117 days (range 13-1146 days), one 
patient developed a pleural mesothelioma and in one patient a non-suspected lesion 
was resected and turned out to be a NSCLC. There was no  radiological follow up in 
29%(20/78) of patients because the diagnosis was considered clear-cut. 
 
Malignant diagnoses  
Characteristics, diagnosis and tumour stage of 215 patients with a diagnosis of 
malignancy are described in table 3. NSCLC was diagnosed in 74%(159/215) of 
patients, SCLC, metastases from non-pulmonary origin and primary non-epithelial 
malignancies in 13%(29/215), 6%(13/215) respectively 6%(12/215) of patients. 
For almost all patients, a pathologic subtyping of NSCLC was available as shown in 
table 4. 
  
diagnosis No of patients (%) 
  
Malignant Disease¶  
          Pathological diagnosis          202 (68) 
          Diagnosis based on imaging           13  (4) 
Benign Disease§  
          Pathological diagnosis            9   (3) 
          Diagnosis based on imaging           69 (23) 
No abnormalities diagnosed            4   (1) 
  
Total             297 
  
Table 1  
Results of the diagnostic program 
¶ : subdivided in table 3 
§ : subdivided in table 2 
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In 5%(11/215) of patients the diagnosis of NSCLC was based on imaging but 
pathological confirmation was not obtained. Eight of these patients had early disease 
and were offered curative radiotherapy and 3 patients (high age and bad general 
condition) had advanced disease but further analysis was abandoned because of 
lack of clinical consequences. 
In 15%(32/215) of patients the diagnostic day did not provide enough information for 
a final diagnosis (including tumour stage). Additional invasive investigations and 




 No of patients (%) 
   
Age (range,y) 63 (36-81)  
   
Sex 49 63 
       male 29 37 
       female   
   
Diagnosis   
  Infectious Diseases§ 42 54 
  Benign tumours 9 12 
  Scar tissue 4 5 
  Sarcoidosis 5 6 
  Vascular structures 3 4 
  Pulmonary embolism 3 4 
  Pleural thickenings 2 3 
  Rounded atelectasis 2 3 
  Miscelaneous¶ 8 10 
   
Total  78  
   
§ : 40 recovering pneumonias; 1 lung abcess; 1 atypical mycobacteriosis 
¶ : 1 mediastinal lymphadenopathy without FDG uptake on PET scan;  
     1 thyroid; 1 atelectasis; 1 reactive pleural fluid; 1 paralytic diaphragm; 
     1 solitary pulmonary nodule with ground glass appearance and positive  
     on PET scan; 1 ostheophyte; 1 sequestrated segment 
Table 2 
 Benign diagnoses in study group 
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 N(%)  
Sex   
              Male 145 (67)  
              Female    70 (33)  
  Percentage of  
subtotal 
NSCLC Stage   
              Stage I 26       16 
              Stage II 23      14 
              Stage III  47       30 
              Stage IV 54       34 
Multiple synchronous§ 9 6 
   
              Subtotal 159 (74)  
            Percentage of  
subtotal 
SCLC   
             Limited Disease 10       34 
             Extensive Disease 19       66 
   
               Subtotal 29 (13)  




Metastatic Disease 13‡ (6)  
Other Primary Malignancies 14† (7)  
   
Total 215  
   
Table 3  
Characteristics of patients with a Clinical or Pathological  
Diagnosis of Malignancy 
               
               
§ :  8 patients with synchronous lung cancers and 1 patient both a malignant lymphoma 
and a non-small cell lung carcinoma were diagnosed 
‡ : 4 colorectal, 2 urothelial, 2 melanoma, 2 renal cell, 1 breast and 1 prostate metastasis 
† : 4 malignant lymphoma, 2 thymoma, 2 mesothelioma, 5 large cell neuroendocrine 
carcinoma and 1 esophagus carcinoma 
 
NSCLC, non small cell lung cancer; SCLC, small cell lung cancer 
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Timelines For the patient with a diagnosis of malignancy conduction times of the 
diagnostic process until start of treatment were assessed. The median number of 
days between detection of the suspicious abnormalities and first consultation was 9.0 
days in the study period (figure 3).  
The median number of days between the first and final consultation visit (where 
patients were informed about their diagnosis including tumour stage and treatment 
strategy) was 7.0 days. Treatment started after a median of 7,5 days.  
 
Numbers of investigations  
In figure 4 the rates of invasive diagnostic tests and surgical diagnostic procedures 
applied in patients with malignancy are presented. In 2%(4) of patients analysed in 
the study program, no invasive tests were performed at all and the diagnosis was 
based on imaging (3 patients with metastatic disease from a non-pulmonary origin 
and 1 patient with extensively metastasized disease who refused further analysis). 
During the one-day diagnostic workup, in 53%(114/215) of the patients with 
malignancy, the final diagnosis and disease stage were obtained with just one 
invasive investigation. These investigations were bronchoscopies in 26%(56/215), 
EUS in 12%(26/215), EBUS in 2%(4/215) or percutaneous US-guided biopsies 






Squamous cell carcinoma 58 (36) 
Adenocarcinoma 73 (46) 
Large cell carcinoma  4   (3) 
Undifferentiated NSCLC  1   (1) 
BAC and BAC with adenocarcinoma  3   (2) 
Basaloid carcinoma  1   (1) 
Multiple synchronous  8   (5) 
Pleomorphic carcinoma  0   (0) 





Subtypes of NSCLC (Pathological and Clinical) 
  
               
NSCLC,Non-small cell lung cancer; BAC, bronchioalveolar carcinoma 
* :diagnosis based on imaging 
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performed at all during the analysis. For patients who underwent a bronchoscopy, the 
tumour was centrally located in 52% and was peripherally located in 48% of patients. 
Two or more invasive non-surgical tests were applied in 33%(71/215) of patients in 
the study group. 
A stage and diagnosis was obtained in 92%(198/215) of patients with a malignancy 
in the study group with non-surgical investigations but 8%(17/215) of patients 
required surgery to finalize the diagnosis (staging in 14 and subtyping of malignant 











Figure 3. Patient waiting times during the diagnostic program for patients with malignancy.  
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This paper describes the performance of a diagnostic program designed to improve 
the logistics of patients and diagnostic tools and to achieve a more sensible choice of 
invasive diagnostic investigations. Integrated PET-CT is the starting point for 
subsequent investigations to be performed on the same day. The location of biopsies 
is preferentially selected to obtain a tissue diagnosis as well as a verification of 
tumour stage. 
 
Diagnostic results  
Benign disease was diagnosed in 26% of patients which seems fairly high compared 
to 16% reported in a recently published study also with PET-CT as initial imaging 
modality in a fast track program[8]. A better selection could lower this figure. The 
additional metabolic information facilitated nevertheless the diagnostic process for 
Figure 4 
Rates of invasive diagnostic tests* and surgical diagnostic procedures§ applied to obtain 
a diagnosis and disease stage for patients with  malignancy in fast-track diagnostic 
program (study group) and reference group. 
 
⃰ : Bronchoscopy, Ultrasound-guided percutaneous biopsies, Endoscopic Ultrasound-guided fine needle-
aspirations, Endobronchial Ultrasound-guided transbronchial needle aspirations. 
§: Surgical procedures study group: 11 mediastinoscopies, 3 lymph node biopsies, 1 VATS, 1 laparoscopy, 
1 bone biopsy.  
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many patients with benign disease. We abstained for instance from further invasive 
diagnostics when lesions showed no FDG uptake. 
In the vast majority of patients with a malignancy a pathologic diagnosis, including 
confirmation of tumour stage, was acquired on the diagnostic day of the program. 
The routine pathologic elaboration precluded immediate informing of patients the 
same day. From this perspective, our program differs from a fast track diagnostic 
program that was described recently providing a cytologic diagnosis at the end of the 
diagnostic day[8]. However, modern therapy is often customized to histologic 
subtyping and molecular characteristics. It is impossible to perform these refined 
techniques in a fast track (one-day) program although it is currently feasible to 
perform these advanced analyses on cytologic samples. 
 
Diagnosing times 
A short duration of diagnostic time, as one of the main goals of the study, was 
achieved. The time from first visit to consulting the patient about diagnosis, disease 
stage and treatment was just 7 days (including weekend days). This resembles the 
results of a Canadian study that demonstrated a reduction in diagnosing time 
compared to a retrospective preimplementation group. However state of the art 
diagnostics such as FDG-PET, endoscopic ultrasound and surgical staging 
procedures were not included in the workup of that study[9]. Moreover, it is not clear 
if determination of a final disease stage was part of the diagnosis.  
Recommendations, stated in guidelines on waiting times, are met largely in our study 
group[14, 15]. 
 
Invasive diagnostic techniques 
Another aim of this study was was to compress the diagnostic tests in one day,  
customized to the findings on the PET-CT. It was expected that a more adequate 
choice of diagnostic tools could lead to a low rate of invasive diagnostic tests. In this 
program there was a variety of immediately available US guided biopsy techniques 
all performed by pulmonologists. Primary tumours adjacent to the thoracic cage, 
supraclavicular or axillar lymph nodes and distant metastases were localized with 
percutaneous US and biopsied under direct vision. EUS-FNA and in a later phase 
also EBUS-TBNA  was performed for mediastinal staging. Furthermore was EUS-
FNA applied for upper abdominal staging. When imaging showed obviously 
extensive metastatic disease, the easiest accessible lesion was selected for biopsies 
according to the recommendations in a recent guideline of the American College of 
Chest Physicians (ACCP)[16]. 
In one third of patients, percutaneous or endoscopic US-guided needle aspirations in 
a metastasis or mediastinal lymph node, provided the final diagnosis and tumour 
stage at the same time. This observation supports our proposition that invasive non-
surgical tests should be guided by the results of radiological and nuclear imaging. 
Corresponding to the Dutch Guideline on NSCLC,  pulmonologists perform 
bronchoscopy as a standard procedure when lung cancer is suspected unless the 
tumour is smaller than 2 cm and has a peripheral location[15]. In other diagnostic 
programs bronchoscopy was the fixed invasive diagnostic modality after imaging with 
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CT and/or PET[8, 9].  This study demonstrates that bronchoscopy can be omitted in 
a substantial number of lung cancer patients when an appropriate choice from 




Selection of patients was based on chest radiography in combination with clinical 
information in the referral letter. There were no predefined selection criteria. 
Unnecessary PET-CT’s  were made as a consequence of this diagnostic program 
and a cost analysis could elucidate the financial impact of this. To examine this 
properly a randomised controlled trial of initial PET-CT versus initial CT followed by 
the most appropriate diagnostic tests is required. It is possible however that patients 
with a benign outcome in the period before the program would have undergone 
relatively more unnecessary invasive diagnostic tests due to the absence of 
metabolic information provided by PET-CT. In patients in the study group with lesions 
showing no or very low FDG uptake, a wait-and-see strategy was followed and so 
invasive diagnostics could be spared. A clinical index of suspicion deduced from this 
study population or an extended population could help in a better selection of 




In almost all patients, a diagnosis (including tumour stage in patients with 
malignancy) could be made with a PET-CT and subsequent invasive diagnostic tests 
performed the same day. Integrated PET-CT as initial imaging modality is a guide to 
the lesions that provide a diagnosis and tumour stage at one time. These lesions can 
often be approached with percutaneous or endoscopic US-guided biopsy techniques. 
Therefore bronchoscopy is not per definition an obligatory part of the analysis of a 
suspicious abnormality. 
 
CLINICAL PRACTICE POINTS 
 
In reports on fast-track diagnostic programs for lung cancer subjects, CT and 
bronchoscopy are used as standard investigations. To provide a histologic diagnosis 
and a verified disease stage in that context is almost impossible but essential for 
treatment decisions. This study demonstrates that a proper choice of biopsy 
instruments, guided by PET-CT findings, results in a finalized analysis in almost all 
patients in one day. A diagnosis can be obtained by sampling lesions that provide a 
diagnosis and disease stage at once in many patients. Consequently time-
consuming, unpleasant and unnecessary investigations can be prevented. 
Furthermore from this study it is obvious that bronchoscopy is not an obligatory part 
of the diagnostic strategy. After pathologic processing the patients can be informed 
about diagnosis and treatment options in a very short time.  
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Endoscopic ultrasound guided fine-needle aspiration (EUS-FNA) is an established 
way to examine mediastinal and upper abdominal abnormalities with cytologic 
specimen. EUS guided tissue core biopsies (EUS-TCB) provide samples for 
histologic analysis. In this prospective study we compared the diagnostic 
performance of both sampling techniques for pathologic and molecular analysis. 
Methods  
One hundred patients with pulmonary, mediastinal or left adrenal gland masses 
larger than 20mm in the sampling direction were analyzed with 4 passes of EUS-FNA 
followed by 4 times EUS-TCB. When biopsies were adequate, mutation analysis was 
performed.  
Results 
Sensitivities of EUS-FNA, EUS-TCB and both combined are 90.7%, 68.6%, and 
96.5%, respectively. The difference between EUS-FNA and EUS-TCB is significant 
(P=0.00055). In the subgroup with malignancy, EUS-FNA is also significantly 
superior over EUS-TCB (P=0.00028).  
Non-squamous cell carcinoma was diagnosed in 29 patients. In 3/29 patients no 
molecular analysis was performed. Mutation analysis was successful in 12/26 (46%) 
of biopsies and 14/26 (54%) of biopsies were inadequate for molecular analysis.  
Conclusions 
EUS-TCB has no added value over EUS-FNA for pathologic analysis of pulmonary, 
mediastinal or left adrenal masses. Tissue appeared inadequate for molecular 







  core biopsies versus fine-needle aspirations 
INTRODUCTION 
 
Endoscopic ultrasound guided fine-needle aspiration (EUS-FNA) is widely used to 
diagnose pathologic mediastinal masses (upper left paraoesophageal, subcarinal 
and lower paraoesophageal sites) as well as the upper abdominal and left adrenal 
masses. High diagnostic performances of EUS-FNA were described for mediastinal 
lesions with reported sensitivities and specificities ranging from 78-85% and 92-
100%, respectively, and diagnostic accuracies up to 95%[1-9]. 
With EUS-FNA, cytological samples are obtained that provide a diagnosis and stage 
of disease in most patients based on morphology and additional immunocytochemic 
staining of embedded cells. For optimal pathologic analysis however, assessment of 
the tissue structure might help in refining the diagnosis. Furthermore do histologic 
samples usually contain more tumor cells, providing more material for a molecular 
evaluation. Tissue is often obligatory for subtyping of some malignancies, like 
lymphoma and breast cancer[10, 11]  
Endoscopic ultrasound guided tissue core biopsy (EUS-TCB) needles were 
developed to provide small tissue samples enabling evaluation of tumor cells in their 
tissue context. In gastroenterology EUS-TCB was shown to be useful in the 
evaluation of benign and malignant disease in the upper abdomen[7, 12-23]  In 2 
retrospective studies the diagnostic performance of EUS-TCB was described for 
thoracic lesions[24, 25]. For EUS-TCB in mediastinal lesions a diagnostic accuracy of 
90% was reported[24]. In combination with EUS-FNA the accuracy increased to 
98%[25].  
Complication rates for EUS-TCB were not higher than for EUS-FNA (2% for both in 
transgastric use[19]). 
Studies on the appropriateness of EUS-TCB for molecular analysis are not available. 
Therefore we performed a prospective study comparing the results of EUS-TCB with 
EUS-FNA. Our primary objective was to investigate whether EUS-TCB has added 
value over EUS-FNA alone for the diagnosis of mediastinal or left adrenal masses.  
A secondary objective was to study whether EUS-TCB would provide tissue enabling 
molecular analysis adequately in patients with a diagnosis of non-squamous cell 
carcinoma of the lung. 
 
MATERIALS AND METHODS 
 
Patient selection 
Patients with mediastinal masses or enlarged left adrenals of at least 20 mm (as 
measured on CT) entered the study after informed consent was obtained. For 
primary tumor and adrenal gland the largest diameter was used and for lymph nodes 
the short axis diameter was used.  
The study was performed in the Isala Klinieken, Zwolle, the Netherlands and 
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Sampling procedures 
Four fine-needle aspirations followed immediately by intentionally four tissue core 
biopsies were performed in masses measuring at least 20 mm in the biopsy direction 
on ultrasonography(the needle extends 20 mm when biopsies are taken). When the 
TCB needle failed before 4 biopsies were taken, the number of performed biopsies 
was noted. 
EUS was performed by using a Pentax Hitachi linear endoscope (FG-36UX, diameter 
2,4mm and EG-3830UT, diameter 3,8mm). Fine-needle aspiration was performed 
with an Echotip Endoscopic ultrasound needle of 22 G (Cook Ireland Ltd).  
Cytologic material was deposited on two air-dried slides and in Saccomanno’s fluid. 
Biopsies were performed using the 19G Quick core endoscopic ultrasound biopsy 
needle (Cook Ireland Ltd) and collected in formalin 4% (Figure 1). EUS-TCB and 
EUS-FNA was performed by two experienced endoscopists. 
 
Pathologic assessment 
Of each of the EUS-FNA samples, 2 air-dried slides were Giemsa stained and 
assessed by an experienced pathologist. The rest of the sampled material was 
collected in Saccomanno’s fluid (50% v/v ethanol & polyethylene glycol 1500) for the 
preparation of cell paraffin blocks. Four 10-micron slides were cut from the blocks on 
3 levels (approx. 250 microns apart) and stained with hematoxylin and eosin (H&E). 
If >50 tumor cells were found in the H&E slide, additional immunohistochemical 
staining was performed using thyroid transcription factor-1 (TTF1), cytokeratin 7, p63 
and chromogranin A in addition to alcian blue stain. 
Core tissue biopsy material was collected in 4% formalin, and fixed overnight. 
Paraffin blocks were prepared; slides were cut and stained in the same manner as 
the cell paraffin block material. If a metastasis from other primary sites than lung was 
considered, appropriate additional immunohistochemical stains were ordered. 
 
Molecular analysis 
When non-squamous cell carcinoma of the lung was diagnosed, the TCB samples 
were assessed for molecular analysis. Adequate samples were cut into five 10-
micron slides,  DNA was extracted[26], and high resolution melting analysis (HRM) 
was performed for KRAS exon 2 and Epidermal Growth Factor Receptor (EGFR) 
exons 18, 19, 20 and 21. An abnormal HRM curve was followed by Qiagen 
















The upper panel shows the 
ultrasound image of a tissue core 
needle biopsy (19G) in a left adrenal 
metastasis.  
 
The middle panel shows the 
corresponding CT image showing 
enlarged adrenals.  
 
The lower panel shows the Quick 
core endoscopic ultrasound biopsy 
needle (19 G Cook Ireland Ltd) 
closed (above) and opened (below). 
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Statistical Analysis  
Given an alpha of 0.05 and a power of 80% the minimum required total sample size 
is 98 patients to detect an increased sensitivity from 74% for FNA to 94% for 
TCB. Differences in sensitivity, specificity and accuracy between the diagnostic 
modalities have been tested with the McNemar's test for correlated proportions[27]. 
P-values <0.05 were considered significant. Analyses were performed using SPSS-




Between August 2009 and February 2012, 100 patients entered the study. Patient 
characteristics are described in table 1. In 15 patients the EUS-TCB needle failed 


































Age (mean) 22-84 (60) 
  
Male/ Female 70/30 
  
Site of intervention N 
          N2 1 
          N4L 5 
          N7 81 
          N8 3 
          Left adrenal gland 4 
          Primary tumor 6 
  
Diameter on CT  
         Tumor/ Left adrenal gland (largest axis) 25-83 mm 
         Lymph node (short axis) 11-38 mm 
  
Needle passes  N 
          FNA 100 x 4* 
          TCB 1 x 1** 
 5 x 2 
 9 x 3 
 85 x 4 
  
Table 1 
Patient characteristics of 100 patients with enlarged mediastinal 
lymph nodes or enlarged adrenal glands.  
 
*   100 patients had 4 needle passes 
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All diagnoses are summarized in table 2. Half of the patients had a pulmonary 
malignancy; about one third had benign disease.  
 
   Table 2 
   Diagnosis established by EUS-FNA, EUS-TCB or both. 
 
    *: Renal cell carcinoma, rectal carcinoma and melanoma, **: Reactive and normal lymph node, 
    ***: including sample errors, ****: including dry tap and uncertain diagnosis. 
 
 
Final diagnosis No. 
patients 
EUS-FNA EUS-TCB EUS-FNA 
+ TCB 
     
Correct diagnosis 
 
100 88 66 95 
     
  Lung malignancy 51 49 (96%) 34 (67%) 50 (98%) 
     
       NSCLC 38 36 (95%) 24 (63%) 37 (97%) 
             Non-squamous 29 24 (83%) 17 (59%) 28 (97%) 
             Mutation analysis 22 19 (86%) 12 (55%) 22 (100%) 
       SCLC 13 13 (100%) 10 (77%) 13 (100%) 
     
  Lymphoma 3 3 (100%) 3 (100%) 3 (100%) 
     
  Other malignancy* 7 7 (100%) 7 (100%) 7 (100%) 
     
  Granulomatous 
  Disease 
 
25 19 (76%) 15 (60%) 23 (92%) 
  Benign** 14 11 (79%) 7 (50%) 12 (86%) 
     
Incorrect diagnosis  12 34 5 
     
  False diagnosis*** 
 
 6 2 1 
  Inadequate**** 
 
 6 32 4 
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A definitive diagnosis was obtained by EUS (n=84), mediastinoscopy (n=2) or 
broncheoalveolar lavage (n=1). In 14 patients mediastinal lymphadenopathy was 
considered reactive, based on test results in combination with clinical follow up. One 
patient with lymphoid tissue in EUS-FNA was diagnosed as sarcoidosis based on 
bronchoalveolar lavage results and radiologic appearance. In one patient, EUS-FNA 
and EUS-TCB were inadequate and uncertain respectively. The patient died of 
disseminated melanoma without radiologic suspicion of mediastinal involvement. 
Table 3 shows the diagnostic performances of EUS-TCB and EUS-FNA. The 
sensitivities of EUS-FNA and EUS-TCB are 90.7% (95%CI: 82.7;95.2), respectively 
68.6% (95%CI: 58.2;77.4). The difference is significant (P = 0.00055; 95%CI: 
10.7;33.4). The sensitivity of the combined procedure is 96.5% (95%CI: 90.2;98.8). 
The diagnostic accuracy for EUS-FNA, EUS-TCB and both combined is 91.0%, 
73.0% and 96.0% respectively. The difference in diagnostic accuracy is significant 
(P<0.01; 95%CI: 5.6;30.4). 
In malignant disease (N=61) sensitivity of EUS-FNA, EUS-TCB and both combined is 
96.7% (95%CI: 88.8;99.1), 72.1% (95%CI: 59.8;81.8), and 98.4% (95%CI: 91.3;99.7) 
respectively (table 3). Difference between both FNA and TCB for determining 
malignant disease is significant (P = 0.00028; 95%CI: 12.9;36.3). 
In the subgroup of patients with granulomatous disease (N=25) sensitivity of EUS-
FNA, EUS-TCB and both combined is 76.0% (95%CI: 56.6;88.5), 60.0% (95%CI: 
40.7;76.6) and 92.0% (95%CI: 75.0;97.8) respectively. Difference between EUS-FNA 




Table 3  
Operating characteristics of EUS-FNA, EUS-TCB and both. 
 
* p=0,00055 EUS-FNA vs. EUS-TCB, **p=0,00028 EUS-FNA vs. EUS-TCB. 
 
 
  sensitivity  specificity accuracy 
      








 N=100 N=61 N=25 N=100 N=100 
      
EUS-FNA 90.7% 96.7% 76.0% 92.9% 91.0% 
      
EUS-TCB 68.6%* 72.1%** 60.0% 100.0% 73.0% 
      
EUS-FNA + 
EUS-TCB 
96.5% 98.4% 92.0% 92.9% 96.0% 
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Molecular analysis 
In three out of 29 patients with non-squamous carcinoma, biopsies were not 
assessed for molecular analysis for unknown reasons. In 12 biopsies,of 26 patients  
with non-squamous cell carcinoma, tumor cellularity was above 10% with good DNA 
quality and so molecular tests followed. Inadequate material was found in 14/26 
(54%). The diagnostic success rate was 46%. In 8/14 patients with inadequate 
biopsies, mutation analysis was performed on FNA successfully. In 5/14 patients with 
inadequate biopsies, no mutation analysis was performed on FNA and in 1/14 
patients with inadeqate biopsies, also the FNA was inadequate for molecular 
diagnostics. 
In 19/29 patients mutation analysis was performed on aspirated samples. In 1/29 
patients the material was inadequate. The diagnostic success rate was 19/20(95%). 
In 8/29 patients mutation analysis was not performed ( in 3/8 patients mutation 
analysis was already performed on TCB and in 5/8 there was no clinical indication).  
 
Performance of biopsy device 
In 15 patients the EUS-TCB needle failed before 4 biopsies were taken (Table 1). 
Failure of needles means that the needle could not be tightened again for 
subsequent biopsies. In 6/15 patients with 1 or more needle failures a diagnosis 
could not be made on the available samples. In 33/85 patients with all 4 biopsies a 





This prospective study did not demonstrate additional value of EUS-TCB (expressed 
as a higher sensitivity) over EUS-FNA alone in the analysis of mediastinal and 
adrenal masses, unlike previous retrospective studies[24, 25].  
The diagnostic accuracy of 73.0% in our study for EUS-TCB contrasts to the 
accuracy of 90% reported before[24]. The diagnostic accuracy of 96.0% of the 
combination of EUS-TCB and EUS-FNA in our study matches the diagnostic 
performance of 98% reported in a previous study[25].  
A procedural cause for this inferior accuracy cannot be found. FNA and TCB was 
performed in the same order although up to 6 biopsies were obtained in both 
previous studies[24, 25]. In one study the diversity of diagnoses was comparable to 
this study[25]. In the other study, performed in a referral centre for granulomatous 
disease, there was a preponderance of granulomatous disease[24].   
In this study, the pathologist was unable to diagnose biopsies adequately in a high 
proportion of patients compared to cytologic samples. This could be explained by the 
characteristics of samples obtained with both procedures. In TCB, the maximum 
biopsy size is theoretically 20 by 0.9 mm but in practice smaller. Moreover, TCB 
contains often fibrous and/or necrotic tissue precluding a confident diagnosis. The 
FNA samples often contain a mixture of 'micro-biopsies' of fibrotic tissue and 
aspirated separate cells as can be clearly seen in cell block slides. 
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Variation in the direction of sampling is smaller with the more rigid TCB needle 
compared to the FNA needle that enables sampling of a greater proportion of the 
lymph node by multiple passes in different directions.  
Another reason for inferior performance of TCB is failure of needles. We observed 
needle failure in a substantial number of patients before the preplanned number of 4 
biopsies was reached. This contrasts to the FNA needle that allowed always 4 
passes in every patient. So, overall, less TCB than FNA was performed in the total 
group. In 6/15 failures it contributed to a worse clear diagnosis. 
As in previous studies no complications were seen in performing EUS-FNA and EUS-





Figure 2. EUS-FNA with (A) Giemsa stained smear and (B) cell block with TTF1-
immunohistochemistry showing positive nuclei. Corresponding quick core biopsy with 
(C) H&E and (D) TTF1 stains. All show adenocarcinoma. Granuloma in smear (E) as 
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Performance characteristics in subgroups  
EUS-FNA was significantly more sensitive than EUS-TCB for the subgroup of 
malignant disease. Although in tumor subtyping histology is still the golden standard, 
an adequate diagnosis is also possible with immunohistochemical staining of 
cytologic samples (figure 2). So, not only the interconnective structures but also the 
volume and quality of samples is of importanceIn this study we observed that in 
experienced hands EUS-FNA and EUS-TCB do not differ with respect to amount of 
tumor material obtained. In patients with granulomatous disease a difference 
between EUS-FNA and EUS-TCB was not obvious but the group was small. In this 
subgroup we often experienced a low to even absent yield in TCB samples. The solid 
rubbery texture in many granulomatous nodes is a possible explanation for the often 
very small or empty biopsies. 
It was disappointing to observe that EUS-TCB had no additional value in 6 patients 
with malignant lymphoma as for this diagnosis histologic samples are almost 
invariably necessary for further subtyping.  
 
Molecular analysis 
TCB often contained insufficient material (or no material at all) for molecular analysis 
in more than half of patients. This contrasted with the high diagnostic success rate of 
mutation analysis in FNA. There was only one patient with a failing molecular 
analysis on FNA but it failed on biopsies as well. The high diagnostic success of 
mutation analysis in EUS-FNA is supported by several recent studies[28-30]. 
Consequently, there is no need to obtain EUS-TCB for mutation analysis.    
 
Limitations 
Our study on the diagnostic performance of EUS-TCB is probably influenced by 
needle failures and the fact that core biopsies of 19 Gauge are still small. Refining 
the needles in order to improve repeated biopsies, enlarging the needles to produce 
larger samples or developing other techniques like ProCore[31], where larger 
structures of histologic material can be obtained, may result in better outcomes.The 
subgroups of granulomatous disease and malignant lymphoma were too small for an 
adequate analysis of the performance of EUS-TCB versus EUS-FNA.  
Also for the comparison of the appropriateness of both sampling techniques for 
molecular analysis,  larger groups should be analyzed and biopsies as well as FNA 
should be compared in all patients. 
 
CONCLUSION 
In conclusion, although the technique of the EUS-TCB by Quick Core is safe, it has 
no added value over EUS-FNA in diagnosing mediastinal or left adrenal masses, 
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ABSTRACT 
 
Introduction: Patients with stage IV non-small cell lung cancer (NSCLC) harbouring 
an activating epidermal growth factor receptor (EGFR) mutation are eligible for 
treatment with EGFR tyrosine kinase inhibitors. With pyrosequencing, low-frequency 
mutations may be detected more easily even in small diagnostic samples like 
endoscopic or endobronchial ultrasound guided needle aspirations (EUS-FNA and 
EBUS-TBNA). The diagnostic performance of pyrosequencing in analysing 
cytological specimens is compared with the routinely used high resolution melting 
(HRM) and Sanger sequencing. 
Methods: Patients diagnosed with adenocarcinoma of the lung were selected from a 
FNA and TBNA specimen database. If formalin fixed paraffin-embedded tumor 
blocks were available, mutation analysis was performed for EGFR and V-Ki-ras2 
Kirsten rat sarcoma viral oncogene homolog (KRAS) genes using both 
pyrosequencing and HRM. When HRM showed abnormalities, Sanger sequencing 
was used. 
Results: A total of 126 samples were available for mutation analysis. The analysis 
success rate for pyrosequencing and HRM were 97% and 93%, respectively. HRM 
failures were observed in fragmented DNA showing chains of 100-200 base pairs 
(bp). A significant correlation between length of DNA fragments (100-300 versus 300-
400 bp) and mean sample age (797 days versus 317 days) was found (P<0.0001) 
suggesting an influence of sample age on DNA quality. 
Conclusion: Pyrosequencing on cytological blocks, especially older tumor blocks, is 
feasible with a high diagnostic success rate. Failures in HRM were observed in DNA 


























A subset of the pulmonary adenocarcinomas harbouring mutated epidermal growth 
factor receptor (EGFR) genes have a prolonged survival irrespective of treatment[1]. 
Mutations cause alterations in the intracellular part of the transmembrane EGFR. 
This results in a stronger binding of tyrosine kinase inhibitors (TKIs) than ATP with 
subsequent inhibition of EGFR[2]. When compared to chemotherapy, treatment with 
EGFR-TKIs showed higher response rates and significant better progression-free 
survival with mild toxicity[1, 3-6].  
This benefit in patients with activating EGFR mutations requires mutation analysis as 
a standard diagnostic procedure in patients with stage IV adenocarcinoma of the 
lung.  
Another even more frequently encountered mutation in adenocarcinomas of the lung 
occurs in the V-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog (KRAS) gene. 
Recommendations on tissue and test characteristics for EGFR mutation analysis 
were recently published in an European consensus report[7]. The authors prefer the 
use of histology and mention the possible mutation analysis in cytological specimens. 
In reported large clinical studies, mutation analysis is almost invariably performed on 
tissue samples.  
In routine clinical practice tissue samples are required, however, a diagnosis is often 
made on cytological specimens. Tissue biopsies are not always available. Therefore, 
mutation analysis of small tumor samples is necessary. Mutation analysis on 
cytological specimen, including transbronchial and transesophageal aspirates, is 
reported previously in several studies[8-20]. This is particularly relevant for the 
majority of stage III patients progressing to stage IV, enabling archived mediastinal 
aspiration cell blocks to be used for molecular processing. Those aspirates can be 
performed in the same lymph node in different directions gathering multiple aspirates 
from different parts of the same node metastasis thereby increasing the yield of 
tumor cells. 
Although it is not clear which method is the best for mutation analysis in NSCLC, a 
combination of DNA amplification and direct sequencing is the most practiced. 
After DNA extraction, amplification of target sequences with the polymerase chain 
reaction (PCR) is the next step. Prescreening for abnormal target alleles is possible 
with high resolution melting (HRM)[21]. The sensitivity of detecting mutations can be 
increased by amplification refractory mutation system (ARMS-PC)[22], allele specific 
PCR[23, 24], peptide nucleic acid (PNA) clamping methods[25, 26]  or preferential 
amplification of mutant alleles with co-amplification at lower denaturation 
temperature-PCR technique (COLD-PCR)[20]. 
When genomic abnormalities are detected, further characterization with DNA 
sequencing follows. Various techniques for sequencing have been developed. Test 
characteristics improved over time and more recently developed tests require less 
tumor cells. 
The question remains whether screening should precede sequencing or whether 
sequencing should be performed upfront. The diagnostic accuracy of tests in relation 
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to the quality of samples as well as the costs and diagnostic speed are important 
factors in designing the optimal testing strategy. 
Pyrosequencing is one of the latest assays using luminometric instead of 
electrophoretic detection[27]. This technique enables characterization of mutations 
and quantification of mutated alleles in samples with low tumor cell density and 
detection with high accuracy rates[28].  
The objective of this study is to compare the diagnostic performance of 
pyrosequencing with the comprehensive strategy of HRM (followed by Sanger 
sequencing[29] in case of abnormalities) for EGFR and KRAS mutation analysis in 
paraffin-embedded cytological specimens of adenocarcinoma patients obtained with 
EUS and EBUS. The analysis success rates and concordance rates for both 
techniques are determined. 
 
PATIENTS AND METHODS 
 
Patients 
Patients with a cytological diagnosis of adenocarcinoma established on EUS or 
EBUS derived samples were selected from our local patient database. The diagnosis 
was based on morphologic and immunohistochemical characteristics for all tumors. 
All samples were coded and managed independently. The study was approved by 
the Medical Ethical Committee of the Isala Clinics in Zwolle, the Netherlands. 
 
EUS and EBUS 
EUS and EBUS was performed with Pentax ultrasound endoscopes (EUS FG-36UX 
respectively EBUS EB-1970UK; Pentax, Tokyo, Japan) with a Hitachi EUB-5500 
processor (Hitachi, Tokyo, Japan). The fine needle aspirations (FNA) were performed 
under conscious sedation with midazolam and with local anaesthesia sprayed in the 
oropharynx (lidocain 1%) and lidocain gel 20 mg/ml. Needles of 22-Gauge were used 
for sampling and at least two aspirates were smeared on slides initially. Aspirations 
per site (3-4 passes in different directions of the tumor or enlarged mediastinal lymph 
node) were performed and deposited in carbowax 2% fixative. Cell blocks were made 
using cell pellets embedded in AGAR 10%, followed by formalin fixation, dehydration 
and paraffinization.   
 
Tumor cell density estimation 
Sections were cut from formalin fixed paraffin-embedded (FFPE) tissue blocks. The 
first and last sections were stained with haematoxylin & eosin (H&E) for 
histopathological examination. The percentage of tumor cells is estimated using the 
first and last HE section. The estimated ratio is based upon the tumor cell amount 
compared to stromal cells and lymphocytic background. 
 
DNA extraction 
Genomic DNA was extracted from the remaining sections. The sections used for 
DNA extraction were deparaffinated and genomic DNA was extracted using the 
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QIAamp DNA FFPE Tissue Kit (Qiagen, Venlo, the Netherlands) according to the 
manufacturer’s instruction. The extracted DNA was eluted in 100 µl ATE buffer.  
DNA quality was checked by multiplex ladder PCR[30]. 3µl Mastermix (500 µl 10x 
Gold buffer, 40 µl 100 mM Gene Amp dNTP Blend, 250 µl Glycerol 87%, 50 µl Cresol 
Red, 300 µl 25 mM MgCl2, 360 µl double-distilled H2O (ddH2O)); 5 µl primermix; 0,08 
µl Amplitaq Gold (Applied Biosystems, Nieuwerkerk a/d IJssel, the Netherlands); 200 
nM of each primer; 1,0 µl ddH2O and 1 µl sample per test were used. Primers used 
are listed in e-Table 1. PCR cycling was performed on a Veriti 96-well Thermal 
Cycler (Applied Biosystems, Nieuwerkerk a/d IJssel, the Netherlands) using the 
following conditions, one 12-minute cycle at 94,4°C was followed by 30 cycles of 
respectively 30 sec at 95°C, 30 sec at 59°C, 45 sec at 72°C and finally one cycle of 5 
min at 72°C. The produced DNA amplicons were separated using agarose gel 
electrophoresis (3% agarose gel, 200 volt for 1 hour) and assessed with UV light. 
 
Mutation analysis 
Exons 18, 19, 20 and 21 of the EGFR gene and exons 2 and 3 of the KRAS gene 
were examined with HRM as previously described[21, 31]. HRM was performed in a 
total volume of 10 µl, containing 4 µl LightScanner mastermix (Idaho Technology Inc. 
Salt Lake City, Utah, USA), 2 µl genomic DNA, 2 µl 100 nM of each primer and 2 µl 
ddH2O. PCR cycling and HRM analysis were performed on a LightCycler 480II 
(Roche Diagnostics, Almere, the Netherlands) according to conditions previously 
described[32]. When the HRM plots were abnormal  HRM amplicons were checked 
with Sanger sequencing. HRM products were purified using ExoSAP-IT (GE 
Healthcare, Hoevelaken, the Netherlands) according to the manufacturer’s 
instruction. Primers used are listed in e-Table 2. 
The purified HRM products were used for Sanger sequencing using the Big Dye 
Terminator v3.1 kit (Applied Biosystems, Nieuwerkerk a/d IJssel, the Netherlands). 
The reaction mix consisted of 2 µl Sequencing RR-100, 3 µl  5x Sequencing buffer, 
4µl  ddH2O, 1 µl purified PCR product and 10 µl 2.5 µM M13 primer in a final volume 
of 20 µl.  
The sequence reaction was run on a Veriti 96-well Thermal Cycler (Applied 
Biosystems) using the following conditions, one cycle of 96°C for 1 minute followed 
by 25 cycles of 96°C for 10 sec, 60°C for 125 sec and at 4°C subsequently. The 
products were purified using the DyeEx 2.0 Spin Kit (Qiagen) according to the 
manufacturer’s instructions and run on a 3130 Genetic Analyzer (Applied 
Biosystems). Afterwards the sequences were analyzed using the Sequencer 3.0 
software (Applied Biosystems).  
Pyrosequencing was performed using the PyroMark Q24 (Qiagen). The therascreen 
EGFR and KRAS Pyro Kits (Qiagen) were used according to the manufacturer’s 
instruction. The targeted sequences of EGFR and KRAS were amplified using PCR 
(Veriti 96-well Thermal Cycler, Applied Biosystems) using the following conditions, 
one 15 minute cycle at 95°C followed by 42 cycles of respectively 20 sec at 95°C, 30 
sec at 53°C, 20 sec at 72°C and finally one cycle of 5 min at 72°C. Each PCR 
product was used as a template. The sequencing primer hybridizes close to the 
sequence of interest. Pyrosequencing was performed using PyroMark Gold Q96 
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reagents (Qiagen) containing enzyme and substrate mixture, dATP-S, dCTP, dGTP 
and dTTP. Nucleotide incorporation is followed by release of ATP. Luciferin and ATP 
generates light emission following a reaction catalyzed by luciferase. The unique 
dispensing order described by the manufacturer is used to detect possible mutations 
in the targeted sequence. The pyrogram is analyzed using the pyrosequencing data 
analysis software (Qiagen).  
 
Costs of materials and handling time 
The costs of materials to run a single sample for HRM, Sanger sequencing and 
pyrosequencing are 100$, 355$ and 700$, respectively. If possible, costs can be 
reduced by analysing up to two patient samples per run for EGFR exon 18-21 and 
KRAS exon 2-3 (520$ per patient for two cases including blanc controls). The time 
required for a laboratory technician to perform a single HRM analysis is 50 minutes. 
When Sanger sequencing follows HRM the total handling time is 90 minutes. 
Pyrosequencing takes 100 minutes and the total time required for HRM followed by 
pyrosequencing is 150 minutes.   
 
Statistical analysis 
Patient characteristics were examined with descriptive statistics. A Pearson 
correlation coefficient was used to assess the association between estimated tumor 
density and allele frequency. The difference in mean sample age between base pairs 






Between June 2008 and September 2011, pulmonary adenocarcinoma was 
diagnosed in 169 patients by different pathologists using EUS-FNA (N=90) or EBUS-
TBNA(N=79). 
After reviewing the slides for study purposes the diagnoses changed to a different 
pathologic classification in five patients. For all other patients (N=164) there was an 
inquiry for adequate tumor material in deposit. From 24 patients no agar embedded 
material was stored and from 14 other patients no DNA was available (figure 1). 
In six patients DNA had been isolated previously and was not available anymore. 
FFPE tissue blocks did not contain material to re do the DNA extraction after the first 
extraction and immunohistochemical analysis. HRM had been performed in the 
samples of all of these patients followed by Sanger sequencing in three cases. There 
were five EGFR and KRAS wild type and one EGFR exon 19 deletion. 
Tumor samples of 126 patients were processed for DNA analysis. Patient 















Amplification was not successful in 4/126 patients resulting in 122 samples that were 
further analysed with both HRM and pyrosequencing.  
Due to insufficient DNA quality in five samples, HRM was unsuccessful (HRM for 
both EGFR and KRAS failed in 3 patients and HRM for EGFR alone failed in 2 
patients).   
In 39/117 (33%) patients, HRM showed abnormalities in the EGFR exons and in 
50/119 (42%) patients, HRM showed abnormalities in the KRAS exons. In these 
patients direct sequencing was performed to confirm or exclude mutations. In 24 
patients EGFR as well as KRAS sequencing was performed due to abnormalities in 
both gene sets. 
 
Mutations 
Table 2 shows the results of pyrosequencing for EGFR and KRAS in EUS and EBUS 
samples. In 122 samples of adenocarcinoma, 15(12%) EGFR mutations (12 
activating and 3 inhibiting mutations) and 51(42%) KRAS mutations were detected. 
Figure 1 Flow chart showing the selection of patient samples and the successive   
stages of processing and analysis performed on them 
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Detection rate and tumor analysis success rate 
The detection rate of pyrosequencing for EGFR and KRAS mutations was 
122/122(100%) and the tumor analysis success rate was 97%(122/126) for both 
genes. 
The detection rate for EGFR mutations in all endosonography guided samples with 
HRM in combination with Sanger sequencing was 117/122 (96%) and the tumor 
analysis success rate 93% (117/126).  
Sanger sequencing for EGFR and/or KRAS genes following HRM was performed in 
76/119 samples showing single-nucleotide polymorphisms (SNP) in 19 samples 
when HRM was abnormal for exons 18(N=11) and 21(N=8). Detection of SNP’s is 
relatively high due to the chosen primer sets which include a common SNP18 
hotspot. The SNP rate for exon 18 could be reduced by using different primer sets. 
For KRAS the analysis success rate was 94%(119/126). Abnormalities detected with 
HRM in codon 12, 13 and 61 were all based on mutations. 
 
Concordance rates 
For EGFR mutation analysis, HRM with Sanger sequencing in case of HRM 
abnormalities and pyrosequencing showed a concordance rate of 100%(117/117). 
For KRAS mutation analysis the concordance rate was 98%(115/117). In two 
Age ,average (range), yr 66(26-85) 
  
Gender  
      Male 65 
      Female 61 
EUS : EBUS 63:63 
  
Tumor stage  
      Stage 1b 2 
      Stage 2a 4 
      Stage 2b 2 
      Stage 3a 63 
      Stage 3b 12 
      Stage  4 43 
  
Mean sample age in days (range)  
 
585(2-1323) 




Characteristics of 126 patients eligible for DNA processing 
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patients pyrosequencing revealed a G12C point mutation that was not discovered 
with HRM. 
 
Tumor cell density 
The mean estimated tumor density in samples with mutations was 35.5% (range 5-
90%). The mean frequency of the mutated alleles provided by the pyrosequencing 
software was 38.7% (range 5.7-89.3%). The estimated tumor density and the 
frequency of mutated alleles were well associated (Pearson correlation coefficient of 
0.57 (P<0.001). 
 
Factors influencing test results  
The quality of DNA, expressed as the length of base pairs (bp) was studied with 
agarose gel electrophoresis of PCR products. Shorter DNA chains indicate more 
fragmentation. All patients were classified into two subgroups with DNA of 100-300 
bp and 300-400 bp showing mean sample ages of 784 days and 354 days, 
respectively (P<0.0001). All five HRM failures showed short DNA fragments (100-200 
bp). 
The estimated tumor cell density in five samples, that proved to be inadequate for 
HRM analysis, was 5% (n=1), 10% (n=1), 30% (n=2) and 50% (n=1). In the four 
samples with an amplification failure, the estimated tumor cell densities were 












  Number(perc)   Number(perc) 
      
Exon 19 delE746-A750 4  (27%) Exon 2 G12C 24 (47%) 
Exon 19 delL747-P753insP 1  (  7%) Exon 2 G12A   8 (16%) 
Exon 20 T790M 3  (20%) Exon 2 G12V   7 (14%) 
Exon 21 L858R 7  (47%) Exon 2 G12D   6 (12%) 
   Exon 2 G12R   1 (  2%) 
   Exon 3 G13C   1 (  2%) 
   Exon 3 G13D   3 (  6%) 
   Exon 3 Q61H   1 (  2%) 
      
Total  15   51 
      
Table 2 
Mutations found in EUS and EBUS guided fine-needle aspirations of 122 patients 
with pyrosequencing technique. 
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DISCUSSION 
 
In this study, the diagnostic performances of two sequencing strategies were 
compared on cytological samples from mediastinal lymph node metastases in 
patients with adenocarcinoma. Pyrosequencing was compared with HRM followed by 
Sanger sequencing for EGFR and KRAS mutations in specimens obtained by EUS 
and EBUS. Pyrosequencing on cytological blocks especially older tumor blocks is 
feasible. The diagnostic performance of both tests was good. HRM failed in a few 
samples in which the DNA was degraded as a result of longer sample storage times. 
 
Diagnostic success rates 
The high diagnostic success rates of both pyrosequencing (97%) and HRM (93%) in 
this study confirm that cytological aspirates from EUS and EBUS are suitable for 
molecular analysis. In a few samples we were unable to yield DNA with sufficient 
quality for HRM and pyrosequencing.  After DNA amplification, HRM failed in a few 
more samples as well. In contrast to HRM analysis, pyrosequencing was successful 
in all samples indicating a better sensitivity.  
EGFR mutation analysis has been performed previously on various kinds of cytologic 
samples like pleural effusion cell blocks, percutaneous aspirates[8, 15, 33], 
pericardial effusion and BAL[9] and also endobronchial [8-10, 12, 14-16, 19, 33, 34] 
and endoscopic ultrasound guided aspirates[14, 16, 33].  Reported success rates of 
mutation analysis on EUS-guided or EBUS-guided fine needle aspirates ranged from 
72-99% in previous studies[8, 9, 11, 12, 14, 16, 17, 20]  
A comparison of the diagnostic performance of pyrosequencing with other 
sequencing techniques is difficult. In contrast to our study, samples in previous 
studies were often selected on estimated tumor density and most studies were 
prospective studies and consequently used relatively younger specimen.  
 
Concordance rates 
In all but five patients with amplifiable DNA, HRM could be performed. The 
concordance between pyrosequencing and HRM was 100% for EGFR and 98% for 
KRAS. Two samples showed wild type KRAS using HRM analysis but turned out to 
be KRAS mutated after pyrosequencing. This finding is likely related to the higher 
test sensitivity.  
Two previous reports compared different sequencing methods but none described 
pyrosequencing. A recent study of 49 cytologic samples of bronchial brushings and 
pleural effusions compared five different sequencing tests (PCR-Invader®, peptide 
nucleic acid-locked nucleic acid PCR clamp, direct sequencing, Cycleave™ and 
Scorpion Amplification Refractory Mutation System (ARMS)®)[18]. Concordance 
rates between different methods ranged from 93.1-100% (bronchial brushings) and 
85-100% (pleural effusions). In a report on 94 patients, Sanger sequencing was less 
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Tumor cell density 
In this study a significant, although modest correlation was found between the 
estimated tumor cell density and the allele frequency of different EGFR and KRAS 
mutations.  
Previous studies used predefined cut off values of tumor cell density to consider 
samples suitable for molecular analysis[8, 13, 16, 33]. The cut off values ranged from 
25%[33] to 70%[13]. In one report, authors claimed that as little as eight tumor cells 
from paraffin-embedded or fresh specimens obtained after microdissection were 
considered sufficient for mutation analysis in various cytological specimens[9]. Other 
studies on molecular analysis of cytological samples described no cut off values at 
all[10-12, 15, 18]. Estimation of tumor cell percentages is not as relevant as 
previously stated. Moreover, tumor content is a subjective measure with 
interobserver variation. Finding a mutation in a sample with very low tumor density is 
considered a true positive finding. However, the finding of a wildtype in a very low 
tumor density sample could result in a false negative interpretation of a present 
mutation. In addition to this technical issue the question remains whether these very 




A relationship between sample age and DNA chain lengths after PCR was 
demonstrated. All HRM failures showed short DNA fragments in the ladder PCR 
suggesting a relationship between sample age and successful molecular analysis. 
Nevertheless, we found only a few samples unsuitable for molecular analysis, 
despite long storage times for up to 3.5 years. 
This observation is relevant in case of using archival cytological specimen. Subtyping 
and staging is frequently performed at once in stage III NSCLC by EUS or EBUS.  
However, there is no clinical reason to analyze the mutation status in stage III 
disease since treatment with TKIs is not indicated according to present insights.  
Most patients with stage III disease however, progress to stage IV during follow up. 
When adequate material is available for these patients, samples can easily be 
reprocessed for molecular analysis without new invasive tests. 
  
Pyrosequencing in relation to other assays 
The high concordance rate between HRM and pyrosequencing, demonstrates the 
value of both tests for DNA analysis of EUS and EBUS derived samples. Since 
previous reports selected samples based on tumor cell percentages and were 
obtained from different sites with various sampling techniques, comparison with other 
methods is difficult. In contrast to previous studies, this study used samples derived 
from archival tissue with suboptimal (fragmented) DNA.  
Comparable diagnostic performances for EGFR and KRAS mutation analysis 
however, were described with COLD-PCR in combination with Sanger sequencing in 
EBUS samples, enabling the detection of mutation frequencies as low as 5-10%[20].  
Tumor percentages in the same range of 5-10% allowed for mutation detection in our 
study as well although there is some doubt to call a sample a wild type when no 
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mutations are detected in these samples. With pyrosequencing, analysis in samples 
with tumor percentages below 5% is feasible and can be used to confirm HRM 
analysis. 
Other features, particularly cost aspects, are important to accomplish the comparison 
between pyrosequencing and other methods.  
 
Financial considerations 
The least expensive method is HRM combined with Sanger sequencing. 
Pyrosequencing  is too expensive to be used as a routine method in daily practice. 
The financial gap between HRM followed by Sanger sequencing and pyrosequencing 
is irreconcilable, even when more patient samples are analyzed in one run. More 
relevant is the comparison of costs between HRM prescreening followed by Sanger 
sequencing and HRM prescreening followed by pyrosequencing. A 38% increase in 
expenses was calculated for the latter option. 
The difference in costs when Sanger sequencing is replaced by pyrosequencing for 
samples with an abnormal HRM, is substantial, nevertheless, replacement of Sanger 
sequencing by pyrosequencing does have considerable advantages (described 
below) that compensate the surplus of costs to some extend 
 
 
The position of pyrosequencing in mutation analysis 
Sanger sequencing is performed on amplified DNA following HRM analysis. Failure 
of the HRM, due to poor DNA quality, will consequently result in a failure for Sanger 
sequencing as well. 
Identification of mutations with pyrosequencing, if the HRM melting curve and 
difference plots show deviations from the wild type curves, could serve as an 
alternative for Sanger sequencing. An important advantage of such a combined 
approach is that the molecular analysis is based on two independent techniques 
allowing for a more confident molecular diagnosis.  
The high sensitivity of pyrosequencing enables detection of low-frequency mutations 
and analysis in samples with a low tumor content or fragmented DNA. Sample  
characteristics such as tumor cell percentage, older sample age and short DNA 
fragments in the ladder PCR (for example below 200 bp), could serve as criteria to 
choose pyrosequencing over Sanger sequencing. 
 
Results of mutation analysis 
The EGFR mutation incidence was 12% and is somewhat lower when compared to 
large European series (14-16.6%)[3, 35]. In contrast, the incidence of KRAS 
mutations in this study (42%) is considerably higher compared to a large French 
study (14%) The difference in mutation incidence is likely the result of patient 
selection. The French study was performed nationwide, and consisted of stage IV 
patients. Our study population is derived from a relatively small rural area and 
includes stage III and IV patients. In a previous study from the Netherlands a 
comparable incidence for KRAS mutations (37%) and an even lower incidence for 
EGFR mutations (7%) has been described[14]. 
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Important for the patient is a fast diagnostic track to allow a treatment start as soon 
as possible. Performing HRM as an initial screening step is a swift method to 
separate wildtype samples from mutated samples. The disadvantage is that this 
method requires a few days more when HRM abnormalities have to be determined 
by sequencing (in this study 65% of patients) in contrast to the use of 





Mutation analysis in EUS and EBUS guided needle aspirates using pyrosequencing 
is feasible and showed a high diagnostic success rate. The use of cytological 
specimens did not lead to analytical difficulties and mutation frequencies were similar 
to known EGFR and KRAS mutation frequencies in our population. When comparing 
pyrosequencing to HRM, a high concordance rate was found. All HRM failures were 
observed in samples with fragmented DNA associated with longer storage times of 
the formalin fixed and paraffin embedded cell blocks. Mutation analysis by 
pyrosequencing enables the use of shorter DNA fragments increasing the yield of 
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AF4 Forward 5’-CCGCAGCAAGCAACGAACC-3’ 
 Reverse 5’-GCTTTCCTCTGGCGGCTCC-3’ 
   
PLFZ Forward 5’-TGCGATGTGGTCATCATGGTG-3’ 
 Reverse 5’-CGTGTCATTGTCGTCTGAGGC-3’ 
   
RAG1 Forward 5’-TGTTGACTCGATCCACCCCA-3’ 
 Reverse 5’-TGAGCTGCAAGTTTGGCTGAA-3’ 
   
TBXAS1 Forward 5’-GCCCGACATTCTGCAAGTCC-3’ 
 Reverse 5’-GGTGTTGCCGGGAAGGGTT-3’ 
   
    
EGFR exon 18 Forward 5’-GTAAAACGACGGCCAGGACCCTTGTCTCTGTGTTCTTGT-3’ 213bp 
EGFR exon 18 Reverse 5’-CCACCAGACCATGAGAGGC-3’  
    
EGFR exon 19 Forward 5’-GTAAAACGACGGCCAGCGTCTTCCTTCTCTCTCTGTCAT-3’ 146bp 
EGFR exon 19 Reverse 5’-ACACAGCAAAGCAGAAAC-3’  
    
EGFR exon 20d Forward 5’-CACCTCCACCGTGCAG*CTC-3’ 97bp 
EGFR exon 20d Reverse 5’-GTAAAACGACGGCCAGCAGGTACTGGGAGCCAATA-3’  
    
EGFR exon 20p Forward 5’-GTAAAACGACGGCCAGCCACACTGACGTGCCTCT-3’ 216bp 
EGFR exon 20p Reverse 5’-AGCTGCGTGATGAGT*TGCA-3’  
    
EGFR exon 21 Forward 5’-GTAAAACGACGGCCAGTCCCATGATGATCTGTCCCTCACAG-3’ 201bp 
EGFR exon 21 Reverse 5’-TGCCTCCTTCTGCATGGTATTCTT-3’  
    
KRAS exon 2 Forward 5’-GTAAAACGACGGCCAGTCACATTTTCATTATTTTTATTATAAGGC-3’ 117bp 
KRAS exon 2 Reverse 5’-GATTCTGAATTAGCTGTATCGTCAAG-3’  
    
KRAS WT probe  5’-CTTGCCTACGCCACCAGCTCCAACT[SpcC3]-3’  
    
KRAS exon 3 Forward 5’-TGTGTTTCTCCCTTCTCAGGA-3’ 158bp 
KRAS exon 3 Reverse 5’-GTAAAACGACGGCCAGTGGCAAATACACAAAGAAAGC-3’  
    
e-Table 1  




EGFR and KRAS HRM primer pairs with the M13 moiety underlined  
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 Chest radiography 
 Computerized tomography 
 Positron emission tomography 
 Integrated positron emission tomography and computerized tomography 
 Other nuclear imaging 
 Magnetic resonance imaging  
Invasive diagnostics 
 Local thoracic disease 
 Nodal disease 




































For the analysis of abnormal chest radiographs that are suspicious for a thoracic 
malignancy, pulmonologist have a large and variable array of diagnostics such as 
thoracic imaging with computerized tomography (CT), positron emission tomography 
(PET) or magnetic resonance imaging (MRI), invasive (endoscopic) tests and 
subsequently pathologic and molecular tests to determine stage and diagnosis of the 
patient.  
Depending on availability of tests and skills, pulmonologists will structure the 
diagnostic path in close dialogue with the patient in such a way that a minimum 
number of investigations are required delivering maximum information in the shortest 
possible time span.  
The optimal sequence is first imaging to localise the primary tumor and possible 
metastases, establishing a diagnosis by histology from the best accessible tumor and 
staging by (endoscopic) needle aspirations. Although expensive and superfluous for 
a benign diagnosis, FDG-PET/CT is the optimal starting point when malignancy is 
suspected. Sampling for pathology should preferably result in a diagnosis and 
confirmation of disease stage at one time. Histology is preferred for a diagnosis but 
with adequately provided cytologic material, refined characterization of most primary 
pulmonary malignancies is possible even up to the level of molecular analysis. 
In this review, the optimal diagnostic approach from an abnormal chest radiograph 
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INTRODUCTION 
 
The analysis of thoracic masses found on standard chest radiographs or 
computerized tomography (CT) is one of the most challenging activities of 
pulmonology practice. An immediate and adequate diagnostic approach is obliged to 
shorten the patients’ anxious uncertainty about diagnosis and outcome.  
Starting off from baseline information, medical history, comorbidity, the assessment 
of risk for a thoracic malignancy, choices have to be made for further diagnostic 
analysis while taking into account the wishes of the patient and the consequences for 
eventual treatment. 
The headlines for further evaluation can be divided in the use of different imaging 
techniques, invasive mainly endoscopic procedures and pathologic and molecular 
analysis. Important is the timely sequence of different diagnostic modalities. The aim 
is to obtain maximum information with a minimum number of tests in order to reduce 
the burden for the patient and to finalize the diagnostic track in the shortest possible 
time.  
In this review we describe the diagnostic procedures to evaluate thoracic masses 
and evaluate optimalization of integrated diagnostic modalities. Surgical diagnostic 






An abnormal standard chest radiography, suspicious for malignancy, is the main 
reason for a diagnostic referral to a hospital or medical center.   
Further imaging of masses or tumors on chest radiography is almost invariably 
required[1] and has two major purposes: anatomic localisation of the abnormality and 
its characterization, and determination of extensiveness (staging). For an optimal 
evaluation, the necessary information is often derived from combinations of imaging 
modalities often requiring contrast media to delineate mediastinal lymph nodes or to 
explore the presence of abnormal vessels.  
 
Computerized tomography 
Advanced imaging by means of a CT is generally performed as the next step to 
determine nature, size and exact site of disease[2]. In case of malignancy, local 
tumor characteristics, hilar and mediastinal metastatic disease as well as distant 
metastatic disease are visualized and contribute to a clinical TNM classification[3].  
There are however serious limitations to CT interpretation. The diagnostic accuracy 
to determine the T-stage with CT is low[4]. A sensitivity of 63% in distinguishing T3-
T4 tumors from T0-T2 tumors and a specificity of 84% were reported [5]. For 
mediastinal metastatic disease the figures are comparable with a sensitivity and 
specificity of 51% and 85% respectively[6]. In 5-15% of patients with apparent N0 
disease on CT determined by size (shortest diameter < 1 cm), surgical lymph node 
sampling will reveal node metastasis[7]. 
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Many patients with newly diagnosed non-small cell lung cancer (NSCLC) have 
unsuspected extrathoracic metastatic disease. Brain, bone, liver, adrenal and soft 
tissue metastasis were detected with CT in 21-25% of patients with presumed N0 
disease[8, 9]. In routine CT evaluation the upper abdomen is therefore included. 
Although CT provides indispensable information on anatomic details, the addition of 
metabolic characteristics and pathologic confirmation accomplishes modern thoracic 
tumor evaluation. 
 
Positron emission tomography 
Adding metabolic information to lesions observed with CT imaging, positron emission 
tomography (PET) helps in distinguishing benign from malignant masses although 
inflammatory or infectious disease is often metabolically active and malignant 
disease sometimes not. The metabolic tracer most used is fludeoxyglucose (FDG). 
FDG-PET is essential in guiding subsequent diagnostic steps or justifying a wait-and-
see strategy.  
In NSCLC PET is essential for mediastinal staging as well as for detecting distant 
metastatic disease. The sensitivity and specificity of PET scanning for identifying 
mediastinal lymph node metastasis are 74% and 85%, respectively[6]. Non-palpable 
supraclavicular metastasis can be demonstrated by FDG-PET with a diagnostic 
accuracy of 71% [10]. For detection of unanticipated metastatic disease, FDG-PET is 
also valuable. In 6.3% to up to 19% of patients with tumors considered resectable, 
PET identified metastasis and so precluded unnecessary surgery[11-13]. 
In small cell lung cancer (SCLC), stage migration was described in a median of 13% 
in several studies after imaging with PET. Not only upstaging, due to improved 
detection of distant metatatic disease, but also downstaging was observed. Due to 
the poor quality of these small studies, the role of PET in staging SCLC is however 
still not clearly established.  
Despite the valuable performance characteristics of FDG-PET, there are some 
limitations. Small lesions (7-10 mm) are usually not detectable as are higher 
differentiated malignancies like carcinoid and bronchioloalveolar cell carcinomas. For 
the detection of brain metastasis, FDG-PET has no relevance because smaller 
lesions cannot be discriminated from the background metabolic uptake of the brains. 
The positive and negative predictive values for detecting brain metastasis with FDG-
PET is very low and magnetic resonance imaging (MRI) or perhaps contrast-
enhanced CT perform much better and are standard imaging procedures for 
suspected brain metastasis. 
 
Integrated PET-CT 
The addition of FDG-PET to CT increases the diagnostic accuracy for thoracic 
malignancies. Integrated PET-CT combines advantages of both imaging modalities 
and resulted in superior tumor staging and nodal staging compared to CT alone, PET 
alone or visual correlation of both modalities. And PET-CT facilitates the detection 
and localisation of distant metastasis[14-16]. Combination with low-dose or 
diagnostic (contrast-enhanced) CT are possible. 
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Other nuclear imaging 
FDG-PET has become essential in the workup of thoracic masses but apart from 
quantitative lung perfusion scintigraphy (to estimate postoperative lung function) the 
role of nuclear imaging is otherwise limited. 
The detection of bone metastasis with 99mTc-labeled phosphonates is sensitive but 
with the emergence of PET, skeletal scintigraphy diminished. Although the sensitivity 
of PET to detect skeletal metastases is slightly lower, its specificity of 98% compares 
favourably with skeletal scintigraphy (61% specificity)[17].  
Some neuroendocrine tumors express high levels of somatostatine or dopamine 
receptors on their cell surface. Especially in carcinoid tumors, often showing less 
uptake of FDG, radiolabeled somatostatine or dopamine analogues demonstrate the 
primary tumor and metastasis with high sensitivity[18]. 
 
Magnetic resonance imaging  
The role of MRI in the evaluation of thoracic masses is limited. Nevertheless, MRI is 
often applied in the preoperative analysis of superior sulcus tumors because the local 
assessment of the primary tumor, especially the relationship with cardiovascular 
structures and neurovascular structures, is superior.  
Also for the diagnosis of leptomeningeal and small cerebral metastatic disease, MRI 
is the best imaging tool. MRI is more sensitive than CT in detecting brain 
metastasis[19]. Asymptomatic brain metastases are found in 0-10% of patients with 
NSCLC. Higher incidences of asymptomatic brain metastases are found in stage III 
patients and MRI is therefore recommended to preclude multimodality treatment[6, 
20]. Guidelines on staging SCLC recommend MRI or contrast CT of the brain for all 
patients[21]. 
 
SAMPLING PATHOLOGIC SPECIMEN 
 
Noninvasive diagnostics 
With sputum cytology a diagnosis of lung cancer can be established with a high 
specificity (99%) and without aggravating investigations for the patient. The 
sensitivity however is low (pooled sensitivity of 66%) and depends highly on tumor 
location, sputum collection and processing logistics[22] In general it only has a 




Evaluation of local disease 
Almost all thoracic masses require tissue sampling for a definitive diagnosis and only 
a few diagnoses are made on radiologic appearance alone like bronchogenic or 
cardiac cysts and hydatid cysts. 
Distinguishing benign disease from malignant disease is difficult on CT alone. PET is 
helpful in determining the need for further diagnostic interventions. When masses are 
not FDG avide, differential diagnostic considerations narrow and often justify a more 
observational attitude. In our own diagnostic program for abnormal standard chest 
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radiographies, 88% of benign diagnoses was based on integrated FDG-PET-CT 
without pathologic confirmation but with follow up [23]. 
To analyze a thoracic lesion without evidence of mediastinal or distant metastasis, 
several techniques are available to obtain tissue specimen for a pathological 
diagnosis. 
For central lesions, bronchoscopy is preferred by many pulmonologists for its 
diagnostic sensitivity of 89% but for peripheral lesions the sensitivity decreases to 
69% and even 33% for lesions smaller than 2 cm.[24]. The performance of 
bronchoscopy can be increased for these small lesions when sampling is guided by a 
radial ultrasound (US) probe [25]. Another technique to improve results for sampling 
peripheral lung lesions is electromagnetic navigation but the impact on diagnostic 
results still has to be established and weighed against the costs[26].  
Centrally located tumors invading or originating from the mediastinum or hilus or 
situated in close contact with the mediastinum can be diagnosed with bronchoscopy, 
endoscopic ultrasound (EUS) or endobronchial ultrasound (EBUS) depending on site 
and preference of the endoscopist. For EUS and EBUS both a diagnostic accuracy of 
94% was reported for mediastinal masses of unknown origin and without central 
endobronchial involvement[27, 28].  
Transthoracic needle aspiration (TTNA) or core tissue biopsies (CTB) performed 
under CT or ultrasound (US) guidance is very helpful to diagnose peripheral and 
pleural lesions. The sensitivity of CT guided percutaneous biopsies is 92% but the 
sensitivity depends obviously on size[22]. 
US guided transthoracic sampling has practical advantages over CT guidance 
because it is widely available, easy to learn and cheap. The real-time characteristic 
of US facilitates the biopsy procedure and increases safety. Lesions however must 
lie in contact with the pleura or originate from the pleura. If these criteria are fulfilled, 
high diagnostic success rates are possible[29-31]. 
For mesothelioma, image-guided sampling with either CT or US has a good 
diagnostic performance (sensitivity of 88%) [32]. Since mesothelioma presents in 
most cases with pleural effusion, thoracoscopic evaluation is preferred because 
immediate pleurodesis after evacuation of the effusion is possible. When 
mesothelioma presents without pleural effusion or with loculated effusions, US 
guided CTB is a very useful and safe diagnostic alternative as was recently 
demonstrated in our own series[33]. 
 
Evaluation of nodal disease 
The analysis of primary thoracic malignancies requires special attention for hilar, 
mediastinal and supraclavicular regions because lymphogenic spread of primary 
pulmonary tumors evolve to these nodes and determine the N-stage of disease. 
Hilar regions are easily accessible with ultrasound guided transbronchial needle 
aspiration (EBUS-TBNA). The excellent diagnostic characteristics of EBUS provide a 
diagnosis in most benign or malignant hilar disease sites[34, 35]. Although the finding 
of hilar metastasis in lung cancer does not preclude surgery, the extend of resection 
may depend on hilar involvement. Confirmation of hilar involvement during the 
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preoperative analysis is also important to determine the need for further assessment 
of upstream lymphogenic mediastinal spread. 
The sensitivity of aspirations of hilar lymph nodes (stations 10 and 11) is not different 
from the sensitivity of aspiring mediastinal lymph nodes as was demonstrated in a 
large multicenter study[36]. 
Before US guided devices were developed, blind CT guided transbronchial needle 
aspiration (TBNA) was used to sample suspected mediastinal lymph nodes. Despite 
reasonably high accuracy rates in experienced hands and a high range of variation in 
yield described in reviews, a head to head comparison showed superiority of 
EBUS[37]. 
Nowadays the preferred first step in the approach of suspected mediastinal 
metastatic disease is EBUS-TBNA, endoscopic ultrasound guided fine-needle 
aspirations (EUS-FNA) or combinations of both. The diagnostic performance of these 
minimally invasive staging devices is outstanding and pushed surgical staging 
(mediastinoscopy) to the background in the last decade [38]. In a recent study, 
mediastinal staging with EUS and EBUS followed by mediastinoscopy (in case of 
negative endoscopy results) had higher sensitivity than surgical staging alone[39]. 
Even in patients without visible mediastinal nodes on CT, EUS was able to detect 
metastasis in 25% of patients with lung cancer[40]. A report on EBUS in patients with 
a negative mediastinum on PET and CT, demonstrated in 9% of patients with stage I 
disease mediastinal metastasis[40][41]. The combination of both EBUS and EUS in a 
CT negative mediastinum was better than EBUS alone and almost significantly better 
than EUS alone[42]. 
Supraclavicular lymph nodes are frequently involved in thoracic malignancies and are 
important for prognosis and therapeutic decisions.  
After visualization with PET-CT, adequate pathologic sampling by fine needle 
aspirations (FNA) is possible under US guidance with a diagnostic accuracy of 
85%[31].  
 
Evaluation of distant metastatic disease 
If imaging shows abnormalities suspect for metastatic disease of a primary thoracic 
tumor the most efficient way to make a diagnosis and confirm disease stage is to 
perform needle biopsies. Pleural effusion, soft tissue, destructed bone, axillary, 
retromandibular, retroauricular, intercostal and skin metastasis can be sampled after 
palpation, under CT-guidance or under real-time US guidance with high success 
rates if not surrounded by air or covered by bone[31]. 
Deeper located lesions eg. in the left adrenal gland, the celiac region, the spleen, the 
pancreas or left liver lobe can be reached by EUS-FNA effectively[43, 44].  
When imaging obviously demonstrates metastatic disease that is hard to reach for 
pathologic sampling, it is recommended in guidelines to approach easier accessible 
lesions like the primary tumor or a lymph node to obtain tissue specimen[22]. 
Nevertheless, clinical situations exist that require surgical procedures such as 
(wedge) resections to verify metastatic disease like for instance multiple lung lesions 
or a solitary right adrenal metastasis. 
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A pathologic analysis of tissue samples is the next step in diagnosing thoracic 
abnormalities such as those suspect for malignancy. For the diagnosis of lung 
lesions in general, histologic specimen, with their intact morphology, are preferred for 
pathologic analysis but that is particularly the case in benign and infrequent 
diagnoses. It was demonstrated that percutaneous tissue core biopsies were 
relatively more adequate than needle aspirations for a definitive diagnosis of lung 
lesions in general[45].  
 
Differentiating SCLC from NSCLC 
The main part of patients referred for thoracic masses, finally receive a diagnosis of 
lung cancer[23, 46]. The choice of treatment is dependent on histological subtyping 
and pathologic results also determine the need for further immunohistochemistry and 
molecular analysis [47, 48]. 
To differentiate SCLC from NSCLC, a morphologic examination is usually adequate 
and can be performed on both histologic and cytologic material. An almost perfect 
interobserver agreement for distinguishing SCLC from NSCLC was described 
recently for all specimen types[49]. 
 
Subtyping NSCLC 
A diagnosis of NSCLC needs further subtyping. Distinguishing adenocarcinoma from 
squamous cell carcinoma is of major importance for treatment and the number of 
patients with a final diagnosis of unclassified NSCLC (NSCLC-NOS) should be 
minimized.  
The diagnosis is generally made on small biopsies or cytology. In comparative 
studies, small biopsies were not superior to cytology in differentiating the subtypes. 
The combination of both however greatly reduced the number of NSCLC-NOS and 
so it is recommended to review, if available, both together in order to achieve optimal 
specification and concordance. A recent guideline did not express a clear preference 
for the kind of material. Small biopsies are not indisputably superior to certain 
cytologic preparations since biopsies often contain stromal reaction and aspirates or 
effusions may contain more tumor cells[50].  
When cytology is obtained it is important that cell blocks are prepared in order to 
enable further immunohistochemical and molecular diagnosics. In all kinds of 
cytologic samples, a NSCLC subclassification could be made on a combination of 
morphology and immunocytochemistry in 94% and 100% of cases[51, 52]. 
Immunohistochemistry should be performed tactfully with a small but sensitive panel 
of markers, in order to preserve the limited resources of material for additional 
molecular testing[53].  
The major factors impeding subtyping were poor differentiation, low specimen 
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Tumor heterogeneity 
Another phenomenon disturbing interpretation of pathology results is tumor 
heterogeneity. For lung cancer this heterogeneity is evident for biomarker expression 
as well as occurrence of mutations and is described between primary tumor and 
metastasis or within tumor sites[54]. It is unknown how and to what extend sampling 
mode (biopy versus aspiration) or sampling site and number could influence the 
results. 
 
Diagnoses other than lung cancer 
For benign disease, the diagnostic results of cytology, as obtained with EBUS, were 
significantly lower when compared to malignant disease[55]. For rare thoracic 
diseases the diagnostic performances of biopsy devices and the advantage of 
histology over cytology are unknown. For more common diseases such as 
sarcoidosis and malignant lymphoma, several reports have been published. 
Sarcoidosis can be diagnosed very well with fine needle aspirates. With EBUS, 
performed in patients with sarcoidosis, a diagnostic yield of 84% was described in a 
prospective study[56]. And after a negative bronchoscopy, with EUS a diagnostic 
sensitivity of 71 was found in a large multicenter study[57]. 
Malignant lymphoma, situated in the mediastinum, can be diagnosed with EUS when 
the aspirates are analyzed with additional flow cytometry[58]. In this study however, 
in 3 out of 11 lymphomas, exact subtyping in histology was still required. In a study of 
10 patients with lymphoma diagnosed with EUS (with flow cytometry), the diagnostic 
sensitivity was 74%[59]. The diagnostic sensitivity of EBUS in a study in 21 patients 
with lymphoma was 57%[60]. Diagnosing lymphoma with EBUS was found more 





Currently relevant tests 
In patients with NSCLC, certain mutations in the epidermal growth factor receptor 
(EGFR) gene predict good clinical response to treatment with tyrosine kinase 
inhibitors (TKI’s). For stage IV patients, molecular analysis to detect EGFR mutations 
is now an essential part of the routine workup. As these mutations are almost 
invariably found in samples with non-squamous cell carcinoma, patients can be 
selected for further molecular analysis based on subtyping results.  
Another frequently encountered mutation in adenocarcinomas of the lung is V-Ki-ras2 
Kirsten rat sarcoma viral oncogene homolog (KRAS). KRAS is also involved in 
signalling pathways downstream the EGFR but its clinical significance is not 
completely clear. DNA mutations or amplifications that have predictive value can be 
used as molecular diagnostic tool. The presence of a translocation of microtubule 
associated protein-like 4 with anaplastic lymphoma kinase genes (EML-ALK) leads to 
ALK protein production that can be blocked with specific ALK inhibitors (crizotinib). 
BRAF mutations are sensitive for BRAF inhibitors such as vemurafinib or dabrafenib. 
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This list is increasing quickly and future will tell whether this new targeted and 
personalized approach will change treatment of lung cancer fundamentally.  
 
Sample characteristics 
Recommendations on tissue and test characteristics for EGFR mutation analysis 
were recently published in a European consensus report[61]. The authors prefer the 
use of histology but mention the possibility of using cytology for mutation analysis. In 
large clinical studies comparing chemotherapy with TKI as first line treatment, 
mutation analysis was almost invariably performed on tissue samples.  
Other studies demonstrated however the feasibility of molecular analysis in cytologic 
specimen of NSCLC for EGFR, KRAS as well as EML-ALK[62].  
EGFR mutation analysis has been performed on various kinds of cytologic samples 
like pleural effusion cell blocks, percutaneous ultrasound guided and CT guided 
aspirates[52, 62-64], pericardial effusion and BAL[62, 65]  endobronchial [52, 63-70] 
and endoscopic ultrasound guided aspirates[52, 68, 69]. The suitability to perform 
EGFR mutation analysis in cytologic specimen derived with EBUS-TBNA ranged 
from 72% to 99%[71]. 
KRAS detection was also performed in a variety of cytologic specimen like TBNA 
obtained with EBUS or percutaneous FNA under CT or US guidance and 
endobronchial brushes and washings[52, 52, 63, 67-69].  
Fusions of the ALK and EML4 genes are demonstrated with fluorescent in situ 
hybridisation (FISH). This technique was also applied on cytologic specimen but only 
described for EBUS sofar[72]. 
 
Tumor heterogeneity 
Important in the discussion on sample features is the presence of enough tumor cells 
in either cytological or histological specimen that deliver high-quality DNA. It is clear 
that molecular analysis can be performed in specimen with low tumor cell content but 
still there are some hesitations concerning the representation of FNA specimen for 
the entire tumor[73]. Tumor heterogeneity is a phenomenon that might influence the 
results of molecular analysis especially when the diagnosis is made on very small 
specimen. Low frequency mutations sometimes responsible for resistance to 
treatment after exposure to specific targeted inhibitors can only be found in samples 
that contain large number of tumor cells.  
Even more confusing is the fact that discordance in mutations or phenotypic 
expression is not only found within a tumor site but also between between primary 
tumor and metastasis[54].  
These issues are not fully understood and clear recommendations for the clinician in 
this respect are not available.  
 
PLANNING OF DIAGNOSTICS 
 
Planning and timing of diagnostics is important to prevent unnecessary tests and 
investigations and to shorten patients waiting time and uncertainty. Although the 
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oncologic significance of delay in obtaining a diagnosis is unclear, recommendations 
on timelines are described in guidelines[74]. 
 
Before start of analysis  
An estimation of comorbidity and an evaluation of the patients’ wishes and 
expectations are essential to determine whether diagnostics should be applied. It is 




Diagnostic programs for abnormal standard chest radiographs have been described.  
Benign disease was found in 16-35% of patients with these diagnostic programs[23, 
46, 75] 
Standard bronchoscopy after CT or PET-CT was used as invasive diagnostic 
modality in 3 studies[46, 75, 76]. We described our own diagnostic program of 
invasive diagnostics performed on the same day as the PET-CT[23]. This study is 
distinctive from other programs in the immediate choice from bronchoscopy, US 
guided percutaneous biopsies, EUS and EBUS depending on the imaging results. 
Ideally a pathologic diagnosis and confirmation of disease stage were made at once. 
In 40% of patients with a malignancy, bronchoscopy was not necessary to perform.  
The design of our program resulted in a shorter time from start of the analysis to start 
therapy in patients with malignancies (14.5 versus 26 days) when compared to a 
program with standard bronchoscopy after PET-CT[46]. 
The difference is obviously caused by the need for additional staging investigations 
when only bronchoscopy is performed. 
 
Sequence of diagnostics 
Two flowcharts showing the possible diagnostic tracts for patients suspected of 
having a thoracic malignancy are superimposed in the figure. It is clear that a CT of 
the chest and upper abdomen as initial advanced imaging modality is adequate in 
case of a benign diagnosis. When a non-primary pulmonary malignancy is found, 
also further imaging is usually not necessary.  
A CT is also sufficient when stage IV disease is demonstrated and verified by 
pathologic analysis. However, when stage III disease is demonstrated with CT, a 
cerebral MRI as well as a FDG-PET scan should be performed for accurate staging 
(to exclude distant metastases)  thereby precluding unnecessary treatments. After 
FDG-PET-CT, only a cerebral MRI should follow to exclude asymptomatic brain 
metastasis.  
For stages I and II NSCLC applies the same. After CT, further staging with FDG-PET 
is advised because asymptomatic metastasis will be detected in a substantial amount 
of patients. When SCLC is diagnosed, standard staging with bone scintigraphy and 
cerebral MRI or, probably more accurate, staging with FDG-PET and cerebral MRI is 















Figure. Flowchart showing the diagnostic tracts of abnormal standard chest 
radiographs (suspicious for malignancy) starting initially with an integrated positron 
emission tomography (solid lines) or starting initially with a computerized 
tomography of thorax and upper abdomen (dotted lines). 
 
PET-CT, integrated positron emission tomography and computerized tomography; CT, 
computerized tomography; PET, positron emission tomography; US, ultrasound; E(B)US, 
endoscopic ultrasound and /or endobronchial ultrasound; EUS, endoscopic ultrasound; NSCLC, 
non-small cell lung cancer; EGFR, epidermal growth factor receptor; EML-ALK, microtubule 
associated protein-like 4  with  anaplastic lymphoma kinase gene reallocation; SCLC small cell lung 
cancer; MRI, magnetic resonance imaging 
 
143
chapter 11    
Additional imaging takes more time in diagnosing patients, for example when new 
findings appear that need again pathological verification and when non-squamous 
cell carcinoma is upstaged to IV requiring further molecular analysis. So, apart from a 
delay in time, patients often have to undergo additional invasive tests that in fact 
overrule the initial invasive tests. This illustrates the complexity of the lung cancer 
diagnostic roads. 
 
PET-CT after abnormal chest radiography 
From the point of view of diagnostic speed and convenience for the patient, initial 
imaging with FDG-PET-CT is ideal. The main disadvantage of this diagnostic 
strategy is that a relatively large number of patients with a benign diagnosis will have 
this expensive kind of imaging. Two studies on diagnostic tracts with an initial PET-
CT, reported 20% and 26% of benign diagnoses[23, 46]. These numbers seem high 
but when only a CT would have been made, additional FDG-PET scanning would 
probably have followed in some of these cases to facilitate clinical decision-making. 
The FDG-PET results also helped in determining the need for invasive diagnostics in 
many patients as demonstrated by the high rates of benign diagnoses without 
pathological verification. In both studies describing a diagnostic strategy with initial 
PET-CT, almost all benign diagnoses were not pathologically confirmed but based on 
imaging and follow up results[23, 46]. In one study no abnormalities at all were found 





The contemporary analysis of thoracic masses stretches, at the base, from abnormal 
chest radiograph to eventually DNA analysis on tumor tissue at the far end. In 
between, the pulmonologist has to make choices from an array of many diagnostic 
options. 
A general principle in the sequence of analysis is first imaging and than invasive 
diagnostics. (There is an exception for cerebral MRI in this context since invasive 
cerebral diagnostics are hardly performed.) This principle precludes extra 
(particularly stage verifying) tests.  
A general principle in the kind of diagnostic tests is to choose a biopsy mode that 
enables a diagnosis and verifies disease stage (in case of malignancy) at one time. 
Histology is preferred (especially for benign diagnoses) but for malignancy, cytologic 
specimen, provided they are correctly prepared, will do very well even for more 
advanced processing. 
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SUMMARY 
 
Diagnosing thoracic masses is a challenge for the pulmonologist. The diagnostic 
approaches to evaluate patients are diverse and cover the fields of imaging, 
interventional pulmonology and pathology, including molecular biologics, to come to 
a final diagnosis. Exploring and refining these diagnostic applications and fine-tuning 
of all diagnostic modalities, in order to optimize patient care, is an important task for 
professionals.  
In this thesis, the introduction of some of modalities and a critical appraisal of the 
integration of several tests is described. Moreover, practical problems in diagnostic 
approaches have been studied to come to a better patient care, with case reports 
and explorative studies.   
 
In chapter 2, the results of restaging patients with stage III non-small cell lung cancer 
(NSCLC) after induction treatment (mostly concurrent chemoradiotherapy) are 
described.  We compared endoscopic ultrasound guided fine-needle aspirations 
(EUS-FNA) with positron emission tomography (PET).  
In 15/28 patients, repeated EUS-FNA in previously tumor-positive mediastinal lymph 
nodes, showed no tumor cells anymore and only one case was inconclusive. Of the 
15 down-staged patients, 11 were confirmed with surgery and 1 showed persistent 
malignant disease. The 3 other patients had no mediastinal verification because 2 
were not operated and 1 had no lymph node dissection. Follow up with imaging was 
used to assess their fate. There was concordance between pathologic results and 
PET in 17/27 patients. We concluded that EUS-FNA predicted the absence of nodal 
metastasis reliably (with an accuracy of 92.3%) and was superior to PET in this 
respect. Furthermore we concluded that EUS-FNA was safe although many patients 
suffered from radiation esophagitis.  
The relevance of downstaging was illustrated previously by several studies showing 
that mediastinal downstaging is one of the strongest prognostic factors. The meaning 
of downstaging for eventual subsequent surgery however, is less clear. The most 
important question in this particular field is still not solved. We do not know whether 
surgery should be performed in all downstaged patients after concurrent 
chemoradiotherapy. The role of further patient selection should be investigated. Has 
additional surgery a positive effect on survival or is the induction treatment with 
chemoradiation sufficient in these patients? The observation that vital tumor tissue is 
still present in resected material of many patients is an argument favouring surgery 
but the frequent appearance of metastatic disease during the course of many 
patients is an argument against surgery. 
A study to answer this question by randomizing downstaged patients between 
adjuvant surgery versus a wait and see strategy is never performed. 
A second crucial point to address is the question of vitality of tumor cells after 
treatment. When a pathologist recognizes vital tumor cells in restaging samples, is 
the presence of these cells prognostic? The same question applies for resected 
tumor. It could be helpful if reliable biomarkers for cell death were developed. 
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The diagnostic properties of EUS-FNA are further underscored in chapter 3. Two 
patients with relatively mild symptoms were referred for EUS-FNA in masses of the 
posterior mediastinum with involvement of the spine. In both patients EUS-FNA 
demonstrated infectious spondylodiscitis with staphylococcus aureus. This diagnosis 
was easily obtained without the need for an orthopaedic diagnostic intervention. Both 
cases illustrated that thoracic spinal pathology, situated at the frontal side, is not 
difficult to reach from the lumen of the esophagus. Furthermore do these cases 
emphasize the importance of ”looking over each others fence” in medicine.  
How to increase mutual awareness of techniques and skills of different specialists, 
acting in adjacent fields is however the question. The key for this is discussing 
patients in regular multidisciplinary meetings in a hospital or on a regional scale and 
cooperative publications in literature for a wider scale. 
 
The potential hazard of EUS is illustrated in a case report in chapter 4. A patient with 
NSCLC, on treatment with bevacizumab, is described who developed a fistula 
between a mediastinal metastasis and the esophagus after performing EUS-FNA. 
Although EUS is generally very safe, performing EUS-FNA in patients on treatment 
with bevacizumab is not recommended.  
A disturbance of wound-healing is a known side-effect of bevacizumab but the 
question remains whether fistula formation in the described patient would not have 
occurred without bevacizumab. Introduction of micro-organisms from the esophagus 
into necrotizing tissue might have been sufficient to cause the infection and 
subsequent fistula formation. 
 
The diagnostic results of ultrasound (US) guided aspirations and biopsies were 
studied in a population suspected for lung cancer and described in chapter 5. All 
lesions that were sampled were detected with integrated positron emission 
tomography and computed tomography (PET-CT). PET-CT was not previously 
described as the selecting imaging modality for studies on US guided biopsies in 
pulmonary oncology. But as PET and CT belong to the routine work up of thoracic 
masses nowadays, the relevancy of US guided sampling is obvious. 
A total of 127 patients underwent US guided sampling. The biopsy sites were 
subdivided into local thoracic, supraclavicular and distant metastatic for staging 
reasons. 
Malignancy, benign disease and inadequate samples were found in 79%, 14%, and 
7% of lesions, respectively. The disease stage was confirmed by the aspiration or 
biopsy in 55% of patients with a malignancy. More than half the lesions were 
impalpable on physical examination. 
It was concluded that US guided biopsies and aspirations based on PET-CT imaging 
have excellent diagnostic performances in patients suspected for thoracic 
malignancy.  
 
The accuracy of tissue core biopsies (TCB) obtained under US guidance for patients 
with mesothelioma without pleural effusion or with only loculated pleural effusion is 
described in chapter 6. Some mesotheliomas present primarily without pleural 
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effusion but, more often, it happens that the effusion is already evacuated before a 
final diagnosis is established. A diagnostic thoracoscopy with biopsies is hard to 
perform in these patients. Percutaneous US guided tissue sampling is then the least 
invasive method as diagnostic surgery is the alternative. 
From the pathology database of the Isala Clinics, 56 patients with mesothelioma 
were traced. Twenty of these patients presented without or with locular effusion of 
which 14 patients were diagnosed with TCB. The diagnostic accuracy was 80% with 
only one patient with mild haemoptysis as complication. Therefore it was concluded 
that US guided TCB is worthwhile in this subcategory of patients avoiding more 
invasive procedures or surgery. 
 
Chapter 7 describes the radiologic and pathologic characteristics of mediastinal 
lymphadenopathy, detected incidentally on CT scans made for purposes other than 
oncologic evaluation. 
The relevance of this study becomes evident in a time where much more imaging is 
performed for all kinds of indications such as non-oncological indications like 
pulmonary embolism or coronary angiography. Physicians faced with these 
“incidentalomas” often want to exclude malignancy (especially malignant lymphoma) 
and refer patients for EUS or endobronchial ultrasound (EBUS) to obtain a 
pathological diagnosis.   
This study was performed in 83 patients from 8 different hospitals. The mediastinal 
lymph nodes were characterized by multiplicity (with a median number of enlarged 
nodes of 7),  small size (range between 6 and 14 mm) and hilar node involvement (in 
77%). Needle aspirations showed adequate lymphocellular samples in 66%, well-
formed granulomas compatible with sarcoidosis in 22% and were undeterminate in 
8% of patients. A FDG-PET was available in 29 patients and showed elevated 
metabolic activity in 87%. During follow up, 2 patients developed lung cancer, 2 years 
after mediastinal analysis. 
Because the predictive value for malignancy in these mediastinal incidentalomas was 
very low, a restrictive policy towards invasive diagnostics is warranted and PET has 
no added value in this study. 
The question is whether significant diagnoses will be missed without pathologic 
sampling. Our study does not support this neither supports routine follow up with 
CTs. There is no evidence for a particular approach. Perhaps scheduling a repeat CT 
after a few months is a practical way in outpatients clinics.  
 
A diagnostic program for patients with an abnormal standard radiograph, suspected 
for lung cancer is described in chapter 8. All patients followed a standardized scheme 
with an initial PET-CT in the morning and invasive diagnostic tests in the afternoon. 
The invasive tests were bronchoscopy, EUS, EBUS and US guided biopsies or 
aspirations. The invasive tests chosen should ideally provide a tissue diagnosis and 
confirm disease stage in case of malignancy. The aim was to improve diagnostic 
efficiency by shortening the diagnostic track and by reducing the number of invasive 
tests per patient. 
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A total of 297 patients were analyzed resulting in a diagnosis of malignancy in 72%, a 
benign diagnosis in 26% and no abnormalities at all in 1%. 
For 85% of patients with a malignancy, the diagnostic one-day program was 
sufficient to provide a diagnosis (including disease stage confirmation) although 
definitive pathologic results had to be awaited and was communicated with the 
patient at the next outpatient visit. The diagnosis was made with 1 invasive test in 
53%, 2 or more tests were performed in 33% and diagnostic surgery was necessary 
in 8% of patients with malignancy. Bronchoscopy was performed in 59% of patient 
with a malignant diagnosis. 
The median time from the start of analysis to the time that the final results and 
therapy were discussed with the patient, was 7 days (range,0-50). 
It was concluded that the program provided a diagnosis very efficiently with a very 
short waiting time and without the need of bronchoscopy in a substantial part of 
patients. 
It is clear that speed is important for the patients’ mind but less important from an 
oncologic point of view. This must we weighed against the costs.  
A substantial part of our cohort turned out to have benign disease. Although FDG-
PET is not clearly indicated in this group, pathologic diagnoses lacked in most of 
these patients and FDG-PET was essential in excluding a range of diagnoses. On 
the other hand there was an overshoot of PET scans in patients with a malignancy, 
with indisputable stage IV disease proven by the CT scan.  
Furthermore, from a practical perspective, the one-day program decreases the 
efficiency of the invasive diagnostic ward as it is unknown what kind of further 
diagnostics will follow; timetable planning is difficult and defensive. 
 
In chapter 9 we looked into the problem of histological versus cytological samples to 
obtain adequate tumor cells for molecular tests. Histologic samples obtained with 
EUS-TCB were compared with cytologic samples obtained with EUS-FNA. 
Mediastinal or left adrenal masses of at least 20 mm in puncture direction were 
sampled subsequently during one session with both devices (4 needle passes each 
time in different directions). The samples were assessed independently by 
pathologists. In case of non-squamous cell carcinomas, further molecular analysis for 
epidermal growth factor (EGFR) and V-Ki-ras2 Kirsten rat sarcoma viral oncogene 
homolog (KRAS) mutations was performed.  
The diagnostic performance of EUS-FNA was superior to EUS-TCB with sensitivities 
of 92% respectively 69% (p<0.00018). The sensitivity of both combined was 98%. 
TCB often contained insufficient material (or no material at all) for molecular analysis 
resulting in a diagnostic success rate of 46%. This contrasted with the high 
diagnostic success rate of 95% for mutation analysis in FNA. It was concluded that 
EUS-TCB had no added value over EUS-FNA in pathologic and molecular analysis 
of hilar, mediastinal and left adrenal masses. 
 
DNA pyrosequencing is compared with High Resolution Melting (HRM) for EGFR and 
KRAS mutations in chapter 10. The tests were performed on EUS and EBUS derived 
samples (from adenocarcinomas)  that were stored as formalin fixed paraffin-
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embedded tissue blocks. HRM screens proceeding Sanger sequencing was the 
routine procedure for mutation analysis. Pyrosequencing is very sensitive and 
requires only small amounts of tumor DNA. 
In 126 samples, the analysis success rates for pyrosequencing and HRM were 97% 
and 93%, respectively. A significant relation between sample age and DNA 
fragmentation was observed. As all HRM failures had highly fragmented DNA, this 
suggests that age might have played a role in the failing HRM analysis. 
Many previous studies selected cytologic samples for mutation analysis on estimated 
tumor content. In our study there was only a weak correlation between estimated 
tumor content and true content as measured with pyrosequencing.  
It was concluded that mutation analysis can be performed very effectively on EUS-
FNA  and EBUS-TBNA samples, with both HRM (followed by Sanger sequencing) 
and pyrosequencing.  Pyrosequencing is influenced less by inferior DNA quality, it 
can be performed on short DNA fragments, allowing successful molecular analysis 
on older and less optimal tissue samples. Initial screening with HRM followed by 
pyrosequencing in case of abnormalities in a low number of tumor cells or in case of 
HRM failure is proposed for routine clinical practice.  
An important issue in this context is the question whether small tissue samples 
represent the tumor adequately.Tumors are heterogenous with respect to genotype 
and phenotype and discordance in EGFR mutation analysis between primary tumor 
and metastasis or within tumor sites has been demonstrated previously[1]. Because 
aspirations contain limited amounts of tumor cells, the question raises whether 
cytological samples represent the tumor sufficiently. US guided aspiration however, 
offers the opportunity to sample lesions in various directions, in longitudinal and 
transversal planes and at various depths during one session[2]. Endobronchial 
biopsies, most often used for a diagnosis of lung cancer, do share the same problem 
of tissue representation as they are obtained from a limited part of the tumor 
(repeated biopsies from the margins of a lesion). As heterogeneity is also described 
between primary tumors and metastases it is debatable which tumor site is preferred 
for a diagnosis. The primary tumor site, as original site of metastatic disease or the 
metastasis that defines disease stage and is a representative for tumor migration and 
homing. 
 
One of the most challenging acivities for pulmonologists is the analysis of patients 
with abnormalities suspected for malignancy. A wide range of diagnostics is at their 
disposal. Those can be divided into imaging, interventional pulmonology and 
pathology. From a simple chest radiograph to a PET-CT up to refined DNA 
sequencing there is a lot of decision-making to do before a final diagnosis and 
disease stage are definite. 
Chapter 11 gives an overview of all relevant diagnostic modalities and a discussion 
about their mutual relationships and integration. While planning a diagnostic track, a 
few principles are important to keep in mind. 
To avoid unnecessary invasive tests (especially stage verifying tests), it is important 
to plan imaging before invasive diagnostics. Furthermore, it is preferable to choose a 
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biopsy mode that enables pathologic classification and stage verification (in case of 
malignancy) at one time. 
Although histology is preferred (especially for benign diseases and poorly 
differentiated malignancies), cytologic samples, if processed properly, will generally 







At the moment, screening for lung cancer in patients with elevated risk profiles is a 
hot topic in imaging. A relative reduction in mortality from lung cancer in high-risk 
patients with low-dose CT screening of 20% was described recently[3]. A problem of 
screening is the high rate of false positive results requiring analysis or follow up. 
Furthermore, small nodules (often of subcentimeter size) are frequently encountered 
in daily practice as coincidental findings on CT scans made for all kinds of 
indications. 
All these small abnormalities require advanced analysis. Improvement of imaging 
technique to qualify them reliably is a major effort for equipment manufacturers. 
New PET tracer may be more specific than FDG. Also technological improvements in 
PET will bring a better resolution. The question is, whether all these novelties will 
improve diagnostic pathways. 
Algorithms integrating combinations of non-invasive diagnostics such as biomarkers 
have to be validated in the future to differentiate early stage malignant disease from 
benign findings. 
A promising innovation to combine with state of the art CT imaging in the analysis of 
small abnormalities is exhaled breath analysis[4]. Though not yet sensitive enough, it 
is expected that in the future, breath analysis might play an important role in decision 
making for very small lesions. Other biomarkers such as circulating tumor cells and  
circulating DNA in serum seem promising. 
 
Interventional pulmonology 
The incredible diagnostic shift that endoscopic and endobronchial ultrasound has 
made in pulmonology is hard to repeat because we are able now to diagnose 
formerly inaccessible anatomic areas.  
Other non-surgical interventional modalities for the diagnosis of thoracic masses are 
not evident. Minor steps are made in improving the quality and user comfort of 
needles for EUS, EBUS and percutaneous applications. 
Reports on EUS guided therapy in gastroenterology (particularly in pancreatic 
disease) with a flexible bipolary probe, combining radiofrequency ablation with 
cryothermal cooling are promising also for thoracic approaches[5]. In the future it is 
foreseen that EUS and EBUS will be applied for therapeutic purposes as well in 
pulmonology.  
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For pulmonologists, percutaneous US has gained ground for the analysis of pleural 
effusions but still with restraints. Only a small step further is the use of US to obtain 
more accurately samples for pathology, a field that was previously reserved for 
interventional radiologists. Similar to other disciplines, like cardiology, urology and 
gynaecology, percutaneous US should become an integral part of the pulmonology 
practice as well. 
Although it is reasonable that EUS and EBUS are performed by dedicated 
pulmonologists in specialized centers  due to high equipment costs and limited 
numbers of patients, for percutaneous US the situation is different. 
Percutaneous US is cheap, applicable on a daily base and easy to learn. Training in 
percutaneous US skills, now limited to a few centers, should be offered to every 
pulmonologist during their education. More diagnostics in one hand has great 
advantages for the patient because it increases diagnostic speed and efficiency.  
 
Even though diagnostic surgery is not quite classifiable as interventional 
pulmonology, it should be mentioned in this context. In recent years, important 
developments in diagnostic surgery have been established. Minimal invasive surgery 
evolved and lowered the threshold to consult the surgeon for mediastinal and upper 
abdominal exploration. Initially, video-assisted thoracoscopic surgery (VATS) for 
diagnosing lung lesions and otherwise inaccessible hilar or mediastinal lesions was 
established. Gradually, robotic control is introduced in VATS, enabling even more 
precise handling of instruments and enabling access to more difficult sites in the 
thorax.  
 
Pathology and molecular biology 
The developments in this field are of the most exciting kind. 
New predictive markers for lung cancer are detected and validated with high speed. 
Immunohistochemistry, fluorescent in situ hybridization and DNA sequencing are all 
tests that are performed on patient material. However, more tests have to be 
performed on samples requiring more tumor cells. To counteract this development, 
next-generation sequencing (NGS) on DNA and RNA from paraffine embedded 
specimen provide one kind of test that needs only limited amounts of DNA and RNA. 
This approach is valuable when mutations, focal amplifications, copy number 
aberrations and certain fusion proteins are predictive for the efficacy of targeted 
therapeutics. The success of this approach depends partly on the willingness of 
pulmonologists to obtain larger tumor samples to detect low-frequency mutations.  
Whole genome sequencing equipment is commercially available that is able to 
unravel all abnormalities in cancer genes in small amounts of tumor[6]. The clinical 
meaning of most abnormalities however, is not yet understood.   
Nevertheless it is expected that knowledge of oncologic pathways will increase 
quickly with NGS, resulting in the discovery of more molecular targets and resistance 
mechanisms. New agents or combinations of agents and more insight in benefits and 
harms of certain treatments will improve personalized therapy.  
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The pulmonologist is constantly moving in a field with changing demands of the 
pathologist, depending on technical developments, at one side and changing 
understanding of clinical relevancy at the other side.  
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De diagnostiek naar tumoren in de thorax is een uitdaging voor de longarts. De 
mogelijke benaderingswijzen om tot een uiteindelijke diagnose te komen zijn zeer 
divers en bestrijken de afbeeldende diagnostiek, de interventie longgeneeskunde en 
de pathologie inclusief de moleculaire biologie. Het verkennen en verfijnen van deze 
diagnostische toepassingen en het onderling afstemmen van diagnostische 
modaliteiten, met verbetering van de patiëntenzorg als doel, behoort tot de taken van 
de longarts. 
In dit proefschrift worden toepassingen van enkele van deze diagnostische 
modaliteiten geïntroduceerd en wordt de integratie van verschillende tests kritisch 
geëvalueerd. Verder wordt onderzoek beschreven naar praktische problemen in de 
diagnostiek, door middel van case-reports en exploratieve studies. 
  
In hoofdstuk 2, worden de resultaten beschreven van restadiëringsonderzoek bij 
patiënten met stadium III niet-kleincellig longcarcinoom (NSCLC) na 
inductiebehandeling ( meestal gelijktijdige chemoradiotherapie). We vergeleken 
daarbij resultaten van fijne naald aspiraten, verkregen onder geleide van 
endoscopische echografie (EUS-FNA), met positron emission tomography (PET).  
Bij 15/28 patiënten waren geen tumorcellen meer aantoonbaar bij herhaalde EUS-
puncties in mediastinale klieren die vóór de inductiebehandeling nog tumor-positief 
waren en bij slechts 1 patiënt was de uitslag onzeker. Van deze 15 patiënten kon 
zogenaamde “down-staging” chirurgisch bevestigd worden bij 11 en bleek er toch bij 
1 patiënt persisterende tumoractiviteit te bestaan. Chirurgische verificatie vond bij 3 
patiënten niet plaats omdat er 2 niet geopereerd werden en omdat bij 1 patiënt geen 
lymfklierdissectie plaatsvond tijdens operatie. Bij deze 3 patiënten werd het verdere 
ziektebeloop middels afbeeldende diagnostiek gevolgd. 
Er was overeenstemming tussen de pathologische resultaten en de PET resultaten 
bij 17/27 patiënten. We concludeerden dat EUS-FNA de afwezigheid van 
kliermetastasen betrouwbaar voorspelde (met een nauwkeurigheid van 92,3%) en in 
dat opzicht beter presteerde dan PET. Voorts concludeerden we dat EUS-FNA een 
veilige ingreep was ofschoon veel van de patiënten op het moment van onderzoek 
een radiatie-oesofagitis hadden. 
De relevantie van zogenaamd “downstagen” voor de prognose wordt door meerdere 
kleine studies geïllustreerd. Mediastinale “downstaging” is één van de sterkste 
prognostische factoren. De betekenis van “downstaging” voor eventueel aanvullende 
chirurgische behandeling is echter onduidelijk. De belangrijkste vraag of een operatie 
toegevoegde waarde heeft bij patiënten waarbij, na gelijktijdige chemoradiotherapie, 
geen metastasen in het mediastinum meer aantoonbaar zijn, is nog steeds niet 
beantwoord. De rol van verdergaande patiëntselectie moet onderzocht worden. 
Heeft aanvullende chirurgie een gunstig effect op de overlevingskansen of is de 
inductiebehandeling op zich al toereikend ? De observatie dat er bij vele patiënten 
vaak nog steeds vitaal weefsel in resectiemateriaal aanwezig is, zou een argument 
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kunnen zijn vóór operatie maar het frequent optreden van afstandsmetastasen 
tijdens het ziektebeloop pleit weer tegen. 
Een studie die deze vraag zou kunnen beantwoorden, door patiënten die 
“gedownstaged” zijn te randomiseren tussen chirurgie of een afwachtend beleid, 
werd nooit uitgevoerd. 
Een tweede cruciaal punt van discussie is de vraag in hoeverre als vitaal herkenbaar 
weefsel nog daadwerkelijk vitaal is na voorbehandeling. Als een patholoog nog vitale 
tumorcellen herkent in restadiëringsmonsters wat heeft dit dan voor een betekenis 
voor de prognose ? Dezelfde vraag geldt voor resectiemateriaal. 
De ontwikkeling van betrouwbare biomarkers voor celdood zouden in deze zeer 
behulpzaam zijn. 
 
De diagnostische mogelijkheden van EUS-FNA worden verder benadrukt in 
hoofdstuk 3. Twee patiënten met relatief milde symptomen werden verwezen voor 
EUS-FNA in verband met massa’s in het achterste mediastinum met aantasting van 
de wervelkolom. Bij beide patiënten werd middels EUS-FNA een infectieuze 
spondylodiscitis vastgesteld met staphylococcus aureus als verwekker. 
Deze diagnose werd eenvoudig gesteld zonder dat er orthopaedisch chirurgische 
ingrepen nodig waren. De ziektegevallen tonen aan dat afwijkingen gelocaliseerd 
aan de voorzijde van de thoracale wervelkolom goed bereikbaar zijn vanuit de 
slokdarm. Tevens benadrukken deze ziektegevallen het belang in de geneeskunde 
om als het ware “over de schutting te kijken” bij andere specialismen. 
De vraag resteert echter hoe specialisten van belendende disciplines zich beter op 
de hoogte zouden kunnen stellen van elkaars diagnostische mogelijkheden en 
vaardigheden. Dit zou bereikt kunnen worden, op kleinere schaal, door 
multidisciplinaire besprekingen binnen een ziekenhuis of in regionaal verband of, op 
grotere schaal, door middel van gezamenlijke publicaties in de vakliteratuur.  
 
Een complicatie van EUS wordt geïllustreerd aan de hand van een case report in 
hoofdstuk 4. Er wordt een patiënt met NSCLC beschreven die, onder behandeling 
met het middel bevacizumab, een fistel ontwikkelt tussen een mediastinale 
metastase en de slokdarm, kort nadat EUS-FNA werd uitgevoerd. 
Hoewel EUS-FNA over het algemeen als uiterst veilig wordt beschouwd, lijkt het 
verstandiger om deze ingreep niet te verrichten bij patiënten die behandeld worden 
met bevacizumab.Een bekende bijwerking van bevacizumab is immers een 
gestoorde wondgenezing maar het blijft de vraag of fistelvorming, zoals in de 
beschreven patient, ook niet zou zijn opgetreden zonder dit middel. Door de 
introductie van microörganismen vanuit de slokdarm naar necrotiserend 
tumorweefsel zouden op zich al genoeg voorwaarden aanwezig geweest kunnen zijn 
voor infectie en fistelvorming.   
 
De diagnostische resultaten van echogeleide puncties en biopten, uitgevoerd bij 
patiënten die verdacht werden van longkanker, worden beschreven in hoofdstuk 5. 
Alle afwijkingen die werden bemonsterd, waren gedetecteerd met geïntegreerde 
positron emission tomography en computed tomography (PET-CT). 
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Het gebruik van de PET-CT om afwijkingen te selecteren voor echogeleide biopten in 
de longoncologie, was niet eerder beschreven. PET en CT zijn tegenwoordig echter 
niet weg te denken bij de diagnostiek van thoracale massa’s hetgeen de relevantie 
van echogeleid biopteren van gevonden afwijkingen onderstreept. 
Bij een totaal aantal van 127 patiënten werden echogeleide puncties of biopten 
afgenomen. De te biopteren afwijkingen werden onderverdeeld in lokaal thoracale 
afwijkingen, supraclaviculaire metastasen en afstandsmetastasen. Deze indeling 
houdt verband met de implicaties voor tumorstadiëring. 
Bij 79% van de monsters werd een maligniteit gevonden, bij 14% een goedaardige 
ziekte en 7% van de monsters was inadekwaat. 
Bij 55% van de mensen bij wie een maligniteit werd gevonden werd het 
ziektestadium bewezen door de punctie of het biopt. Meer dan de helft van de 
afwijkingen was niet te vinden bij lichamelijk onderzoek. 
De conclusie van het onderzoek was dat de diagnostische resultaten van 
echogeleide biopten en puncties, van afwijkingen die met PET-CT werden 
gedetecteerd, uitstekend zijn bij patiënten die verdacht worden van een maligniteit. 
 
De diagnostische nauwkeurigheid van weefselnaaldbiopten verkregen onder 
echogeleide bij patiënten met een mesothelioom, gekenmerkt door de afwezigheid 
van pleuravocht of met slechts geloketteerd vocht, wordt beschreven in hoofdstuk 6.  
Sommige mesotheliomen presenteren zich primair zonder vocht maar de situatie 
doet zich vaker voor dat het vocht reeds verwijderd is voordat een zekere diagnose 
werd gesteld. Een thoracoscopie, waarbij tevens pleurabiopten kunnen worden 
genomen, is in die situaties moeilijk uitvoerbaar. Het afnemen van echogeleide 
pleurabiopten is dan de minst belastende methode waarmee chirurgisch 
diagnostische ingrepen kunnen worden voorkomen.  
Vanuit de pathologie database van de Isala Klinieken werden 56 patiënten met de 
diagnose mesothelioom getraceerd. Twintig van deze patiënten presenteerden zich 
zonder pleuravocht of met slechts weinig, geloketteerd, vocht. Van deze 20 patiënten 
werd bij 14 de diagnose verkregen door middel van weefselnaaldbiopten. De 
diagnostische nauwkeurigheid bedroeg 80%. Slechts één patient hoestte na het 
biopteren een geringe hoeveelheid bloed op als complicatie van het onderzoek. 
De conclusie van het onderzoek was dat het zeer de moeite waard is, bij deze 
categorie van patiënten, om echogeleide weefselnaaldbiopten te nemen zodat, de 
meer belastende, chirurgische diagnostiek kan worden vermeden. 
 
In hoofdstuk 7 worden de radiologische en pathologische karakteristieken 
beschreven van mediastinale lymfadenopathie die per toeval werd ontdekt op CT 
scans die voor allerlei andere dan oncologische indicaties (zoals longemboliën en 
coronaire angiografie) werden vervaardigd. 
De relevantie van deze studie zit hem in het feit dat artsen die geconfronteerd 
worden met deze zogenaamde “incidentalomen” vaak een maligniteit (met name 
maligne lymfoom) willen uitsluiten en daarom patiënten verwijzen voor EUS of 
endobronchiale echografie (EBUS). 
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Deze studie werd uitgevoerd bij 83 patiënten uit 8 verschillende ziekenhuizen. De 
mediastinale klieren werden gekenmerkt door hun meervoudigheid (mediane aantal 
vergrote klieren van 7), kleine omvang (tussen de 6 en 14 mm) en door 
betrokkenheid van de hilaire klieren (bij 77% van de patiënten). Fijne naaldmonsters 
toonden adekwate lymfklierpunctaten bij 66% en welgevormde granulomen, 
passende bij sarcoïdose, bij 22% van de patiënten terwijl in 8% van de gevallen de 
puncties geen klassificeerbare diagnose opleverden. 
Bij 29/83 patiënten was ook een PET-CT beschikbaar en metabole activiteit in de 
incidentalomen werd hierop bij 87% gezien. Gedurende de follow up periode 
ontwikkelden 2 patiënten longkanker, beiden 2 jaar na de mediastinale analyse. 
Aangezien de voorspellende waarde voor maligniteit bij deze mediastinale 
incidentalomen erg laag was, is een terughoudend beleid ten aanzien van invasieve 
diagnostiek gerechtvaardigd. De PET-CT heeft bij de analyse van mediastinale 
incidentalomen geen toegevoegde waarde. 
De vraag is of significante diagnoses gemist zullen worden zonder pathologische 
verificatie. Onze studie ondersteund dit echter niet evenmin als een routinematige 
follow up met CT scans wordt ondersteund. Er zijn geen duidelijke bewijzen die voor 
een specifieke follow up pleiten maar wellicht is een herhaald CT onderzoek na 
enkele maanden voor de reguliere praktijk een praktische benadering. 
 
Een diagnostisch programma voor patiënten met een afwijkende thoraxfoto (verdacht 
voor longkanker) wordt beschreven in hoofdstuk 8.  
Alle patiënten doorliepen een gestandaardiseerd programma bestaande uit een PET-
CT in de ochtend gevolgd door invasieve diagnostiek in de middag. Bronchoscopie, 
EUS, EBUS en echogeleide biopten of puncties stonden hierbij ter beschikking. Het 
uitgangspunt bij de keuze van het invasieve diagnosticum was dat idealiter zowel 
een diagnose werd gekregen als het ziektestadium (in geval van maligniteit) werd 
bevestigd. Het doel van de studie was tweeledig : verbetering van diagnostische 
efficiëntie enerzijds en terugbrengen van het aantal invasieve testen per patiënt 
anderzijds. 
Een totaal aantal van 297 patiënten werden volgens protocol geanalyseerd hetgeen 
resulteerde in een diagnose van maligniteit bij 72% en een goedaardige diagnose bij 
26% van de gevallen. Bij 1% van de patiënten bleek er in het geheel geen afwijking 
te bestaan. 
Bij 85% van de patiënten met een maligniteit kon de diagnose (inclusief bevestiging 
van tumorstadium) afgerond worden op de diagnostische dag. Men moet zich daarbij 
wel realiseren dat de uiteindelijke resultaten van het pathologisch onderzoek op de 
reguliere manier afgewacht moest worden en derhalve pas kon worden 
medegedeeld aan de patient tijdens de policontrole die standaard 1 week later 
gepland stond. 
De diagnose werd gesteld met 1 invasieve test bij 53% en met 2 of meer testen bij 
33% van de patiënten. Uiteindelijk werd bij 8% van de patiënten alsnog chirurgische 
diagnostiek toegepast. Bronchoscopie werd uitgevoerd bij 59% van de patiënten bij 
wie een maligniteit werd vastgesteld. 
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De mediane tijd, gerekend vanaf de eerste dag van de analyse tot aan het moment 
waarop de uiteindelijke testresultaten en het voorstel tot therapie met de patiënten 
werd besproken bedroeg 7 dagen (range 0-50 dagen). 
De conclusie van het onderzoek was dat in het kader van dit programma de 
diagnose op een efficiënte manier kon worden verkregen met een zeer korte 
wachttijd. Tevens bleek dat bronchoscopie in een substantieel deel van de patiënten 
niet noodzakelijk was. 
Het is duidelijk dat de patiënt over het algemeen zeer tevreden is met een hoge 
diagnostische snelheid maar het belang vanuit oncologisch perspectief is veel minder 
helder. Dat moet uiteraard gewogen worden tegen de kosten van overbodige PET 
scans en personele inzet.  
In de categorie van patiënten met een benigne diagnose is een PET-CT niet strict 
geïndiceerd. Desalniettemin is de informatie verkregen door een PET-scan in deze 
gevallen vaak uiterst nuttig om een aantal alternatieve diagnoses te kunnen 
wegstrepen temeer daar een pathologische diagnose in deze groep patiënten vaak 
ontbrak. Daarnaast had bij een deel van de patiënten met een maligniteit de PET 
scan nauwelijks toegevoegde waarde als de CT scan al ondubbelzinnige bewijzen 
voor stadium IV ziekte liet zien. 
Vanuit praktisch oogpunt heeft het sneldiagnostiekprogramma wel een ongunstig 
effect op de efficiëntie van de behandelkamer. Het is immers nog onbekend in de 
ochtend welke onderzoeken de patiënten in de middag gaan krijgen zodat het 
plannen van een programma lasting en behoudend is. 
 
In hoofdstuk 9 wordt de vraag beantwoord of histologische naaldbiopten misschien 
beter zijn dan cytologische naaldbiopten (beiden verkregen door middel van EUS) 
voor het verrichten van pathologische diagnostiek maar ook voor het uitvoeren van 
moleculaire diagnostiek. 
Hiervoor werden weefselnaaldbiopten uit mediastinale klier- en bijniermetastasen, 
vergeleken met cytologische punctaten verkregen tijdens dezelfde EUS-sessie uit 
dezelfde tumorlokalisatie. 
De afmeting van de mediastinale of bijnier massa’s moest minstens 20 mm bedragen 
in de prikrichting om gebiopteerd te kunnen worden met de gebruikte histologische 
naalden. Met beide soorten naalden werd 4 maal bemonsterd waarbij getracht werd 
de prikrichting binnen de massa te variëren voor optimale representatie van de lesie. 
De monsters werden onafhankelijk, door verschillende pathologen beoordeeld. Als er 
sprake was van een niet-plaveiselcelcarcinoom, dan werd aanvullend moleculaire 
analyse verricht naar epidermal growth factor receptor (EGFR) en V-Ki-ras2 Kirsten 
rat sarcoma viral oncogene homolog (KRAS) mutaties. 
Het bleek dat de diagnostische kwaliteit van de fijne naaldaspiraten beter was dan 
van de weefselnaaldbiopten met een diagnostische sensitiviteit van 92% voor de 
aspiraten versus 69% voor de biopten hetgeen significant verschillend was 
(P<0.00018). Wanneer beide modaliteiten gecombineerd worden gebruikt is de 
sensitiviteit 98%. 
De weefselnaaldbiopten bevatten vaak zowel kwalitatief als kwantitatief onvoldoende 
materiaal (of soms zelfs helemaal geen material) voor moleculaire analyse waardoor 
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de lage diagnostische success rate van 46% verklaard wordt. Dit in tegenstelling tot 
de hoge diagnostische success rate van 95% die voor fijne naaldaspiraten 
aangetoond werd. 
De conclusie van het onderzoek was dan ook dat de, middels EUS verkregen, 
weefselnaaldbiopten geen toegevoegde waarde hadden aan de fijne naaldaspiraten 
voor de pathologische en moleculaire analyse van hilaire, mediastinale en 
bijniermetastasen. 
 
Twee strategieën voor EGFR en KRAS mutatie analyse in DNA van patiënten met 
een adenocarcinoom worden vergeleken in hoofdstuk 10. Van cytologische samples 
verkregen middels EUS en EBUS en bewaard als formaline gefixeerde paraffine 
blokjes werd daarvoor zowel een mutatie analyse verricht door middel van de 
pyrosequencing techniek als met behulp van High Resolution Melting (HRM). Als er 
een afwijkend uitsmeltpatroon bij HRM werd gevonden volgde aanvullend nog 
Sanger sequencing voor nadere identificatie van gedetecteerde DNA afwijkingen. 
De HRM screening met eventueel Sanger sequencing is de standard procedure en 
werd vergeleken met upfront pyrosequencing, een techniek die gevoeliger is en 
waarvoor slechts kleine hoeveelheden DNA nodig zijn. Het vermoeden bestond dat  
pyrosequencing vaker tot een succesvolle DNA analyse zou leiden op materiaal dat 
vaak al langere tijd in de vriezer bewaard was en dat wellicht ook relatief weinig 
tumorcellen zou bevatten omdat het cytologische punctaten betreft. 
Toch bleken, in deze studie bij 126 monsters, beide analyse methodieken uiterst 
geschikt gezien de hoge diagnostische success rates ( voor pyrosequencing 97% en 
voor HRM 93%). Er werd een significante relatie gezien tussen de leeftijd van de 
preparaten en de mate waarin het DNA gefragmenteerd was. Alle mislukte HRM 
analyses werden gekenmerkt door sterk gefragmenteerd DNA hetgeen suggereert 
dat de leeftijd van monsters een rol speelde bij de mislukte HRM analyses. Eerder 
gepubliceerde studies selecteerden cytologisch material op ingeschat tumorgehalte. 
In onze studie werd maar een zwakke correlatie gevonden tussen geschat 
tumorgehalte en daadwerkelijk tumorpercentage zoals gemeten met pyrosequencing. 
De conclusie was dat mutatie analyse uiterst effectief uitgevoerd kan worden op 
EUS- en EBUS aspiraten zowel door middle van HRM (gevolgd door Sanger 
sequencing) als door middel van pyrosequencing. Pyrosequencing wordt minder 
gehinderd door verminderde DNA kwaliteit omdat het op kortere fragmenten kan 
worden uitgevoerd waardoor succesvolle mutatie analyse kan plaatsvinden op 
oudere en minder optimale monsters. 
Initiële screening met HRM, gevolgd door pyrosequencing als afwijkingen gevonden 
worden in monsters met een laag tumorgehalte of in het geval dat HRM mislukt, 
wordt voorgesteld voor routine mutatie analyse in de klinische praktijk. 
Een belangrijke vraag in deze context is of kleine weefselmonsters de tumor wel 
adekwaat vertegenwoordigen. Tumoren zijn heterogeen voor wat betreft hun 
genotype en fenotype. Er worden daardoor verschillen gevonden bij mutatie analyses 
tussen de primaire tumor en metastase maar ook binnen één tumorlokalisatie zijn 
verschillen in mutaties beschreven[1].  
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Aangezien aspiraten een beperkt aantal tumorcellen bevatten, ontstaat de vraag of 
cytologische monsters de tumor voldoende representeren. Omdat echogeleide 
puncties onder direct zicht plaatsvinden is het goed mogelijk om te puncteren in 
diverse richtingen binnen een tumor zowel in lengterichting als in breedterichting en 
tot op wisselende diepten zoals gedemonstreerd in bijgevoegde video-link[2]. 
Endobronchiaal afgenomen biopten, als meest gebruikte materiaal voor de diagnose 
van longkanker, kennen echter hetzelfde problem. Bronchusbiopten zijn repetitief 
verkregen uit een zeer beperkt en oppervlakkig deel van de tumor en representeren 
de tumor derhalve ook maar in beperkte mate. 
Omdat heterogeniteit ook beschreven is tussen primaire tumor en metastase is het 
een punt van discussie welke tumorlokalisatie de voorkeur van sampling heeft. De 
primaire tumor, als oorsprong van de ziekte, of de metastase die het tumorstadium 
bepaald en de resultante is van tumormigratie en tumornesteling. 
 
De analyse van patiënten met afwijkende thoraxfoto’s, verdacht voor maligniteit, 
behoort tot de meest uitdagende activiteiten van longartsen. Een breed scala aan 
diagnostische middelen staat hen ter beschikking. Deze kunnen onderverdeeld 
worden in afbeeldende diagnostiek, interventie pulmonologie en pathologische 
diagnostiek. 
In het trajekt van simpele longfoto, via een PET-CT tot verfijnde DNA sequencing 
techniek, moet allerlei besluitvorming plaatsvinden om tot een uiteindelijke diagnose, 
inclusief tumorstadium, te komen.  
In hoofdstuk 11 wordt een overzicht gegeven van alle relevante diagnostische 
middelen en wordt hun onderlinge samenhang en integratie besproken. Bij het 
maken van een diagnostisch plan zijn er enkele principes die in gedachten gehouden 
moeten worden. 
Om onnodige invasieve testen te voorkomen (met name stadiumbevestigende 
testen) is het essentiëel om eerst afbeeldende diagnostiek en dan pas invasieve 
diagnostiek te plannen. Verder verdient het de voorkeur om een biopsie methode te 
kiezen die zowel een klassificerende diagnose als een tumorstadium (in geval van 
maligniteit) oplevert. 
Hoewel histologie de voorkeur heeft (vooral bij goedaardige ziektebeelden en slecht 
gedifferentiëerde maligniteiten), zullen cytologische monsters, mits juist 
geprepareerd, over het algemeen een diagnose opleveren en, als er voldoende 






Momenteel is screening voor longkanker bij hoog-risico groepen een hot topic in de 
afbeeldende diagnostiek. Onlangs werd een afname van de sterfte door longkanker 
van 20% gezien bij hoog-risico patiënten die met low-dose CT scans gescreend 
waren[3]. Een probleem bij screening is echter het hoge percentage fout-positieve 
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CT scans die vervolgens weer nadere analyse of radiologische follow up 
noodzakelijk maakt.  
Verder zien we tegenwoordig zeer vaak kleine afwijkingen (vaak kleiner dan 1 cm.) 
op CT scans, die om allerlei niet-oncologische redenen worden gemaakt. 
Ook deze kleine afwijkingen behoeven weer enigerlei vorm van follow up. 
Er is daarom een grote behoefte aan verbeteringen van de afbeeldende technieken, 
om de kleine afwijkingen betrouwbaarder te kwalificeren. Aldus is er een belangrijke 
taak weggelegd voor de fabrikanten van deze apparatuur. 
Nieuwe PET-tracers worden meer specifiek dan het nu gebruikte FDG. Daarnaast 
zullen technologische verbeteringen aan de PET apparatuur resulteren in een betere 
resolutie van beelden. De vraag blijft echter of al deze vernieuwingen ook 
daadwekelijk een verbetering van het diagnostisch traject opleveren. 
Algoritmes die combinaties van niet-invasieve diagnostiek (zoals biomarkers) 
integreren, moeten worden gevalideerd in de toekomst om het onderscheid te 
kunnen maken tussen vroeg stadium maligniteit en goedaardige afwijking. 
Een veelbelovende innovatie die gecombineerd zou kunnen worden met state of the 
art CT onderzoek bij de analyse van zeer kleine afwijkingen, is de analyse van 
uitademingslucht[4]. Hoewel deze techniek nu nog niet gevoelig genoeg is, valt in de 
toekomst te verwachten dat uitademingsluchtanalyse een belangrijke rol gaat spelen 
bij besliskundige aspecten van zeer kleine afwijkingen. Andere biomarkers, zoals 




De enorme diagnostische revolutie die endoscopische en endobronchiale echografie 
te zien heeft gegeven is niet te evenaren. Voorheen anatomisch ontoegankelijke 
plaatsen in het lichaam zijn nu goed benaderbaar. Nieuwe, niet-chirurgische, 
interventiediagnostiek voor de analyse van thoracale massa’s hebben zich 
momenteel nog niet aangediend. Kleine verbeteringen worden gerealiseerd in de 
kwaliteit en het gebruiksgemak van naalden ten behoeve van EUS, EBUS en 
uitwendige toepassingen.  
Wel zijn er prille ontwikkelingen in de therapeutische toepassingen van EUS in de 
gastro-enterologie (met name bij pancreasaandoeningen) waarbij in een flexibele 
bipolaire probe zowel radiofrequency ablatie als cryothermale koeling gecombineerd 
wordt[5]. Mogelijk dat deze techniek in de toekomst ook geëxtrapoleerd kan worden 
naar EUS en EBUS zoals toegepast in de pulmonologie. 
Schoorvoetend zijn longartsen de uitwendige echografie gaan toepassen voor de 
analyse van pleuravocht. Het is echter maar een kleine stap verder om de echografie 
als hulpmiddel te gebruiken bij het verkrijgen van materiaal voor pathologische 
diagnostiek; een terrein dat eerder vrijwel exclusief in handen was van de 
interventieradioloog. Analoog aan andere disciplines als cardiologie, urologie en 
gynaecologie, zou de percutane echografie een integraal onderdeel van de moderne 
pulmonologische praktijk moeten worden. 
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Hoewel het logisch is dat EUS en EBUS wordt uitgevoerd in gespecialiseerde centra, 
vanwege hoge aanschafkosten van apparatuur en beperkte aantallen patiënten, ligt 
de situatie voor de percutane echografie wel degelijk anders. 
Percutane echografie is goedkoop, dagelijks toepasbaar en gemakkelijk te leren. Het 
aanleren van percutane echografische vaardigheden, momenteel slechts beperkt tot 
enkele centra, zou voor iedere longarts in opleiding beschikbaar moeten zijn.  
Meer diagnostiek in één hand heeft een gunstig effect op de snelheid en efficiëntie 
voor het stellen van de uiteindelijke diagnose. 
 
Ofschoon diagnostische chirurgie niet gerangschikt kan worden onder de interventie 
pulmonologie is het wel van belang om de moderne innovaties in dit kader aan te 
stippen. De recente ontwikkelingen binnen de minimaal invasieve chirurgie hebben 
de drempel om de chirurg in te schakelen voor mediastinale en abdominale 
diagnostiek duidelijk verlaagd. 
Video-assisted thoracoscopic surgery (VATS) was de initiële en meest belangrijke 
stap in dit opzicht waarmee zowel longafwijkingen als anderszins onbereikbare 
mediastinale en hilaire afwijkingen benaderd kunnen worden. Geleidelijk doet nu ook 
de robotchirurgie zijn intrede bij de VATS waardoor instrumentatie nog nauwkeuriger 
kan plaatsvinden en waardoor lastig bereikbare plaatsen in de thorax nog beter 
benaderd kunnen worden. 
  
Pathologie en moleculaire biologie 
De ontwikkelingen op het terrein van de pathologie en moleculaire biologie behoren 
wel tot de meest spectaculaire binnen de pulmonale oncologie. Nieuwe predictieve 
markers voor longkanker worden ontdekt en gevalideerd in een enorm tempo.  
Immuunhistochemie, fluorescent in situ hibridisatie en DNA sequencing zijn 
verschillende technieken die daarvoor op patiëntenmateriaal worden uitgevoerd. 
Meer tests brengt met zich mee dat er meer tumorcellen nodig zijn. Een ontwikkeling 
waarmee dit probleem ondervangen kan worden is next-generation sequencing 
(NGS). 
Middels NGS kan op slechts zeer kleine hoeveelheden DNA en RNA analyse 
plaatsvinden in paraffine-ingebed materiaal. Deze methodiek is zeer waardevol als 
mutaties, focale amplificaties, copy number afwijkingen en sommige fusieproteïnen 
een predictieve waarde blijken te hebben voor de effectiviteit van een bepaalde 
doelgerichte (targeted) therapie. Het succes hiervan zal echter deels afhangen van 
de bereidheid van longartsen om grotere tumormonsters te vergaren zodat ook 
laagfrequente mutaties gedetecteerd kunnen worden. 
Apparatuur waarmee het complete genoom gesequenced kan worden is thans 
commercieel verkrijgbaar waardoor alle afwijkingen  in kankergenen opgespoord 
kunnen worden in slechts kleine hoeveelheden tumormateriaal[6].  
De klinische betekenis van de meeste afwijkingen is echter nog niet bekend. 
Desalniettemin mag men verwachten dat de kennis van oncologische pathways snel 
zal toenemen met NGS, waardoor meer moleculaire doelen en 
resistentiemechanismen zullen worden ontdekt. Nieuwe medicamenten of 
combinaties van medicamenten en meer inzicht in de positieve en negatieve effecten 
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van medicamenten zullen de behandeling van longkanker steeds verder 
individualiseren. 
De longarts manoeuvreert constant in een speelveld met enerzijds veranderende 
eisen van de patholoog ten aanzien van het aan te leveren patiëntmateriaal 
(afhankelijk van technische ontwikkelingen) en anderzijds een veranderend inzicht in 
de klinische relevantie van zekere bevindingen. 
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